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ABSTRACT
     FACULTY OF MEDICINE, HEALTH AND BIOLOGICAL SCIENCES
Doctor of Philosophy
 MATERNAL DIET AND PROGRAMMING OF EMBRYO AND FETAL 
DEVELOPMENT IN THE MOUSE
By Rose Diana Panton
Plasticity is a prominent feature of early development, and is necessary to allow the fetus 
in utero to adapt to the continual variation in nutrient and oxygen supply it receives from 
the mother.  In contrast to adaptations made in adult life, those made during fetal life tend 
to become permanent and irreversible (i.e. programmed).  This is due to the existence of 
sensitive periods which are brief windows of growth and development in early life during 
which there is an increased susceptibility to programming influences (Barker, 1999). 
Under-nutrition (or other adverse influences) occurring during fetal life or immediately 
after birth may thus induce developmental plasticity.
 
  This study examined the impact of a relatively mild dietary protein restriction in the 
mouse during pregnancy on the subsequent development of the fetus.  The responses of 
the fetus to the maternal dietary challenge were studied close to the end of gestation (at 
day 17) using three broadly different approaches.  Fetal hepatic tissue was examined for a 
response to the maternal dietary challenge in terms of global gene expression with the use 
of Affymetrix micro-arrays.  The protein expression profiles of two related proteins were 
also studied in response to dietary manipulations in fetal liver tissue.  Finally, blastocyst 
stage embryo-transfers were performed in an attempt to elucidate the relative 
contributions of the early embryo experience versus the ongoing maternal environment to 
the subsequent fetal growth.  Overall, the approaches used suggest that the growth and 
protein expression of the fetus are altered by maternal dietary manipulation when the 
challenge is restricted to the pre implantation period of development.List of Contents
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       General Introduction
1.1 Developmental Origins of Health & Disease
1.1.1 Programming 
Plasticity is a prominent feature of early development, and is necessary to allow the fetus 
in utero to adapt to the continual variation in nutrient and oxygen supply it receives from 
the mother.  In contrast to adaptations made in adult life, those made during fetal life tend 
to become permanent and irreversible (i.e. programmed).  This is due to the existence of 
sensitive periods which are brief windows of growth and development in fetal life and 
infancy during which there is an increased susceptibility to programming influences 
(Barker, 1999).
Under-nutrition (or other adverse influences) occurring during fetal life or immediately 
after birth may thus induce developmental plasticity and have a permanent effect on the 
body’s structure, physiology and metabolism.  The specific effects of under-nutrition 
depend on the period of development during which it occurs because tissues develop in a 
predetermined sequence from conception to maturity.  Different organs and tissues 
undergo periods of rapid cell division, during which they are more sensitive, at different 
times; hence under-nutrition at particular points during early development will 
programme different effects (Barker, 1999).1.1.2 The Barker hypothesis
 
The “Developmental Origins of Health and Disease” (DOHAD) hypothesis proposes 
that the developing conceptus adapts to a limited supply of maternal nutrients and 
permanently alters its physiology and metabolism.  This response may protect the growth 
of its key organs for survival, such as the brain and it is such alterations which may in 
turn increase its risk of developing disease in later life (Barker, 1999).  Evidence from 
geographical studies provided the first indication that susceptibility to coronary heart 
disease and stroke in adult life might be linked to under nourishment as a baby (Barker, 
1999).  Human epidemiological studies have used size at birth as a marker of fetal 
nutrition and related it in groups of men and women to the occurrence of several chronic 
diseases in later life:  
Hertfordshire
The largest set of records in Britain concerning maternity and infant welfare in the early 
part of the twentieth century was made by health visitors in Hertfordshire who kept 
details of the birth weight and early health and development of all children born in the 
county between 1911 and 1945 (Barker, 1999).  Around 1986 the recovery of these 
records meant that it was possible to relate early growth to health in later life.  Men born 
in Hertfordshire between 1911 and 1930 and women born in the county between 1923 
and 1930 were traced.  By relating the birth and death records of the men and women 
traced, the study revealed that standardised mortality ratios for both coronary heart 
disease and stroke in men fell with increasing birth-weight.  In addition, stronger and highly significant trends existed with weight at one year in men (Figures 1.1, 1.2), 
notably, no corresponding trends existed where deaths from non-cardiovascular causes 
were examined.  In women, it was revealed that, as in men, deaths from coronary heart 
disease fell with increasing birth weight, but amongst women there was no trend with 
weight at one year as there was in men (Figures 1.1, 1.2).  Thus, in both men and women, 
low birth-weight reflective of low rates of fetal growth rather than length of gestation was 
associated with raised death rates from cardiovascular disease in later life (Barker, 1999). 
                 
Figure 1.1: Standardised mortality ratios for coronary heart disease (below the age 
of 65) according to birth weight for men and women respectively (Barker, 1999).              
Figure 1.2: Standardised mortality ratios for coronary heart disease (below the age 
of 65) according to weight at 1 year for men and women respectively (Barker, 1999).
In these cohorts from Hertfordshire, the only recorded measure of body size was weight 
(i.e. birth-weight, weight at one year) so the records provide only a crude summary of 
newborn and infant physique.  Weight measures are more informative when coupled to 
measures of the body length.  This information gives a better idea of the thinness of the 
infant which is a more representative indicator of early nutrition than weight alone 
(Barker, 1999).  The results from the Hertfordshire study have been confirmed by 
Barker’s group in other cohorts in Preston and Sheffield with more detailed birth size 
data.
Preston
The aim of this study was to determine whether lower birth weight, used as an indicator 
of reduced fetal growth and nutrition, is related to the occurrence of “Metabolic 
Syndrome”, also known as Syndrome X.  The metabolic syndrome refers to a cluster of cardiovascular risk factors which include insulin resistance, alterations in glucose and 
lipid metabolism, increased blood pressure and visceral obesity (Draper and Stewart, 
2005).  
The Preston cohort included men and women born in Preston, UK, between 1935 and 
1943 whose size at birth had been measured in detail.  In both men and women, the 
prevalence of metabolic syndrome fell progressively from those who had the lowest to 
those who had the highest birth-weights.  Amongst 64-year-old men whose birth-weights 
were 6.5 pounds or less, 22% had metabolic syndrome.  Their risk of developing 
metabolic syndrome was over ten times that of men whose birth-weights were more than 
9.5 pounds.  In addition to low birth weight, subjects with metabolic syndrome had small 
head circumference and low ponderal index at birth and low weight at year 1 of age. 
From the study, it was concluded that type 2 diabetes and hypertension have a common 
origin in suboptimal development in utero, and that metabolic syndrome should be re-
named “the small baby syndrome” because the prevalence of metabolic syndrome was 
strongly related to birth-weight (Barker et al., 1993).
1.1.3 Criticism of the Barker hypothesis
The Developmental Origins of Health and Disease model was proposed on the basis of 
retrospective epidemiological studies of human populations.  However, the relative size 
and importance of such developmental and non-genetic effects has been a matter of 
dispute.  For instance, it is argued that bias in the reporting of results from studies of the association between birth-weight and subsequent blood pressure may have led to an over-
estimation of the strength of the apparent association.  Other criticisms of the hypothesis 
include failure to take sufficient account of the impact of random error and inappropriate 
and inadequate adjustment for potential confounders (Huxley et al., 2002).
 
1.1.3.1 The role of birth size
It is argued that birth-weight is of little relevance to blood pressure levels in later life 
(Huxley et al., 2002).  However, the observed relationship between birth size and risk of 
disease parameters such as raised systolic blood pressure does not simply imply a causal 
role of being born small but rather it reflects the sensitivity of fetal growth to adverse 
intrauterine influences.  Hence, it is considered that environmental influences during 
early development act as the causal trigger for disease risk (Gluckman and Hanson, 
2004b).  Indeed, it is indicated in the Dutch famine of 1944-45 that adverse 
developmental influences can affect disease risk in the long term in humans without 
birth-size necessarily being altered (Roseboom et al., 2001).  Hence, reduced birth size is 
not pivotal in predicting disease risk.  Gluckman and Hanson point out that the most 
frequent misunderstanding in this field is the role of birth size, and one which has led to 
much misinformed criticism of the general paradigm.  They highlight that in 
epidemiological studies where birth size is used it is merely intended to be a crude 
surrogate measure reflecting interactions between fetal environment and fetal genome 
(Gluckman and Hanson, 2004c).  Despite support for the Barker hypothesis from animal 
studies (see section 1.1.4), in humans it is argued that evidence concerning the effects of 
maternal diets that influence birth-weight on later blood pressure is limited and often contradictory (Huxley et al., 2002).  Often problems with inconsistent results have arisen 
because most studies have used surrogate/indirect or proxy measures of disease risk, such 
as systolic blood pressure or fasting insulin/glucose ratios.  Indeed, where clinical 
cardiovascular or metabolic disease is the measured outcome, the effect of early 
environment influences is clearer (Gluckman and Hanson, 2004b) (Figure 1.3).
Figure 1.3: Association in men over 40 years of age between birth size and risk of 
developing clinically significant hypertension or diabetes mellitus.  No relationship 
exists with systolic blood pressure.  The need for studying outcomes rather than 
surrogate measures of disease is illustrated, (from Gluckman and Hanson, 2004b).
1.1.4 Support for the Barker hypothesis: Experimental evidence 
Numerous rat models support the notion that maternal under-nutrition during pregnancy 
alters early growth and development of chronic disease indicators, such as raised systolic blood pressure, in the adult offspring.  Maternal low protein diet models of fetal 
programming have been extensively used to study the mechanisms that link maternal 
nutrition with impaired fetal growth and later cardiovascular disease and diabetes 
(Bertram and Hanson, 2001).  For instance, in rats where isocaloric maternal low protein 
diet was maintained throughout pregnancy but not in offspring, an inverse relationship 
between maternal protein intake and the systolic blood pressure of the adult offspring was 
observed.  At 9 weeks of age, systolic blood pressure was significantly elevated for all 
offspring from low protein fed mothers compared with offspring from control fed 
mothers (Langley and Jackson, 1994).
The effect of fetal exposure to maternal low protein diet was similarly demonstrated by 
Langley-Evans et al, here, hypertension was observed in the weanling offspring of rats 
exposed to low protein (9% casein) diet during discrete gestational periods in early, mid 
or late gestation, as well as throughout pregnancy.  The effect in early gestation was only 
significant in male animals.  Interestingly, despite the changes in systolic blood pressures 
evident between the offspring of mothers fed different diets, birth-weights were largely 
unchanged by the maternal dietary regime (Langley-Evans et al., 1996b).  However, in 
similar studies on rats, offspring birth-weight as well as systolic blood pressure has been 
altered by the maternal low protein diet, fed throughout pregnancy (Bertram et al., 2001). 
Similarly, birth-weights of rats exposed to the low protein (9% casein) diet in utero were 
significantly smaller than those of the offspring of rats fed the 18% casein control diet, 
and the postnatal systolic blood pressures (at 4 weeks or 7 weeks) of male and female rats exposed to low protein diets in utero were significantly higher than those of rats exposed 
to the control diet in utero (Langley-Evans et al., 1996a; Langley-Evans, 1997a). 
More recently, it has been demonstrated that maternal protein under-nutrition specifically 
during the period before implantation of the embryo may be critical for the programming 
of cardiovascular health of the resultant offspring.  Male rat pups exposed to low-protein 
(9% casein) diet for the first 4.25 days of gestation only (with return to control diet for 
remainder of gestation) had significantly elevated systolic blood pressures at 4 and 11 
weeks of age compared with control offspring (Kwong et al., 2000).  Similarly, in mice 
fed low protein diets (9% casein) either throughout pregnancy or 0-3.5 days and then fed 
a control diet for the remainder of gestation, altered parameters of post-natal health such 
as persistently raised systolic blood pressure were shown in the offspring from 15 weeks 
of age, both male and female.  This was also shown for offspring of mice exposed to a 
low protein diet throughout gestation (Watkins et al., 2008).   
The protein requirement for pregnant rats is between 9% and 12% by weight (Nelson and 
Evans, 1953).  Hence, the use of the 9% casein low protein diets outlined above 
represents only a relatively mild dietary manipulation.  However, as illustrated in Figure 
1.1 for the human, an association with a diseased phenotype is evident even across the 
normal range of birth-weights (it is not exclusive to the extremes).  Even when the 
maternal dietary regime is not harsh enough to elicit a severely compromised offspring 
birth-weight, a phenotype in the offspring is still observable.  Thus, even a mild maternal 
dietary restriction may be sufficient to programme a diseased phenotype in the offspring. It is an important point to note that the diets used by Langley-Evans and subsequent 
Southampton University-based workers supply extra amounts of the sulphur-containing 
amino acid methionine, (CH3SCH2CH2CHNH2COOH).  Protein in the form of casein, as 
used in the diets from Langley-Evans et al., provides under half of the cysteine (the other 
sulphur-containing amino acid) that is required by rats during gestation (Reeves et al., 
1993).  Thus in order to avoid sulphur deficiency associated with a casein-based diet the 
extra methionine is added to the diets to compensate, so that rats may produce cysteine by 
transulfuration of homocysteine (Rees et al., 2000; Langley and Jackson, 1994).  As the 
same methionine supplement (5g/kg) is added to both the low protein and control diets 
the protein-deficient animals are supplied with an excess of methionine relative to other 
amino acids, along-side the global casein restriction (Rees et al., 2000).  Therefore, it is 
possible that the critical factor in the nutritional programming of long-term health effects 
in the fetus is the amino acid balance in the maternal diet rather than total protein content 
per se.  Indeed, studies of pregnant rats fed diets devoid of single essential amino acids 
have revealed that fetal growth is most sensitive to deficiencies of methionine, valine and 
isoleucine (Niiyama et al., 1973).  Similarly, Rees et al., (2000) argue that imbalances in 
specific amino acids associated with maternal low protein diet feeding result in metabolic 
disturbance which may programme cardiovascular health (Langley-Evans, 2001). 
Moreover, the balance of specific amino acids may be critical in determining DNA 
methylation status in the fetus and the specific outcomes of the maternal low protein diet 
during pregnancy (Rees et al., 2000).1.1.5 A modified hypothesis 
The most recent modification to the Barker hypothesis involves the fetus making 
“Predictive Adaptive Responses” in order to prepare its physiology for the level of 
nutrient availability in the post natal environment.  As opposed to the level of pre-natal 
nutrition per se influencing disease risk in the offspring, this model highlights the 
importance of continuity of the same level of nutrition in both pre- and post-natal 
environments.  The fetus constantly interprets and responds to changes in the 
environment in utero.  Predictive Adaptive Responses (PARs) are invoked in response to 
changes in such environmental stimuli.  They confer little immediate survival advantage 
but induce future adaptive advantage by establishing a metabolic physiology appropriate 
for the predicted postnatal environment (Gluckman and Hanson, 2004a).
Evidence in favour of the concept of PARs comes from the meadow vole (Microtus 
pennsylvanicus); in this species, the coat at birth is thicker in animals born in the autumn 
compared to those born on the spring (Lee and Zucker, 1988).  Hence, it is argued that 
the fetal vole has predicted the future environment to which it will be exposed after birth 
based on maternal signals and, by the processes of developmental plasticity, determined 
post-natal coat thickness accordingly while in utero.  Although this alteration in coat 
thickness confers no immediate survival advantage (the temperature to which pups are 
exposed in utero and in the nest is similar whatever the season), it may reflect an 
anticipation of the later environment and hence promotes survival (Gluckman and 
Hanson, 2004a). The appropriateness of the PARs made by the fetus is determined by the predicted and 
actual postnatal environment.  The fetus in utero sets a range of homeostatic settings 
appropriate for postnatal life according to the information about the postnatal 
environment it receives from its mother.  If the nature of the actual postnatal environment 
matches that which was predicted, the PARs are appropriate and disease risk is low. 
However, if the actual and predicted post natal environments do not match, risk of 
disease is increased.  For instance, fetal prediction of a nutritionally poor postnatal 
environment (based upon a compromised environment in utero) is associated with a 
developmental pathway appropriate for a low postnatal nutritional range (Gluckman and 
Hanson, 2004a).  However, if the postnatal environment is plentiful in nutrients, PARs 
made on the basis of the intra-uterine experience of a deprived environment will be 
inappropriate and disease risk increased (Gluckman and Hanson, 2004b) (Figure 1.4- see 
red arrow).  There is a considerable potential for such discrepancy between the predicted 
and actual postnatal environment because of maternal and/or placental disease, and 
maternal constraint, all of which limit the availability of nutrients to the uterine 
environment (Gluckman and Hanson, 2004a).  
Figure 1.4: PARs model.  Appropriate PARs lie within the shaded area; red lines 
indicate the upper and lower limits of the nutrient range in the postnatal 
environment (Gluckman and Hanson, 2004b).
This situation of discrepancy between predicted and actual post natal environments, is 
common in the developing world where fetal growth is often constrained by small 
maternal size, maternal disease and poor nutrition, and where food availability in the 
postnatal environment is increasing (Gluckman and Hanson, 2004b).  Hence, the PAR 
model may explain the rapid rise in insulin resistance/metabolic syndrome seen in 
deprived populations migrating into more prosperous circumstances.  For example, the 
epidemic of type 2 diabetes in the Indian subcontinent may be a consequence of 
improved nutrition against a background of impaired fetal growth as a result of severe 
maternal constraint and small maternal size.  From this, it is clear that the rate of 
nutritional transition in a society is critical, due to the prenatal environment changing 
much more slowly than the postnatal environment.  This is because the prenatal environment is determined by maternal size, body composition and metabolism, features 
partly laid down when the mother herself was a fetus (Gluckman and Hanson, 2004c)!
Finally, because the upper limit of the postnatal nutrient environment is rising rapidly 
globally (see upper red line on Figure 1.4), even individuals who had optimal early 
development may be at risk from disease because of the larger amount of food now 
available in the postnatal environment in many developed countries; thus, making PARs 
more likely to fall outside the appropriate range (Gluckman and Hanson, 2004b).
This research project makes use of a mouse model, Mus musculus to investigate 
mechanisms of fetal programming; the findings from which may form the basis upon 
which to investigate programming mechanisms in the human.  Indeed, genes or 
physiological activities identified as being susceptible to programming in the mouse may 
become candidates for examination in the human in future research projects.  This is 
because the mouse and the human are both Eutherian (placental) mammals and the 
growth and development of the embryo is sufficiently similar between the two species for 
the mouse to provide a useful model of human development.  Furthermore, over 90% of 
the mouse and human genomes can be partitioned into corresponding regions 
of conserved synteny, reflecting segments in which the gene order in the most 
recent common ancestor has been conserved in both species (Waterston et al., 
2002).  1.2 Murine Reproduction and Embryo Development 
1.2.1 Physiology of the uterus
The uterus has two horns and a caudal section (cropus uteri) that is undivided.  The 
uterine horns are suspended from the dorsal body wall by mesometria and extend from 
the oviducts and unite to form the corpus (Hummel et al., 1966) (Figure 1.5).
                               
Figure 1.5: Drawing of mouse uterus: uterine horns are the sites of implantation 
(Hummel et al., 1966).
The uterine mucosa of the horns (endometrium) makes up most of the uterine wall and 
lies between the epithelia lining the lumen and smooth muscle (myometrium).  It is 
arranged into folds and is well supplied with blood vessels (Hummel et al., 1966).1.2.2 Oestrus cycle
At maturity, each ovary contains approximately 10
4 oocytes at different stages of 
development (Hogan et al., 1994).  Female mice reach sexual maturity around 6 weeks of 
age, depending on the strain.  Sexually mature non-pregnant females maintained under a 
constant light-dark cycle tend to ovulate once every 4-5 days, 3-5 hours after the onset of 
the dark period, (Hogan et al., 1994).  The periodicity of oestrus observed in mature 
females is a direct result of cyclic changes in the ovary which are brought about by 
alterations in hypothalamic activity and secretion of the gonadotrophins follicle 
stimulating hormone (FSH) and luteinizing hormone (LH).  The hypothalamus stimulates 
FSH secretion by the anterior pituitary gland which promotes ovarian follicle growth. 
LH is also secreted by the anterior pituitary and aids in the final development of the 
mature follicle.  LH also facilitates oestrogen production by theca interna cells of the 
FSH-primed follicle (oestrogen acts to suppress further FSH release and promote more 
LH secretion).  Further LH release results in rupture of the follicle and ovulation of 
secondary oocytes into the oviduct (Oestrus).  Progesterone released by the ovary during 
the follicular growth phase enhances LH release and therefore promotes ovulation.  The 
development of the corpus luteum is induced by mating and when this does not occur 
gonadal hormone levels decrease which allows for the succession of a new cycle 
(Bronson et al., 1966). See Figure 1.6.Figure 1.6: Stages of the oestrus cycle in the rodent (rat) and the sequence of 
endocrine changes involved; taken from 
http://pubs.niaaa.nih.gov/publications/arh26-4/images/emanuele3.gif
As outlined in Figure 1.6, there are four stages to the oestrus cycle, namely, Dioestrus, 
Proestrus, Oestrus (heat) and Metoestrus.  Proestrus and oestrus are anabolic stages 
characterised by active growth in the reproductive tract.  This part of the cycle culminates 
in ovulation.  Metoestrus is a catabolic phase and is thus characterised by degenerative 
changes in the reproductive tract.  The last (or first) stage is dioestrus which is a 
quiescent period of slow growth (Bronson  et al., 1966).
1.2.3 Mating
Males maintained under the same constant light-dark cycle as female mice will copulate 
with females in oestrus (i.e. ovulating females) at around the midpoint of the dark period. 
Usually, naturally mated females each contain between 7 and 13 fertilized eggs, depending on the strain (Hogan et al., 1994); the average litter size is usually between 
eight and ten.
1.2.4 Fertilisation
Fertilisation of the egg takes place in the ampulla region of the oviduct and involves 
activation of the ovum by a spermatozoon (sperm cell) and the union of male and female 
haploid chromosomes (pronuclei) into a single diploid zygote (Rugh R, 1990).
Sperm maturation, by a process known as capacitation, takes place inside the oviduct up 
to an hour after ejaculation.  Once mature, in order to reach the surface of the egg, the 
sperm must first penetrate the cumulus mass surrounding it and then the zona pellucida 
membrane.  The glycoprotein ZP3 has been identified as the sperm-binding protein in the 
zona membrane.  Sperm binding to ZP3 induces an acrosomal reaction in which 
hydrolytic enzymes are released from a secretory structure in the sperm head which allow 
the sperm to penetrate the zona and fertilise the egg.  During fertilisation, the sperm head 
containing a haploid nucleus, the mid-piece and some of the tail all enter into the egg 
cytoplasm.  While the mid-piece of the sperm contributes paternal centrioles and 
mitochondria to the zygote, the mitochondria are very much diluted out by the oocyte 
mitochondria (Hogan et al., 1994).  The activation by the sperm stimulates the secondary 
oocyte to complete its second meiotic division by which it develops into a mature haploid 
ovum.  Nuclear membranes form around the maternal and paternal chromosomes forming 
separate haploid male and female pronuclei that each move towards the centre of the egg cell.  After DNA replication, the pronuclear membranes break down and both sets of 
chromosomes assemble on a common mitotic spindle; the first cleavage division of the 
fertilised egg ensues and the diploid embryonic genome is established (Gilbert, 2000; 
Hogan et al., 1994).
At the time of fertilisation in vivo, some studies indicate that the orientation of the future 
developmental axes is evident upon extrusion of the second polar body from the egg after 
completion of its second meiotic division.  The position of this polar body provides a 
marker of the animal pole of the zygote and subsequently the animal-vegetal axis of the 
early embryo is specified.  Some studies indicate the embryonic-abembryonic axis 
develops subsequently perpendicularly to this first axis (Gardner, 1997), although this is 
disputed.  More recently, there have been suggestions that an extrinsic factor, namely the 
point of sperm entry to the egg, might provide a surface marker for the first cleavage 
plane of the mouse zygote and thus be involved in spatial patterning of the early mouse 
embryo (Piotrowska and Zernicka-Goetz, 2001; Plusa et al., 2002)  However, this 
suggestion has been contested due to apparent flaws in the method (Davies and Gardner, 
2002).
1.2.5 Embryonic and fetal development
Embryonic development in the mouse begins at fertilisation.  The gestational period of 
development in the mouse is short, usually lasting 19-21 days depending on strain, 
(Figure 1.7).  Figure 1.7: Embryonic and fetal development in the mouse: 0-5 days cleavage and 
blastulation; 5-10 days implantation, gastrulation, and early organogenesis; 10-14 
days organogenesis; 14-19 days fetal growth and development (Hogan et al., 1994).
By 24 hours post fertilisation, the mouse embryo is still at the two cell stage and 
continues to divide slowly over the next couple of days without any increase in mass as it 
makes its way along the oviduct towards the uterus for implantation into the uterine wall 
~4.5 days after fertilisation.  Subsequent cleavage divisions generate a 4-cell and then an 
8-cell embryo.  At the 8-cell stage compaction begins in which the cells of the embryo 
become differentiated into one of two cell lineages, the differentiated 16-celled embryo is 
termed a morula; at 3-4 days post fertilisation the 32/64-cell blastocyst is formed (Hogan 
et al., 1994).  See section 1.2.5.1 for further details of the sequence of events taking place 
during pre-implantation development; sections 1.2.5.2 and 1.2.5.3 summarise 
developmental events at implantation and beyond.
The relatively slow early development of the mouse embryo enables the uterine tissue 
time to prepare for receiving the embryo.  Whilst in the oviduct shortly before implantation, the first two differentiated tissue lineages (trophectoderm and primitive 
endoderm) are generated in the embryo which form an integral part of the placenta and 
extra-embryonic yolk sacs required for successful interaction with the mother (Hogan et 
al., 1994) (Figure 1.8).
Figure 1.8: Summary of the lineages of tissues constituting the mouse embryo. 
Hatched boxes = tissues that will give rise to the embryo proper and extraembryonic 
cells; Shaded boxes = extraembryonic tissues; Open boxes = tissues of the embryo 
proper (Hogan et al., 1994).1.2.5.1 Pre-implantation development
Figure 1.9: Sequence of events during the pre-implantation period of mouse 
embryonic development according to days post fertilisation (Hogan et al., 1994).
Pre-implantation development is illustrated in Figure 1.9.  Up until the early 8-cell stage 
morula, it is believed that the individual cells (blastomeres) of the mouse embryo are 
each capable of giving rise to a mouse (i.e. they are totipotent).  As cleavage divisions 
continue to the 16 cell stage, however, there is a gradual restriction in the developmental 
potency of the cells which eventually results in the generation of two distinct cell 
lineages: trophectoderm (TE) and the inner cell mass (ICM).  This process of 
differentiation begins with compaction of the 8-cell embryo which is characterised by a 
flattening of blastomeres and increased contacts between them.  At this point, 
blastomeres develop apical and basal membranes and distinct cytoplasmic domains (a 
process known as polarisation) (Hogan et al., 1994).After compaction, the cleavage plane of dividing polarised 8-cell blastomeres can 
generate either polar:polar daughters cells (conservative division) or polar:non-polar 
daughters (differentiative division).  In the 16-cell morula, polar and non-polar cell types 
occupy outer and inner positions respectively; in vivo, cells that end up on the inside of 
the compacted embryo give rise to the ICM whereas those on the outside surface give rise 
to TE (Fleming and Johnson, 1988).  The cellular differentiation becomes permanent 
upon the formation of a fully expanded blastocyst (at the 32-cell stage) which consists of 
a hollow vesicle of TE cells surrounding a fluid-filled cavity (blastocoel) and a group of 
ICM cells.  The TE has the features of a typical epithelium and forms a permeability seal 
against the outside environment, and transports selected factors into the ICM (Hogan et 
al., 1994).
The fluid-filled blastocoel cavity is formed by the selective transport of specific ions 
across the TE into extra-cellular spaces.  This produces a concentration gradient which 
then drives the movement of water into the extra-cellular spaces.  Na
+ is one of the main 
ions involved in the formation of the blastocoel cavity (Manejwala et al., 1989).
The pre-implantation embryo is unique in its capacity to develop in the absence of any 
direct cellular contact with the reproductive tract before implanting into the uterus.  It is 
free-floating, lacks a blood supply and is moved continuously by the reproductive tract 
through a changing fluid environment.  During this time, it is dependent on the luminal 
secretions of the oviduct and uterus for its nutrition; its cellular activities, such as cell 
division, gene expression and metabolism, are all influenced by this environment and the 
factors produced by the cells of the reproductive tract.  For normal development and implantation to occur, there must be effective maternal-embryonic communication, 
mediated by growth factors e.g. insulin, IGFs.  A range of such growth factors are 
produced by the reproductive tract and pre-implantation embryo, and many of their 
receptors may be detected on the embryo surface (Hardy and Spanos, 2002) (Figure 
1.10).  The mammalian reproductive tract is also a good source of exogenous protein and 
amino acids that the developing embryo can utilise in the biosynthesis of its own proteins 
(Gardner and Leese, 1990).
Figure 1.10: Cellular responses of the embryo and maternal reproductive tract to 
maternally and embryonically derived growth factors (Hardy and Spanos, 2002).Exogenous growth factors do not however appear to be essential for pre-implantation 
development as evidenced by mammalian embryos that are able to survive and develop to 
the blastocyst stage in vitro in a simple salt solution supplemented only with the nutrients 
pyruvate and albumin (Devreker et al., 1998).  The nutrient requirements of the 
mammalian embryo change during pre-implantation development, in particular the 
preferred energy substrate for metabolism.  Glucose, pyruvate and lactate are key 
nutrients required during the mammalian pre-implantation period.  In human embryos in 
vitro, pyruvate uptake was significantly higher in embryos that went on to form 
blastocysts than by those that failed to develop to the blastocyst stage (Gardner et al., 
2001).  Likewise pyruvate uptake by fertilised human embryos which arrested at cleavage 
stages was significantly lower than those which developed to the blastocyst stage (Hardy 
et al., 1989).  This suggests that pyruvate in particular is important for metabolism of the 
mammalian pre-implantation embryo at the pre-blastocyst stages.  Glucose uptake in 
vitro was highest in human blastocysts of the highest morphological ‘grade,’ whereas 
pyruvate uptake was similar irrespective of blastocyst grade (Gardner et al., 2001). 
Therefore, it appears that glucose is the more important nutrient for the metabolism of the 
mammalian embryo by the blastocyst stage (Gardner et al., 2001; Hardy et al., 1989; 
Gardner and Leese, 1987; Renard et al., 1980).  This is further supported by normal 
fertilised human embryos in culture, whereby pyruvate uptake exceeds that of glucose in 
the early developmental stages before glucose becomes the predominant substrate in the 
blastocyst.  Meanwhile, for single human pre-implantation embryos that arrested in 
culture, values of pyruvate and glucose uptake and lactate production were below that for 
embryos which developed normally (Gott et al., 1990).Importantly, the mammalian reproductive tract is regionally specialised to meet the 
changing metabolic requirements of the embryos as it develops.  After ovulation, the 
human embryo in the oviduct it is exposed to relatively high concentrations of pyruvate 
and lactate (metabolite of glucose) and a lower concentration of glucose (Gardner et al., 
1996).  This is appropriate for pre-compact embryos found in this region.  While in the 
uterus, there is a lower concentration of pyruvate and lactate and an increased glucose 
concentration compared to the oviduct (Gardner et al., 1996), reflecting the altered needs 
of the embryo at compaction and upon blastocyst formation.  This is important 
particularly as it has been suggested by in vitro culture experiments that exposure of the 
pre-compact mammalian embryo to high levels of glucose may be inhibitory to cleavage 
development (Conaghan et al., 1993).
1.2.5.2 Implantation
Hatching of the blastocyst from the zona pellucida precedes implantation.  At the time of 
implantation, changes in the surface of the uterine epithelium make it conducive for 
blastocyst attachment.  Blastocyst attachment induces formation of a uterine crypt and 
stimulates the uterine stroma to form decidual tissue (a spongy mass of cells).  This 
subsequently causes a rapid increase in permeability of local capillaries which causes 
swelling of the uterine stroma.  Stromal cells in the uterine tissue proliferate and increase 
in size and the epithelium separating blastocyst from the stroma gradually erodes which 
allows the trophoblast cells to invade the deciduum (Hogan et al., 1994).At the time of implantation (~ 4.5 days post conception), the blastocyst is made up of 
three tissue lineages: trophectoderm (TE), primitive endoderm (derived from ICM) 
and epiblast (primitive ectoderm- derived from ICM also).  At this time, the TE 
becomes regionally specialised in terms of morphology and developmental potential 
(Figure 1.8); TE cells which overly the ICM directly are known as polar TE, whereas TE 
cells surrounding the blastocoel cavity become mural TE.  At this point the epiblast is the 
smallest population consisting of 20-25 cells only and is situated between the polar 
trophectoderm and the primitive endoderm (Hogan et al., 1994) (Figure 1.11).
  
Figure 1.11: Image of a mouse blastocyst ~4.5 days of development (PrEnd = 
Primitive endoderm; TE= Trophectoderm) (Hogan et al., 1994).
Differential expression of regulatory transcription factors underlies the lineage 
diversification and cell fate as the blastocyst develops.  Oct-4 is present in the nuclei of mouse blastomeres at all cleavage stages but becomes restricted to the ICM and 
subsequently the epiblast as development progresses, indicating that Oct-4 is a 
pluripotency marker (Palmieri et al., 1994).  In contrast, the homeodomain protein Cdx2 
is expressed in a reciprocal pattern to Oct-4 and becomes restricted to the TE lineage by 
the blastocyst stage (Beck et al., 1995).  The importance of Cdx2 for development of 
trophoblastic cells derived from the TE lineage is demonstrated by homozygous Cdx-2 
knockout embryos failing to implant (Chawengsaksophak et al., 1997).
   
1.2.5.3 Post-implantation development
Once the blastocyst has implanted into the uterus, there is a major increase in the rate of 
embryonic growth.  This is especially evident in the small group of pluripotent (epiblast) 
cells from which the fetus will develop.  5-10 days post fertilisation, as a result of 
gastrulation, the three primary germ layers- ectoderm, mesoderm and definitive 
endoderm, differentiate.  At this stage the basic body plan and organ primordial of the 
future mouse are established.  Between 10-14 days organogenesis is completed and 
thereafter until term the fetus grows rapidly building upon the basic body axes (Hogan et 
al., 1994).1.3 The Liver
1.3.1 Liver development 
Hepatic tissue develops from endoderm in the embryo that extends out from the foregut 
(Gilbert, 2000).  At 16 days post conception the upper part of the peritoneum in the 
mouse is largely occupied by the liver.  The liver is arranged into definitive lobes by this 
time and histological analyses of hepatic tissue indicate there is a considerable amount of 
haemopoietic activity at this stage (Kaufman, 1992).  In adult mammals the haemopoietic 
system of stem cells resides in the bone marrow of the larger bones of the skeleton 
however in the embryo it is to be found at various other sites.  Initially, it is in the yolk 
sac, later it is in the liver, spleen and lymph nodes due to cell migration from the original 
sites (Slack, 2006).
Many tissues and organs e.g. the brain, gut and kidneys are not imperative for intrauterine 
life.  However, the placenta, yolk sac, fetal liver (all sites of haemopoiesis), and 
cardiovascular system are central to survival through the embryonic period (Cross and 
Rossant, 2001).  The fetal liver is one of the main sites of fetal gluconeogensis.  Under 
normal physiological conditions there is minimal net gluconeogenesis undertaken by the 
fetus.  However, during adverse conditions such as maternal under-nutrition, glucose 
production in the fetus is stepped up.  In the fetal liver, gluconeogenesis occurs by 
glycogenolysis from glycogen stores.  It may also occur by gluconeogensis from lactate 
and amino acids.  The ability of the fetus to produced glucose in this way increases towards term, as hepatic glycogen content rises and the activities of the gluconeogenic 
enzymes increase (Fowden, 2001).
Nutrients that are taken up by fetal tissues are used primarily for tissue growth or 
oxidation, see Figure 1.12 (Fowden, 2001).
Maternal nutrient pool
        Trans-placental transfer Placental production and 
modification
Umbilical uptake
Fetal nutrient pool Fetal production 
Oxidation and
Energy production Tissue growth 
   Fuel reserves   Structural tissue
          e.g fat, glycogen              e.g. lipid, protein
Figure 1.12: Nutrient fluxes between maternal, placental and fetal tissues during 
late gestation (Fowden, 2001).1.3.2 Liver function
The liver is an accessory gland of the mammalian digestive system although it performs a 
diverse range of functions pivotal to homeostasis.  In terms of its role in digestion, the 
liver produces bile which contains salts that act as detergents to help in the digestion and 
adsorption of fats (Campbell et al., 1999).  Another related function is regulation of blood 
sugar levels.  The hepatic portal vein takes blood, carrying digestion products such as 
sugars and amino acids, from the intestine directly to the liver.  Under the influence of 
insulin, much of the glucose present is taken up into hepatocytes.  Here, glucose is 
converted into glycogen granules for energy storage and subsequent release into the 
circulation as required (after conversion back into glucose).  Glycogen breakdown and 
sugar, fat and amino acid metabolism are all under strict hormonal control (Randall et al., 
2002).
1.3.3 Diet and hepatic programming
It has been demonstrated that a low protein diet during pregnancy and lactation in rats has 
an effect on hepatocyte proliferation, liver growth and morphology in the resulting 
offspring (Burns et al., 1997; El Khattabi et al., 2003).  In offspring of rat dams fed a 
low-protein diet during pregnancy decreased activities of hepatic glucokinase and 
glutamine synthase, which regulate glucose uptake, have been reported.  Plus, an increase 
in the activity of catabolic enzymes in the liver such as PEPCK, important in regulating 
gluconeogenesis was observed in these offspring (Desai et al., 1997a; Desai et al., 1997b; Burns et al., 1997).  These authors suggest that rat pups exposed to early maternal 
malnutrition have their metabolic control point shifted in the direction of poor nutrition 
so that the liver develops to favour production rather than utilisation of glucose; as the 
activity of anabolic glucose-utilising enzymes in the liver were decreased while the 
activity of catabolic glucose-producing enzymes increased.  
In studies that have mapped metabolic function within the liver in rats, a diminished 
perivenous uptake of glucose in the livers of offspring exposed to a low protein diet 
throughout gestation and lactation has been reported (Burns et al., 1997).  Thus, it has 
been suggested that fetal programming may partly operate through altered glucokinase 
expression in the perivenous region.  Interestingly, patients with type 2 diabetes display 
decreased activity of hepatic glucokinase also (Caro et al., 1995).
1.4 Mechanisms of Intrauterine Programming 
As intrauterine growth retardation can be related to specific postnatal outcomes and 
hormones regulate fetal growth and the development of fetal tissues, it is likely that 
hormones will have pivotal role in intrauterine programming.  Hormones such as insulin, 
insulin-like growth factors (IGFs), thyroid hormones and the glucocorticoids act as 
nutritional and maturational signals in utero and adapt fetal development to intrauterine 
conditions which prevail in order to maximise the chances of survival in utero and at birth.  However such adaptations may have long-term consequences as previously 
mentioned (Fowden and Forhead, 2004).
Hormones present in fetal circulation may be secreted by the fetal endocrine glands, or 
they may be derived from uteroplacental tissues, by transplacental diffusion (lipophilic 
hormones) or finally they may come from circulating precursors by metabolism in fetal 
or placental tissues (Fowden and Forhead, 2004).  The concentration of hormones in fetal 
circulation is affected by nutritional signals; nutritional challenges that reduce fetal 
nutrient availability will usually decrease the concentration of anabolic hormones (such 
as insulin, IGF-I and thyroxine - T4) and increase catabolic hormone concentrations (e.g. 
cortisol, and growth hormone) (Figure 1.13).  Fetal insulin for instance is a growth-
promoting hormone, which acts as a signal of nutrient plenty.
Figure 1.13: Relationship between nutritional state of the fetus, hormone 
concentrations, metabolism and tissue growth and differentiation (from Fowden 
and Forhead, 2004).Of the hormones known to control fetal development, glucocorticoids are most likely to 
cause tissue programming in utero.  In the long term, prenatal glucocorticoid exposure 
can permanently reset endocrine systems (such as the Hypothalamic Pituitary Adrenal –
HPA-axis) which may in turn contribute to the pathogenesis of adult metabolic 
dysfunctions e.g. insulin resistance, dyslipidemia, glucose intolerance, hyperglycaemia 
(Fowden and Forhead, 2004; Fowden et al., 2005).  Patients with circulating cortisol 
excess, Cushing’s syndrome, display many features associated with metabolic syndrome 
(Draper and Stewart, 2005) which may indicate a role for glucocorticoids in the 
mechanisms involved in programming of features of metabolic syndrome in offspring 
from mothers fed protein restricted diets for all or part of pregnancy.  Glucocorticoids 
(cortisol/corticosterone) are steroid hormones synthesised in the zona fasciculata region 
(mid zone) of the adrenal cortex (Funder, 1996).  They are released into the blood stream 
in response to adreno-corticotrophic hormone (ACTH) secretion from the anterior 
pituitary gland, in turn stimulated by corticosteroid-releasing hormone (CRH) release 
from the hypothalamus.  Hypothalamic CRH is secreted in response to hippocampal 
signals or pituitary/adrenal feedback messages.  Hence, glucocorticoid release is under 
the control of the Hypothalamic-Pituitary-Adrenal stress axis.  The majority of circulating 
glucocorticoid is bound by corticosteroid-binding-globulin leaving only 10% free to enter 
cells and interact with glucocorticoid receptors (Bertram and Hanson, 2002).  Being 
lipohilic substances, steroids are able to diffuse readily across cell membranes 
(Bamberger et al., 1996). 1.4.1 Glucocorticoids and development
Glucocorticoids affect both fetal and adult tissues and have a variety of key physiological 
roles including the regulation of salt and water homeostasis, blood pressure, 
immunological responses and metabolism (Bertram and Hanson, 2002).  Glucocorticoids 
also have a key role in mediating anti-inflammatory effects, as evidenced by the 
therapeutic use of inhaled glucocorticoids in the treatment of asthma (Barnes and 
Adcock, 1998).
1.4.1.1 Fetal organ maturation
Glucocorticoids exert their maximal effect on mammalian fetal organs, specifically the 
heart, liver and lung, immediately prior to birth (Thompson et al., 2004).  Perinatally, 
glucocorticoids promote maturational changes to fetal organ systems critical for 
immediate post-natal survival.  For example, glucocorticoids are able to induce catabolic 
enzymes in the developing fetal liver such as PEPCK, which are key to survival in early 
post-natal life; glycogen accumulates in the liver and gluconeogenesis is stimulated by 
glucocorticoids in order to meet glucose demands until feeding begins.  The structural 
and functional maturation of the developing lungs is also regulated perinatally by 
glucocorticoids which enable them to cope when air enters the alveoli with the first 
breath (Liggins, 1994).  Severe abnormalities are evident in offspring of targeted 
glucorticoid receptor (GR) gene disruptions; GR-/- mice die within a few hours of birth 
due to respiratory failure, and newborn liver has a reduced capacity to activate genes for key gluconeogenesis enzymes, further supporting the role for glucocorticoids in 
stimulating maturational events perinatally (Cole et al., 1995).
Liggins and Howe (Liggins and Howie, 1972) first provided an important indication that 
glucocorticoids might serve a vital function in mediating the successful transition of the 
term fetus to extra-uterine existence which led to the widespread use of prenatal 
glucocorticoid therapy to prevent life threatening complications of pre-term birth. 
Indeed, the clinical administration of the synthetic, poorly-metabolised glucocorticoid, 
dexamethasone, to women in pre-term labour is widely used as a means to promote fetal 
lung maturation and hence reduce the chances of respiratory distress syndrome occurring 
(Langley-Evans, 2001).  However, fetal exposure to synthetic glucocorticoids in utero 
has been linked to longer term health risks.
1.4.1.2 Fetal growth
During normal mammalian fetal development, circulating glucocorticoid concentrations 
are considerably lower in the fetal compartment in comparison to the maternal system.  In 
many species there is a natural surge in fetal plasma glucocorticoid concentration in late 
gestation associated with the maturation of the fetal adrenal (Arishima et al., 1977).  As 
the rate of fetal growth naturally decreases towards term, this has been linked to 
increased fetal plasma cortisol occurring at this time.  This is supported by the 
observation that fetal adrenalectomy results in increased body weight in the final week of 
gestation (Bertram and Hanson, 2002).  High levels of maternal glucocorticoid therapy during pregnancy has confirmed the 
growth-retarding influence of glucocorticoid exposure on the developing fetus in both 
primates and rodents alike; effects include intra-uterine growth restriction, as evidenced 
by reduced birth weight of the fetuses of treated mothers, and disproportionate fetal organ 
growth (Reinisch et al., 1978; Novy and Walsh, 1983).  This effect has been further 
documented by Ikegami et al who found that multiple fetal glucocorticoid exposure 
during the final third of gestation to preterm lambs improved post-natal lung function, but 
had a detrimental effect on birth weight and postnatal growth (Ikegami et al., 1997).
In contrast to insulin and the thyroid hormones, glucocorticoids affect the expression of 
both the Igf genes (Fowden, Li and Forhead, 1998).  In many species, both Igf1 and Igf2 
are expressed in fetal tissues from the earliest stage of pre-implantation development to 
the final stage of tissue maturation just prior to birth (Watson et al., 1994; Fowden, Li 
and Forhead, 1998).  In rodents and humans, during mid to late gestation the Igf2 gene is 
widespread in fetal tissues and is expressed more abundantly than Igf1 (Hill, 1990; 
Delhanty and Han, 1993).  However, after birth in rodents there is a fall in IGF-II 
(protein) expression such that by weaning its expression has disappeared from most 
tissues (Lee, Lintar and Efstratiadis, 1990).  In contrast, tissue expression and plasma 
levels of the IGF-I protein are low in utero compared to post-natal levels (Singh, Rall and 
Styne, 1991).  Such findings have given rise to the concept that that IGF-II is the IGF 
protein primarily responsible for fetal growth (Gluckman, 1995; Jones and Clemmons, 
1995).In mice, deletion of either the Igf1 or Igf2 gene or the Igf1r (receptor) gene leads to 
retardations in fetal growth, shown by reduction in fetus weights in late gestation 
(Efstratiadis, 1998) whereas over-expression of IGF-II leads to fetal overgrowth 
(Eggenschwiler et al., 1997).  
Both Igf genes have a specific role to play in fetal growth but their expression and 
specific actions are different (Fowden, 2003).  Whilst Igf1 gene expression is low in the 
fetus, it appears to have a more prominent role than IGF-II in modulating cell 
proliferation in relation to the nutritional climate in utero (Fowden, 2003).  Alternatively, 
the Igf2 gene is highly expressed in utero and has a key role in nutrient transfer across the 
placenta and placental growth.  Whilst it is relatively unresponsive to nutritional stimuli it 
does respond to changes in the fetal glucorticoid concentration in specific fetal tissues 
(Fowden, 2003).
1.4.1.3 Fetal cardiovascular control
Glucocorticoids increase blood pressure in fetal and adult animals.  Activation of the fetal 
Renin-Angiotensin System (RAS) may be one mechanism by which cortisol induces 
hypertension in utero (Forhead et al., 2000; Langley-Evans, 1997c) (Figure 1.14).  The 
pre-partum cortisol surge mentioned earlier coincides with an increase in fetal blood 
pressure and is associated with a number of maturational changes in the activity of the 
fetal RAS in several species.  In fetal sheep, the rise in blood pressure caused by an 
intravenous infusion of cortisol has been associated with increased vascular sensitivity to 
exogenous angiotensin II (Tangalakis et al., 1992) as well as increased circulating concentrations of angiotensin II, renin and angiotensinogen (Forhead et al., 2000). 
Glucocorticoid exposure in utero may act to induce organisational changes in the activity 
of the RAS which persist after birth into adult life and programme hypertension (Forhead 
et al., 2000).  Indeed, it appears that components of RAS may be permanently influenced 
by the intra-uterine environment as indicated by the hypertension seen in adult offspring 
of rats fed low protein diet during pregnancy which was accompanied by increased 
plasma and pulmonary ACE concentrations (Langley and Jackson, 1994; Langley-Evans 
and Jackson, 1995).
Figure 1.14: The Renin-Angiotensin System (RAS) plays an important role in the 
regulation of the physiological responses of the cardiovascular system.  The 
hormone Angiotensin II (AII) is the primary effector molecule of this system.  AII is 
formed by enzymatic cleavage of the circulating precursor Angiotensinogen to Angiotensin I (AI) by the protease Renin with subsequent conversion of AI to AII by 
Angiotensin Converting Enzyme (ACE) as blood passes through the lungs.  AII has 
several important functions which culminate in raised arterial blood pressure. 
Schematic taken from: http://www.cvphysiology.com/ 
In view of the deleterious consequences described of both absence and excess 
glucocorticoid during fetal life, maintaining fetal exposure to glucocorticoids at 
appropriate levels is critical for normal embryonic development.  Clearly, the tight 
control of glucocorticoid action within fetal tissues by its receptor (GR) and by enzymic 
glucocorticoid metabolism is likely to play an imperative role in prenatal development.  
1.4.2 Glucocorticoid receptor (GR) structure
The GR is an intracellular steroid hormone receptor belonging to the super-family of 
nuclear hormone receptors (Mangelsdorf et al., 1995; Funder, 1996).  These receptors are 
capable of interacting with target gene promoters upon cognate ligand binding, so they 
are also referred to as ligand-dependent transcription factors (Mangelsdorf et al., 1995).
Two phenotypically distinct isoforms of GR have been identified in humans: GRa, (the 
predominant physiological isoform) and GRβ (Hollenberg et al., 1985) of molecular 
weight 94 kDa and 90 kDa, respectively (Oakley et al., 1996).  In the rodent, GR cDNAs 
that have been identified are homologues of the GRa isoform (Danielsen et al., 1986).  Each GR isoform in the human is encoded by nine exons, of which the first eight are 
identical and the ninth heterologous.  Exon 1 encodes the 5’ un-translated sequence, the 
amino terminal sequence is found in exon 2, DNA binding domains are encoded by exons 
3 and 4, and the cortisol-binding domain is formed from 5-9 exons (Encio and Detera-
Wadleigh, 1991) (Figure 1.15).
Figure 1.15: Structures of the human GR-a and β genes and proteins.  Functional 
sub-domains of the a-isoform are stated beneath the diagram; functional sub-
domains of the β-isoform are largely undefined (Bamberger et al., 1996).
All members of the nuclear hormone receptor super-family are organised into three 
structurally and functionally defined domains.  Specifically, the GRa isoform has an N- 
terminal domain which is concerned with activation of target genes, a central DNA-
binding domain involved in interactions with DNA sequences of target genes and a C-terminal domain for ligand (glucocorticoid) binding (Oakley et al., 1996).  The C-
terminal domain is more complex, as it is also involved in heat shock protein binding 
(Dalman et al., 1991), nuclear translocation (Picard and Yamamoto, 1987), receptor 
dimerization (Dahlman-Wright et al., 1992) and trans-activation (Hollenberg and Evans, 
1988).  
Sequence analysis reveals that the GRa and β polypeptides in humans are 777 and 742 
amino acids in length, respectively.  The first 727 amino acids are identical in either 
isoform; the distinction only comes at the C-terminus with the substitution of the last 50 
amino acids of GRa with a non-homologous 15 amino acid sequence in the case of GRβ 
(Hollenberg et al., 1985) (Figure 1.15).  The two isoforms of the human GR are generated 
from the same gene by alternative splicing of the human GR primary transcript (Encio 
and Detera-Wadleigh, 1991; Oakley et al., 1996).  The heterologous region of the 
carboxy terminal residues and the 3’ untranslated regions of the two human GR isoforms 
are encoded separately by two different ninth exons: 9a and 9β (Encio and Detera-
Wadleigh, 1991).  The unique C-terminal end of human GRβ alters several key 
biochemical properties of this isoform which functionally distinguish it from the GRa 
isoform (Oakley et al., 1996).  For instance, the steroid binding properties characteristic 
of GRa are absent in GRβ (Hollenberg et al., 1985; Bamberger et al., 1995).  
In the absence of glucocorticoid, GRa is located predominantly in the cytoplasm of cells 
as part of a multi-protein complex (Oakley et al., 1996).  The complex consists of the 
receptor, two molecules of hsp90 and one molecule each of hsp70 and hsp56, its main function being to retain the receptor protein in a silent yet responsive state (Pratt, 1993) 
(Figure 1.16).
In contrast to GRa, GRβ in human cells is localised primarily in the nucleus, independent 
of the presence of glucocorticoid hormone (Oakley et al., 1996).  However, as GR 
cDNAs that have been described in rodents are homologues of the human GRa isoform 
(Danielsen et al., 1986), only this isoform will be discussed further now.
1.4.3 Mechanism of action of GRa
Cognate hormone binding induces a conformational change in GRa which leads to 
dissociation from the heat shock complex and concomitant hyper-phosporylation of GR. 
Nuclear localisation signals within the C-terminal domain are unmasked and receptor 
molecules, with glucocorticoid bound, translocate to the nucleus (Bamberger et al., 
1996).  Two alternative mechanisms have been presented to describe the mechanism of 
hormone-activated GRa action within the nucleus (Figure 1.16).    Type 1 mechanism:                     Type 2 mechanism:
Figure 1.16: Model of GRa-mediated transcriptional modulation.  The type 1 
mechanism involves GRa homo-dimers binding to regulatory regions of target 
genes and usually results in stimulation of target gene transcription, although 
inhibition of transcription may occur (less frequently) by this mechanism.
The type 2 mechanism most frequently results in inhibition of transcription and 
involves interactions between a GRa monomer and other transcription factors 
(Bamberger et al., 1996).
Key to Figure 1.15: GC = Glucocorticoid; GRE = Glucocorticoid response element; 
      AP-1 = Activating Protein-1
Type 1 mechanism: (Figure 1.16, left hand side).
The first mechanism is the classic model of GRa action and refers to homo-dimerisation 
of activated GRa molecules which enables binding of glucocorticoid responsive 
elements, (GREs).  These are specific palindromically arranged DNA sequence motifs in the promoter regions of glucocorticoid target genes within the nucleus.  Once bound to 
the GRE, the GRa homo-dimer interacts with the basal transcription machinery directly 
or via ‘bridging molecules’ to enhance transcription by RNA polymerase II. 
Occasionally, binding of negative GREs by three active GRa molecules causes inhibition 
as opposed to enhancement of transcription by this mechanism (Bamberger et al., 1996). 
Thus, binding of GREs by this receptor isoform can enhance or repress transcription of 
the linked gene (Oakley et al., 1996). 
Type 2 mechanism: (Figure 1.16, right hand side)
As an alternative to GRE binding, the second mechanism by which GRa may mediate 
glucocorticoid action is via interaction with other transcription factors.  As the repression 
of immune genes has an important part to play in the anti-inflammatory/immuno 
-suppressive role of glucocorticoids, GRa-mediated inhibition of transcription factors for 
the transcription of such target genes is of physiological significance.  For example, AP-1 
is a transcription factor composed of heterodimers of Jun and Fos protein which 
positively regulates immune gene expression by binding to AP-1 sites within the 
promoter regions of such genes.  Active GRa monomers act to inhibit the transcription of 
such genes by binding Fos and Jun proteins.  In this way, GRa acts as a negative 
regulator of the AP-1-mediated expression of immune genes, in the absence of any direct 
DNA binding at the AP-1 site (Figure 1.16).  Similar patterns of GRa-mediated gene 
repression have been shown for other transcription factors, Nuclear Factor-kB, for 
instance which is also involved in activating many immune system genes (Bamberger et 
al., 1996).1.4.4 Mineralocorticoids and the mineralocorticoid receptor
In addition to glucocorticoids, the adrenal cortex also produces the mineralocorticoid 
corticosteroid, aldosterone, but from the outer zona glomerulosa region of the adrenal 
cortex (Funder, 1996).  However, aldosterone is secreted in much lower quantities than 
the glucocorticoid; glucocorticoid circulates at concentrations of 100-1000 times higher 
than aldosterone (Rusvai and Naray-Fejes-Toth, 1993).  Mineralocorticoid receptors 
(MR) belong to the same subfamily of receptors as the glucocorticoid receptors (Funder, 
1996).  MRs are characteristically non-selective receptors; human renal MR in vitro binds 
cortisol and aldosterone with equal affinities (Arriza et al., 1987).  
MRs are expressed in a wide variety of tissues which include both classic 
mineralocorticoid target tissues such as the kidney, parotid and colon, as well as other 
tissues such as the hippocampus and heart (Krozowski and Funder, 1983).  In 
mineralocorticoid target tissues, aldosterone is involved in the regulation of plasma salt-
water balance, ultimately leading to sodium retention and blood pressure homeostasis 
(Funder, 1996).  (See aldosterone mode of action in top section of Figure 1.17).    Cytosol             Nucleus
Figure 1.17: Model of mineralocorticoid receptor activation by aldosterone in a 
mineralocorticoid-target cell (Funder, 1996) [Key: HRE = Hormone response element] 
Although corticosterone (cortisol) and aldosterone are similarly bound in the 
hippocampus and the heart in vivo, the classical mineralocorticoid target tissues are 
selective for aldosterone only, and show negligible corticosterone binding (Sheppard and 
Funder, 1987).  In view of this, it was hypothesised that endogenous glucocorticoids, but 
not aldosterone, are inactivated by the enzyme 11 beta dehydrogenase (11β 
hydroxysteroid dehydrogenase type 2) in mineralocorticoid target cells which prevents 
glucocorticoids from acting as mineralocorticoids and binding the MR, thus allowing 
selective mineralocorticoid action (Funder et al., 1988; Edwards et al., 1988), (Figure 
1.17 - lower section).1.4.5 Enzymatic modulation of glucocorticoid action
11-beta hydroxysteroid dehydrogenase (11β HSD) is a microsomal enzyme complex 
associated with endoplasmic reticulum responsible for catalysing the inter-conversion of 
active cortisol and biologically inactive cortisone (Mahesh and Ulrich, 1960).  Hence, the 
11β HSD family of enzymes play a critical role in controlling local tissue concentrations 
of glucocorticoids (Edwards et al., 1996) and glucocorticoid exposure to the GR (Draper 
and Stewart, 2005).  The enzyme complex is composed of two distinct components, one 
of which catalyses oxidation (the 11β-dehydrogenase) and the other responsible for 
reduction (the 11-oxoreductase) (Lakshmi and Monder, 1985a).
11β HSD type 1 (34 kDa) (Monder and Lakshmi, 1990) predominantly catalyses the 
reduction of cortisone to cortisol (Edwards et al., 1996; Funder, 1996) and is largely 
dependent on binding the co-factor NADP for its activity (Rusvai and Naray-Fejes-Toth, 
1993).  11β HSD type 2 (40 kDa) (Gomez-Sanchez et al., 2001) exclusively catalyses the 
oxidation of cortisol to cortisone (Edwards et al., 1996) and depends almost totally on 
binding co-factor NAD which acts as a hydrogen acceptor (Rusvai and Naray-Fejes-Toth, 
1993) (Figure 1.18).Figure 1.18: Enzymatic actions of 11β hydroxysteroid dehydrogenase on the 
substrates to which it binds (Draper and Stewart, 2005).  Both 11β HSD type-1 and -2 
are glycosylated membrane proteins present in endoplasmic reticulum.
The proportions of the different enzyme components present vary between different 
tissues; in the rat, the liver is the major site of action of 11β HSD type 1 and hence in this 
tissue reduction usually exceeds oxidation (Lakshmi and Monder, 1985b); other tissues 
where this isozyme regenerates cortisol include adipose tissue, the central nervous system 
and the lung (Seckl, 2004).  In adipose tissue the 11β HSD type 1 activity gives rise to 
elevated levels of active intracellular glucocorticoid which alters a number of target 
genes, including leptin (Seckl, 2004).1.4.6 Regulation of glucocorticoid exposure to the GR: a role for reductace (11β 
HSD type 1) activity in glucocorticoid target tissues
Expression of 11β HSD type 1 more closely parallels that of the GR than that of the MR, 
to regulate exposure of cortisol to the GRs (Ricketts et al., 1998).  So, in glucocorticoid 
target tissues, 11β HSD type 1 is highly expressed and facilitates glucocorticoid exposure 
to the GR.  Mouse 11β HSD type 1 knockout studies have highlighted the importance of 
hepatic 11β HSD type 1 in activating gluconeogenic enzymes and regulating hepatic 
glucose output (Draper and Stewart, 2005).  Glucocorticoids stimulate gluconeogenesis 
while phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phophatase catalyse 
the key steps involved.  Upon starvation, these enzymes usually are induced by 
glucocorticoids, but in 11β HSD type 1 knockout mice there is a failure to initiate 
induction of these enzymes.  Conversely, in fed mice liver glycogen accumulates due to a 
lack of glucocorticoid-induced glycogenolysis, thus such mice are able to resist the 
hyperglycaemia found in obese wild types (Kotelevtsev et al., 1997).  In the rat kidney 
the predominant enzymatic conversion is in the opposite direction to the liver, i.e. in 
favour of oxidation (Mahesh and Ulrich, 1960; Edwards et al., 1996).
1.4.7 Protection of MR from glucocorticoids in mineralocorticoid target cells: a role 
for 11β dehydrogenase (11β HSD type 2) activity
The activity of the 11β dehydrogenase component of the 11β HSD enzyme complex is 
shown for homogenates of renal cortex, parotid, hippocampus and heart in Figure 1.19. The highest activity was evident in the kidney with lower levels also apparent in the 
parotid.  In contrast, in the hippocampus and heart, the enzyme activity was minimal or 
absent (Edwards et al., 1988; Funder et al., 1988).
Figure 1.19: Activity of the 11 beta dehydrogenase component of the 11β 
hydroxysteroid dehydrogenase enzyme in rat renal cortex, parotid, hippocampus 
and heart (Edwards et al., 1988).  Note: corticosterone is the rodent equivalent of 
cortisol in humans, and 11-dehydro-corticosterone is equivalent to cortisone.
These results are interesting because the kidney and parotid which showed significant 
11β HSD activity are two major aldosterone-selective tissues.  Furthermore, other organs 
which contain aldosterone receptors but are not aldosterone selective, such as the 
hippocampus and heart, show minimal levels of 11β HSD activity (Edwards et al., 1988).
Corticosterone, (the rodent equivalent of cortisol in humans) is effectively excluded from 
the MR to prevent inappropriate activation of MR in mineralocorticoid target tissues by the dehydrogenase activity of 11β HSD.  The inert product of the reaction does not bind 
MR to any significant extent; it has only ~0.3% of the binding affinity of corticosterone 
(Funder et al., 1988).  The role of this dehydrogenase enzyme in conferring selectivity in 
aldosterone target tissues is indicated by the use of carbenoxolone in vivo which inhibits 
its activity.  In the presence of carbenoxolone, the level of corticosterone binding to MR 
markedly increases and approaches (colon) or equals (kidney and parotid) that of 
aldosterone in mineralocorticoid target tissues (Funder et al., 1988).  Likewise, other 
studies have shown a similar loss of aldosterone selectivity in tissues such as the kidney 
upon inhibition of the dehydrogenase component of 11β HSD (i.e. 11β HSD type 2) 
(Edwards et al., 1988).  In keeping with these observations, congenital deficiency of this 
dehydrogenase activity is clinically associated with the “Syndrome of Apparent 
Mineralocorticoid Excess,” (SAME) characterised by severe hypertension, hypokalaemia 
(abnormally low plasma potassium) and sodium retention (Edwards et al., 1988) in adult 
patients (Ulick et al., 1979; Stewart et al., 1988).  Symptoms of mineralocorticoid excess 
have also been reproduced experimentally in rodents; rats showed an increase in blood 
pressure, hypokalaemia and decreased plasma protein levels, but sodium levels were 
unaffected (Campion et al., 1998).1.4.8 Protection of the fetus in utero from maternal glucocorticoid: a role for 11β 
dehydrogenase (11β HSD type 2) activity in the placenta
The separation of the fetal circulation from glucocorticoids of maternal origin is crucial 
for the normal development of the fetal hypothalamic-pituitary-adrenal axis, and also 
ensures that the correct pattern of gene expression is followed (Chatelain et al., 1980).
Normally, the fetus is protected from the higher levels of physiological glucocorticoids 
(cortisol in humans; corticosterone in rats) in the mother by placental 11β HSD which 
rapidly metabolises these to inert products (Seckl and Brown, 1994).  Hence, the enzyme 
acts as a gatekeeper to prevent glucocorticoids from the maternal circulation from 
flooding the fetal system (Langley-Evans, 2001).
1.4.9 Erroneous glucocorticoid exposure to the fetus
It is hypothesised that: ‘abnormally low placental 11β-dehydrogenase activity, by 
increasing fetal exposure to maternal glucocorticoids, leads to intrauterine growth 
retardation and high blood pressure in adulthood’ (Edwards et al., 1993).  This hypothesis 
is supported, in part, by the finding that in rats after a normal pregnancy, there is a strong 
positive correlation between placental 11β-dehydrogenase activity at term and fetal 
weight at term (Benediktsson et al., 1993) (Figure 1.20). % conversion of 
3H-corticosterone to 
3H-11-dehydrocorticosterone
Figure 1.20: Correlation between fetal weights at term with placental 
dehydrogenase activity (Benediktsson et al., 1993).
Excess levels of glucocorticoid may also have implications for the developing fetus in 
terms of a disruption to the useful roles played by normal levels of glucocorticoid, e.g. in 
fetal liver where glucocorticoids usually control gluconeogenesis and hepatic glucose 
output.
1.4.10 Pharmacological manipulation of fetal exposure to glucocorticoid
Pharmacological manipulation studies in rats of fetal exposure to glucocorticoid offer 
further support for the hypothesis of Edwards et al (1993) that excess exposure of the 
fetus to maternal glucocorticoids may be the link between low birth weight and 
subsequent hypertension in humans, and also indicate a key role for placental 11β HSD in controlling such fetal exposure (Lindsay et al., 1996).  Analogous to the maternal low 
protein model, the treatment of pregnant control-fed rats with a low dose of the synthetic 
glucocorticoid dexamethasone (-a poor substrate for 11β HSD type 2 which crosses the 
placenta freely), throughout pregnancy results in a decrease in offspring birth-weight. 
Furthermore, the maternal dexamethasone treatment significantly increases systolic blood 
pressure in male and female offspring when reaching adulthood (Benediktsson et al., 
1993).  Similarly, maternal carbenoxylone (an inhibitor of 11β HSD type 2) treatment 
throughout pregnancy leads to reduced birth weight (20% mean decrease) and elevated 
blood pressures in male and female adult offspring of carbenoxolone-treated rats 
(Lindsay et al., 1996).  Notably, this effect requires the presence of maternal adrenal 
products, as carbenoxolone treatment given to adrenalectomised mothers had no effect on 
offspring birth weight or blood pressure, thus supporting a role for maternal 
glucocorticoid in this system in mediating the observed offspring effects.  Hence, further 
to the work of Benediktsson et al, 1993 described previously, these results show that in 
the rat model, endogenous maternal glucocorticoids may exert similar effects to synthetic 
glucocorticoids, once the placental enzymic barrier is inhibited (Lindsay et al., 1996).
1.4.11 Nutritional modulation of fetal corticosteroid exposure may underlie the 
programming effects of low protein diets in utero
In rats, near term activity of the placental isoform of 11β HSD was lowered by 33% by 
the maternal low protein diet.  This was not part of an overall attenuation of placental 
function, as activity of other (steroid insensitive) placental enzymes was unaltered by the diet manipulation (Langley-Evans et al., 1996a).  Similarly, placental 11β HSD type 2 
mRNA content has been shown to be decreased in the placentas of rats fed a low protein 
diet throughout pregnancy (Bertram et al., 2001).  Moreover, placental activity of the 
glucocorticoid-inducible enzyme glutamine synthase (GSase) was elevated by 27% in 
rats exposed to the maternal low protein diet in utero which may reflect increased 
glucocorticoid action within the placenta as a consequence of impaired inactivation by 
placental 11β HSD (Langley-Evans et al., 1996a).  The molecular mechanisms through 
which dietary protein restriction selectively lowers placental 11β HSD activity and 
dampens its expression remain to be elucidated.  However, it is possible that an 
epigenetic mechanism may provide an explanation for this link (see section 1.4.12).  If 
indeed epigenetic changes do mediate a link between the low protein diet and the 
expression/activity of this enzyme component, in theory other dietary interventions may 
also mediate its expression i.e. this phenomenon may not be exclusive to dietary protein 
restriction; exposure to high fat diets or global under-nutrition may also produce 
epigenetic alterations in the 11β HSD type 2 gene specific to the dietary intervention. 
Indeed in sheep, placental 11β HSD type 2 mRNA is lowered in mid-gestation placenta 
following global maternal nutrient restriction during early-mid gestation (Whorwood et 
al., 2001). 
Placental deficiency of 11β HSD may be a common mechanism whereby the maternal 
environment (i.e. dietary protein nutrition) alters feto-placental development, and 
programmes hypertension (Langley-Evans et al., 1996a).  Hence, a role for maternal 
glucocorticoids in mediating the effects of maternal low protein diet is implied.  In view of the documented effects of dexamethasone (Benediktsson et al., 1993) and 
carbenoxolone (Lindsay et al., 1996) exposure to fetuses in utero on subsequent blood 
pressure, it is likely that the decrease in placental 11β HSD in low protein diet fed rats 
leads to over-exposure of their fetuses to maternal glucocorticoid hormone action 
(Langley-Evans et al., 1996a) (Figure 1.21).
                             
Figure 1.21: Model of a possible mechanism linking maternal low protein diet to 
hypertension in offspring.  Placental 11β HSD activity normally protects the fetus 
from the programming effects of maternal glucocorticoids, but this barrier is 
susceptible to modulation by nutritional factors (Langley-Evans et al., 1996b).
Interestingly, the treatment of pregnant rats fed a protein-replete control diet throughout 
gestation with carbenoxolone reduced birth-weight and induced hypertension in their 
offspring in a manner equivalent to that observed in the offspring from mothers fed a low protein diet throughout pregnancy (Langley-Evans, 1997b).  The offspring of the protein-
replete animals were exposed to increased levels of endogenous corticosterone, through 
carbenoxolone inhibition of 11β HSD type 2.  Both protein under-nutrition and 
carbenoxolone treatment in pregnancy produced effects on fetal growth, later blood 
pressure and body proportions of the fetus (Langley-Evans, 1997b).  This further 
indicates that the low protein diet may initiate pathways leading to increased exposure to 
endogenous glucocorticoid, analogous to carbenoxolone by causing a down regulation of 
placental 11β HSD activity.   
Metyrapone is an inhibitor of maternal glucocorticoid synthesis and effectively 
pharmacologically adrenalectomises treated animals.  To assess the role of 
glucocorticoids in programming the hypertensive state in offspring from low protein diet 
fed mothers, metyrapone was administered for the first 14 days of pregnancy to dams 
consuming either low protein diet or control diet throughout gestation.  The metyrapone 
treatment of pregnant rats fed low protein diet resulted in offspring at 8 weeks which did 
not develop raised blood pressure, whereas offspring from dams who received a low 
protein diet but no metyrapone exhibited the classical hypertensive state.  Thus, the 
metyrapone treatment during the first 2 weeks of pregnancy had long term programming 
effects on alleviating the maternal-diet induced hypertension in the offspring.  Hence, it 
appears that in the low-protein diet exposed rat fetuses, maternal corticosterone synthesis 
is a pre-requisite for the initiation of the hypersensitive state.  However, this dietary effect 
was not reflected in maternal corticosterone concentrations (Langley-Evans et al., 
1996b).  In a follow up study, corticosterone administration to metyrapone-treated pregnant rats fed the low protein diet restored the hypertensive effect of the diet 
(Langley-Evans, 1997a).  Hence, nutritionally-induced hypertension depends on maternal 
glucocorticoid production and again it appears to be mediated through increased access of 
maternal glucocorticoids to fetal tissues, via the placenta (Langley-Evans, 2001). 
Nevertheless, the precise molecular mechanisms through which maternal dietary protein 
restriction selectively alters placental 11β HSD activity remain to be determined. 
Although the feeding of low protein diets to pregnant rats may result in an over-exposure 
of the fetuses to the programming effects of maternal corticosteroids, the programming of 
later disease states is unlikely to depend on glucocorticoids alone (Langley-Evans et al., 
1996a).
1.4.12 Epigenetic regulation of transcription
It is possible that the molecular mechanism linking maternal low protein diet and 
decreased placental 11β HSD expression might involve epigenetics.  The presence of 
CpG islands along the 11β HSD type 2 gene suggests that it might be regulated in part via 
CpG methylation.  In general, hyper-methylation of normally unmethylated CpG islands 
correlates with transcriptional repression (Alikhani-Koopaei et al., 2004).  DNA 
methylation of the gene encoding 11β HSD type 2 in the placenta would provide a means 
through which a compromised protein diet might down regulate placental expression of 
the enzyme.  Studies in the rat, on the DNA methylation status of the hepatic GR gene in post weaning 
offspring of mothers fed a low protein diet throughout pregnancy have shown that the 
methylation status of the GR promoter, GR exon 1 10 was between 23% to 33% lower in 
these offspring relative to controls, and that the level of mRNA expression of GR was 
greatly increased relative to controls (Lillycrop et al., 2005; Lillycrop et al., 2007).  Such 
findings indicate that the GR gene transcription is increased in response to maternal 
protein restriction and thus suggest a mechanism by which insults in early life might lead 
to persistent changes to offspring phenotype.  Interestingly, it appears that the alterations 
in hepatic GR expression in the F1 offspring persist, and are passed onto the next 
generation in the absence of any further dietary protein restriction (F1 females received a 
control diet throughout their subsequent pregnancies).  These data indicate that alteration 
in the methylation status of the GR gene promoter induced in the F1 generation by 
maternal protein restriction throughout pregnancy is transmitted to the F2 generation 
(Burdge et al., 2007).  Further studies in the rat investigating how the altered epigenetic 
regulation of the hepatic GR promoter is induced in offspring of the protein-restricted 
mothers have found that DNA methyltransferase-1 (Dnmt1) transcript expression was 
lower in offspring from mothers fed a protein restricted diet throughout pregnancy.  Thus, 
hypomethylation of the GR promoter may result from a reduced capacity to methylate 
hemimethylayted DNA during meiosis.  Furthermore, histone modifications that facilitate 
transcription were increased at the GR promoter, and those that suppress methylation 
were decreased.  This suggests that induction of altered epigenetic regulation of the 
hepatic GR promoter in the offspring may be attributed to reduced Dnmt1 expression 
(Lillycrop et al., 2007). 1.5 Main project objective
The overall aim of this investigation is to assess the impact of a relatively mild maternal 
dietary protein restriction in the mouse, imposed either throughout pregnancy or during 
the pre-implantation period only, on the subsequent development of the fetus.  
The aim of the project will be met by studying the responses of the fetus to the maternal 
dietary challenge using three broadly different approaches.  The response of the fetal liver 
to the maternal dietary challenge will be examined close to the end of gestation (at day 
17) in terms of its global gene expression profile with the use of Affymetrix micro-array 
technology.  In this way target genes of interest may be pinpointed as possible candidates 
for further study.  The level of hepatic protein expression will also be examined at this 
stage by immunoblotting and densitometry of specific proteins thought to be involved in 
subsequent programming of growth and development.  Finally, the growth phenotype of 
the conceptus and fetus and component tissues will be analysed at gestational day 17 after 
transfer at day 3.5 of embryos from 9% casein fed mothers to 18% casein fed fosters 
using embryo transfer surgery.1.6 Rationale and relevance to human nutrition
Due to widespread vegetarianism in the developed world the low protein model is 
relevant to human nutrition.  Those who opt for a vegetarian or vegan diet must take extra 
care to ensure that a proper nutrient balance is supplied by their diet.  In particular, the 
diet must contain enough protein, with the correct balance of amino acids to ensure that 
sufficient human protein can be formed following digestion and absorption.  This is 
particularly important during pregnancy, especially as it may not be obvious to the 
pregnant individual that her diet is lacking in total protein or indeed specific amino acids. 
Studies have shown that amino acids have a key role in fetal growth; there appears to be a 
large amino acid deficiency in utero in growth retarded babies (Cetin et al., 1988). 
Amino acids are also the major factors controlling pancreatic Beta-cell growth and 
development in the fetus and insulin section until late in fetal life (De Gasparo et al., 
1978; Snoeck et al., 1990).  As the development of Beta cells usually proceeds rapidly 
during fetal life (Hellerstrom et al., 1988) it is possible to see how it could be vulnerable 
to sub standard nutrition (Hales and Barker, 1992).
Poor early development of pancreatic islets of Langerhans and Beta cells has been 
associated with the aetiology of Type 2 diabetes (Hales and Barker, 1992); thus it is 
possible to visualise links between maternal low protein diets and such metabolic 
disorders.  However, this is not to say that other nutritional defects are excluded from 
contributing to the onset of these metabolic disorders.Chapter 2
       
       Generic Materials and Methods
2.1 Experimental design
Adult MF1 strain female mice between 7 and 8.5 weeks of age were used in this study 
(mice usually reach sexual maturity from 6 weeks of age).  Females were weighed prior 
to mating and those falling within the weight range of 27-33 g were selected.  This was to 
ensure a constant body size/uterus size of the mother to avoid introducing variation into 
uterine environment.  Mothers were also weighed on day of plug, at 3.5 days gestation 
and on day of cull (17 days gestation) to ensure no weight loss occurred during 
pregnancy.
The mouse is a useful model in which to study developmental biology as mice have a 
short gestation period, reach maturity quickly and have a high fertility rate.  Furthermore, 
the mouse and human genomes each seem to contain about 30,000 protein-
coding genes and the proportion of mouse genes with a single identifiable 
orthologue in the human genome is high, approximately 80% (Waterston et al., 
2002).  Finally, as the mouse is also an established transgenic model it is 
possible to follow up genomics studies and analyze specific gene functions in 
programming using transgenic technology.Three dietary treatment groups were used in this study (Figure 2.1): the 18% casein diet 
is a control diet which provides a sufficient amount of protein to a pregnant mouse; the 
9% casein diet provides half the amount of protein as the control diet as may thus be 
referred to as a low protein diet; the switch diet uses both types of diets and comprises the 
9% casein diet for the first 3.5 days of pregnancy (i.e. during the murine pre-implantation 
period) and then the 18% casein diet for the remainder of pregnancy until cull 
(gestational day 17).
Figure     2.1    : Maternal dietary treatment groups administered from day of plug
Key: <3.5 days (approx.) = during pre-implantation embryo development.
9% casein (low protein) diet 
9% 
casein
18% protein (control) diet
18% casein
Day 17 Plug (day 0) Day 20/21 
(Term)
Day 3.5
Murine Gestation Period
Switch 
dietThe allocation of mice to diet groups was rotated evenly to ensure that no single diet 
treatment is assigned all at one time.  This minimises the chance that changes in 
environment over time might confound the results and cause false differences between 
diet groups.
2.2 Animal treatments
All animal experiments were conducted under Licence from the UK Home Office.
Out-bred MF1 mice bred at Southampton University Biomedical Facility were used in 
this study.  Mice were maintained under constant conditions of 24
oC under a controlled 
light-dark cycle (lights on 0700 hours, lights off 1900 hours).
Female mice were fed a standard chow diet and tap water ad libitum and housed in 
groups of up to 12 from time of weaning at 3-4 weeks until 7 weeks of age when 
experimental procedures commenced.  Virgin MF1 females were naturally mated 
overnight with individually housed male MF1 mice and mating was defined by the 
presence of a vaginal plug (coagulated proteins from the male seminal fluid) the 
following morning.  Plug-positive females were then housed individually and randomly 
assigned to synthetic diets; diets were either prepared in-house or bought in ready made 
(Lillico, UK).  Diet composition in either case was as outlined in Table 2.1.  All 
experimental data for the Genomics Analysis (Chapter 4), Protein Analysis 
(Chapter 5) and Embryo Transfer studies (Chapter 6) was collected using mice that 
were fed the bought in diets only.  Mice were fed diet ad libitum until day 17 of pregnancy with free access to tap water.  Note, mating was assumed to take place around 
midnight.
             18% casein       9% casein
Casein 18.0 9.0
Corn starch 42.5 48.5
Cellulose fibre 5.0 5.0
Sucrose 21.3 24.3
Choline chloride 0.2 0.2
DL-Methionine 0.5 0.5
Mineral mix (AIN-76) 2.0 2.0
Vitamin mix (AIN-76) 0.5 0.5
Corn oil 10.0 10.0
                   =100 g        =100 g
Table 2.1: Composition of synthetic isocaloric casein diets (g per 100 g of diet) 
(Langley and Jackson, 1994; Langley-Evans et al., 1996a).  Ingredients supplied by 
Special Diet Services, Cambridge, UK.
In house diets were provided to animals as balls (60-100 g dry weight); bought in diets 
were presented as smaller uniformly sized pellets.  In either case the protein source was 
casein and all diets contained 5g//kg methionine to avoid sulphur deficiency.
The 9% casein and 18% casein diets were always of equivalent total caloric value (i.e. 
4.17 kcal /g).  As the proportion of the total calories contributed by casein (protein) 
differed, the total calories were adjusted by varying the amount of corn starch and also 
the sucrose content as indicated in Table 2.1; Figures 2.2 and 2.3 graphically display the 
difference between the compositions of the diets used.  Whilst adjustments were made to 
the carbohydrate composition of the low protein diet to maintain an equivalent energy content between the diets, these changes are relatively small compared to a halving of 
casein content. 
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Figure 2.2: Nutrient composition of the 18% casein (control) diet.
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Figure 2.3: Nutrient composition of the 9% casein (low protein) diet.2.3 Recovery of conceptuses 
On gestational day 17, pregnant adults were culled by cervical dislocation of the neck and 
the uterus was promptly dissected out and placed in ice cold phosphate buffered saline 
(PBS).  Conceptuses were dissected out of each of the uterine horns on ice and weighed. 
The conceptus weights, total litter size, and the number of conceptuses per horn were all 
recorded.  In order to identify their position in the uterus, conceptuses were given 
references to denote the horn they came from and their position within that horn.  For 
instance, the label ‘R3’ would identify a conceptus from the mother’s right uterine horn 
and denote that it had been the third conceptus in the horn down from the oviduct.  
2.4 Collection of gestational day 17 tissue 
All conceptuses in the uterus were dissected on ice and resulting fetus, placenta, and yolk 
sac weights were recorded.  Each fetus was then culled by decapitation and the fetal liver 
and kidneys were dissected on ice and weighed; fetal tails were also collected and were 
snap-frozen in liquid nitrogen. 
2.5 Statistical analyses 
Gestational day 17 weight data sets were analysed using a multilevel random effects 
regression model (SPSS, version 13) to account for their hierarchical structure.  Model developed by Dr. Clive Osmond, Medical Statistician, MRC Environmental Research 
Centre, Southampton General Hospital, University of Southampton (Kwong et al., 2004).
Maternal and conceptus effects were estimated simultaneously, as both between mother 
and within mother variation was incorporated. 
Unpaired two sample t-tests (Microsoft Excel, 2002) were used to evaluate differences in 
integrated density values (IDVs) for protein analysis data sets.
Changes in the expression of probe sets between diet groups in the genomics analysis 
were analysed using three independent downstream analyses packages: Array Assist 
(Stratgene), GeneSpring (Agilent), and dChip (publicly available software, Li and Wong, 
2001), (see Chapter 4 section 4.2.14 for further details of these data analysis methods).  
In summary, the Array Assist data analysis included comparisons between 9% casein and 
18% casein treatments, switch and 18% casein treatments, and switch and 9% casein 
treatments.  Probe sets that weren’t at least 1.4 fold different between treatments were 
filtered out of the analysis; significant differences between filtered probe sets in each 
treatment were assessed using unpaired t-tests, at p<0.05 (Microsoft Excel, 2002) to 
produce candidate gene lists for each comparison.  
The GeneSpring data analysis was carried out for the treatment comparisons 9% casein v 
18% casein, and switch v 18% casein only.  The analysis was based on probe sets that 
were at least 2-fold different between treatments, and that were called as “present” in at least 3 out of the 4 arrays per treatment; significant differences in these probe sets 
between the treatments were assessed using ANOVA at p<0.05 (Microsoft Excel, 2002).  
The dChip analyses were conducted on the treatments: 9% casein v 18% casein, switch v 
18% casein, and 9% v switch.  Analyses were based on probe sets that were called as 
“present” on at least 1 out of the 4 arrays per treatment, and that exceeded an absolute 
threshold level of expression (imposed to filter out probe sets with very small expression 
values).  The analysis parameters included two levels of stringency relating to fold 
change; the high stringency criteria involved filtering out probe sets that were not 
changing by at least 1.6 fold, whereas the low stringency criteria included probe sets that 
were at least 1.4 fold different between treatments.  Finally, differences between the 
filtered probe sets for each treatment were identified using ANOVA at p<0.05 to produce 
candidate gene lists for each comparison.Chapter 3
3.1 Introduction: Maternal Diet Effect on Gestational day 17 Tissue Weights
The DOHAD hypothesis proposed that the developing conceptus adapts to a limited 
supply of maternal nutrients and permanently alters its physiology and metabolism 
(Barker, 1999).  Human epidemiological studies used size at birth as a marker of fetal 
nutrition and related it in groups of men and women to the occurrence of several chronic 
diseases in later life e.g. in the cohort in Preston, lower birth weight was used as an 
indicator of reduced fetal growth and nutrition and related to evidence of the metabolic 
syndrome.  In both men and women, the prevalence of metabolic syndrome fell 
progressively from those who had the lowest to those who had the highest birth-weights. 
In addition to low birth weight, subjects with metabolic syndrome had small head 
circumference and low ponderal index at birth and low weight at year 1 of age.  From this 
study, it was concluded that type 2 diabetes and hypertension have a common origin in 
suboptimal development in utero, and that metabolic syndrome should be re-named “the 
small baby syndrome” because the prevalence of metabolic syndrome was strongly 
related to birth-weight (Barker et al., 1993).  Unfortunately, such statements have 
attracted criticism of the DOHAD hypothesis due to emphasis being placed on birth 
weight as a causal marker of later disease (Huxley et al., 2002).  However, the observed 
relationship between birth size and risk of disease parameters such as raised systolic 
blood pressure does not simply imply a causal role of being born small but rather it reflects the sensitivity of fetal growth to adverse intrauterine influences (Gluckman and 
Hanson, 2004b).
Numerous rodent models have supported the notion that maternal under-nutrition during 
pregnancy alters early growth (reflected by alterations in birth-weight) and also the 
development of chronic disease indicators, such as raised systolic blood pressure, in the 
adult offspring (Langley-Evans et al., 1996a; Langley-Evans, 1997b; Bertram et al., 
2001; Watkins et al., 2008).  Furthermore, reduced cell numbers first within ICM (early 
blastocyst) and later within both ICM and TE (mid/late blastocyst), have been reported in 
rat embryos in response to maternal low protein diet (Kwong et al., 2000).  This suggests 
that early on, the embryo adopts an altered growth profile (as indicated by a slower 
cellular proliferate rate) in response to the compromised maternal environment.
This chapter aims to examine whether exposure to the maternal diet manipulations 
imposed in this study are manifested as alterations in fetal growth (reflected by weight of 
fetal tissues) in late gestation.
3.2 Materials & Methods
Refer to Chapter 2 (Generic Methods), for further information on Experimental Design 
(section 2.1), Animal Treatments (section 2.2), Recovery of Conceptuses (section 2.3), 
and Collection of gestational day 17 tissue (section 2.4).3.2.1 Collection of gestational day 17 tissue 
 
During collection of the weight data from the gestational day 17 dissections, tissue was 
also specifically selected for genomics analysis (Chapter 4).
3.2.2 Storage of gestational day 17 tissue 
After being weighed, the tissues from three conceptuses per uterine horn were saved and 
stored for further analyses.  Excised tissues from the central conceptus in each uterine 
horn were stored appropriately for genomics analysis (Chapter 4); in addition, the same 
tissues from the immediate neighbours on either side of the central conceptus in each 
horn were snap-frozen in liquid nitrogen after collection, before being stored at -80
oC for 
protein analysis (Chapter 5).  
3.3 Results 
3.3.1 Growth criteria of fetal samples at gestational day 17 with respect to maternal 
diet (in-house diet)
Figure 3.1 indicates that 9% casein fed mothers produce significantly heavier conceptuses 
than mothers fed an 18% casein diet (p= 0.04).  This difference is not reflected in the 
switch treatment group (p= 0.432).  Total litter size has a significant negative effect on 
conceptus weight (independent of diet) (p= 0.032) and it is the 9% casein group that has the smaller average total litter size of the three dietary groups, although litter size is not 
significantly different between groups (Figure 3.2).  
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Figure 3.1: Average conceptus, fetus and placental weights at day 17 in relation to 
maternal diet (in-house diet) before total litter size is incorporated into the analysis; 
(*p= 0.04) n= 93-99 samples and 7-8 mothers per treatment. 
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Figure 3.2: Average total litter size for each of the dietary groups (in-house diet 
cohort).
Other variables, such as the uterine horn from which conceptuses were recovered, 
conceptus position within a uterine horn and mother each do not significantly affect 
conceptus weight (independent of diet).  When these other variables are incorporated in 
turn into the analysis of the effect of diet on conceptus weight, the significant difference 
in conceptus weight described above was not altered by uterine horn, position within a 
horn and mother.  However, the significant increase in conceptus weight in the 9% casein 
diet group compared to the 18% casein diet group is reduced to a trend level increase 
when litter size is incorporated into the analysis alongside diet (p= 0.075).  Overall, the 
statistics indicate that maternal diet has a significant effect on conceptus weight, but that 
the total litter size effect contributes to this.
Fetal weight of the 9% casein diet group is heavier at trend level (p= 0.076) compared to 
that of the 18% casein diet group, (Figure 3.1).  Litter size, horn, position in a horn and mother each had no significant effect on fetus weight.  Again, this trend was not reflected 
in the switch treatment group (p= 0.402).
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Figure 3.3: Average yolk sac and fetal liver weights at day 17 in relation to in-house 
maternal diet.
The fetal liver weights across the different dietary groups shown in Figure 3.3 reflect the 
trends observed in Figure 3.1.  The difference in fetal liver weight between the 9% casein 
and 18% casein diet groups is at trend level (p= 0.075), and is not significant between the 
switch and 18% casein diet groups (p= 0.742).  Fetal liver weights are normally 
distributed, and none of the previously mentioned variables significantly affect fetal liver 
weight.  A similar pattern is seen for both the left and right fetal kidney weights (Figure 
3.4) and there is a trend level increase in the right fetal kidney weight in the 9% casein 
diet group relative to the 18% diet casein group.  These results indicate that the fetal 
p<0.1organ weights analysed are proportional to fetus weight as a whole, in each of the dietary 
groups.
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Figure 3.4: Average fetal kidney weights at day 17 in relation to in-house maternal 
diet.
The data shown in Figure 3.1 do not follow the pattern of previously collected gestational 
day 17 weight data using this diet model in mice (Drs W. Kwong and E.Ursell, 
University of Southampton- unpublished- see section 3.4.1 of Discussion).  To rule out 
the possibility of a problem with the in-house diet used in this experiment, a further 
cohort of mice were fed 9% casein or 18% casein diets that had been commercially 
prepared (Lillico, UK) using an identical specification of ingredients. 
p<0.13.3.1.2 Gestational day 17 weight data (bought in diet) 
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Figure 3.5: Average weights of conceptus, fetus and placenta at day 17 in relation to 
maternal diet (bought in diet).  n= 13-14 mothers and 151-175 samples per 
treatment.
Figure 3.5 indicates that in terms of conceptus and fetus weight, a similar pattern exists in 
the bought in diet as was observed when the diet was made in-house i.e. the 9% casein 
and switch diets appear to produce slightly heavier conceptuses and fetuses than the 18% 
casein diet.  Interestingly, the average conceptus and fetus weights produced are higher in 
all three treatment groups when the bought in diet was used compared to when the in-
house diet was used (Table 3.1).In-house diet Conceptus weight (g)  SEM Fetus weight (g) SEM
9% casein 1.14 ± 0.02 0.87 ± 0.02
18% casein 0.96 ± 0.01 0.70 ± 0.01
switch 1.03 ± 0.02 0.78 ± 0.02
Bought in diet        
9% casein 1.17 ± 0.008 0.89 ± 0.007
18% casein 1.14 ± 0.01 0.85 ± 0.009
switch 1.18 ± 0.01 0.90 ± 0.009
Table 3.1: Average conceptus and fetus weight data at gestational day 17 when 
different cohorts of mothers were fed in-house or bought in diets.
However, for the bought in diet cohort of mice, there was no significant difference in 
conceptus weight between the 9% casein diet group and the 18% casein diet group (p= 
0.529) or between the switch diet group and the 18% casein diet group (p= 0.338). 
Likewise, the extraneous variables: horn, position in horn and mother each had no 
significant impact on conceptus weight.  Litter size however had a significant negative 
impact on conceptus weight (p=0.000).  There was also no significant difference in fetal 
weight between the 9% casein and 18% casein groups (p= 0.169) or between the switch 
and 18% casein groups (p=0.150).  Horn and mother each also had no significant impact 
on fetus weight, but litter size had a significant negative effect (p= 0.000) and position 
within the horn had a significant effect (p= 0.004) on fetus weight.  Both conceptus and 
fetus weights follow a normal distribution.  No significant differences existed in placental 
weight between the 9% casein and 18% casein groups (p= 0.469) or between the switch 
and 18% casein groups (p= 0.928).  There is a trend level difference (p= 0.083) in the 
fetus/placenta weight ratio between the 9% casein and 18% casein dietary groups; the 9% 
casein group has an increased fetal:placental weight ratio relative to the 18% casein 
control group, which may suggest slight disproportionate growth of the fetus relative to the placenta occurred in this treatment group.  Finally, there were no significant 
differences between 9% casein and 18% casein diets (p= 0.168) or between switch diet 
and 18% casein diets (p= 0.149) in terms of average fetus weight per litter.  
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Figure 3.6: Average yolk sac and fetal liver weights at day 17 in relation to maternal 
diet (bought in diet). n= 13-14 mothers and 151-175 samples per treatment.
No significant difference exists in fetal liver weights between the 9% casein and 18% 
casein diet groups (p= 0.364) or between switch and 18% casein groups (p= 0.105) 
(Figure 3.6).  Litter size does have a significant negative effect on fetal liver weight (p= 
0.000).  Fetal liver weight data was normally distributed.  The average fetal liver weights 
(Figure 3.6) and right kidney weights (Figure 3.7) reflect that of the fetus weights (Figure 
3.5), indicating that these organs are largely proportional in size to the fetus in each 
dietary treatment group.  The pattern of the left kidney weight data is affected by the 18% casein group which has a larger amount of variation but there was no significant 
difference in the weights of the fetal kidneys (Figure 3.7).  
The weight data collected for the yolk sac (Figure 3.6) is affected by a relatively large 
amount of variation in the 9% casein diet group.  The variation here may be due to 
difficulty with weighing yolk sac tissue accurately due to the tendency for it to hold onto 
fluid more than the other tissues.  There was no significant difference in yolk sac tissue 
weight between the 9% casein and 18% casein diets (p= 0.312) or between switch and 
18% casein diets (p= 0.563).  None of the extraneous variables significantly affected yolk 
sac weight.
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Figure 3.7: Average fetal kidney weights at day 17 in relation to maternal diet 
(bought in diet). n= 13-14 mothers and 150-173 fetal kidneys per treatment.3.4 Discussion 
3.4.1 Gestational day 17 weight data (in-house diet cohort)
Average conceptus weights were significantly different (p= 0.04) between the 9% casein 
and 18% casein diet groups (Figure 3.1).  However, the difference in conceptus weight 
between these diet groups was not independent of litter size.  Thus it is possible that the 
significant increase in conceptus weight in the 9% casein diet group may be partially 
attributed to the smaller litters in this diet group compared to the 18% casein diet group.  
Nevertheless, trend level differences in average conceptus weight (p= 0.075) and average 
fetus weight (p= 0.076) were identified between the 9% casein and 18% casein diet 
treatments, and these trends were independent of the other variables identified, including 
litter size.  Average placenta weight (Figure 3.1) and average yolk sac weight (Figure 
3.2) are identical between the 9% casein and 18% casein diet groups and so do not 
contribute to the difference in conceptus weights.  Thus, it appears that the changing 
weight of the fetus is the reason for the trend level difference in conceptus weights 
between the 9% casein and 18% casein diet groups.  Finally, the average fetal liver 
weight also showed a trend level difference, (p= 0.075) (see Figure 3.2) between the 9% 
casein and 18% casein diets in line with the differences in the conceptus and fetus 
weights described above.
From these data, it appears that the 9% casein diet treatment has more of an impact on the 
developing conceptus than the switch diet as indicated by tissue weights at day 17. Specifically, in the absence of any significant changes in the switch diet treatment, the 
9% casein diet results in a trend level increase in the weight of the fetus compared to the 
controls when examined at gestational day 17.  This trend does not follow the direction of 
published birth weight data in rodents suggesting that a lower birth weight results from 
protein restriction throughout pregnancy (Langley-Evans et al., 1996a; Langley-Evans et 
al., 1997b; Bertram et al., 2001).  Furthermore, recently, Watkins et al., 2008 have shown 
in mice that the maternal switch diet, as was used in this study, results in a significant rise 
in the birth weights of pups, but the 9% casein treatment throughout gestation has no 
significant effect on birth weight relative to the 18% casein control treatment.  Although, 
in the results gathered for my in house diet data set it appears that the 9% casein 
treatment has more of an effect on weight in late gestation than the switch diet group 
these results may not be wholly reliable due to questions over the diet composition made 
in house as alluded to previously.  
Furthermore, the weight data collected at gestational day 17 from these pregnant mice fed 
in-house made diets also do not follow previous weight data collected in mice, 
specifically at gestational day 17, where maternal diet has been varied in this way and the 
equivalent diet recipe has been used (Drs W. Kwong, and E.Ursell, University of 
Southampton- unpublished).  Also, average weights that have been documented 
previously in mice at gestational day 17 were higher for the 18% casein diet than have 
been found in Figure 3.1 (Drs W. Kwong, and E.Ursell, University of Southampton- 
unpublished).  In an attempt to find an explanation for the trends observed in Figure 3.1, the breeding 
pairs used to produce the females used in this study were analysed in order to look at the 
number of litters already produced (parity number) prior to the litter containing each 
female used as a mother in this study, (Figure 3.8).  
Figure 3.8: Relationship between average fetal weight in the litter produced by a 
mother and the parity number of the breeding pair used to produce the litter into 
which mothers were born.  (Note; the parity of some mothers could not be traced).
Figure 3.8 indicates that there is no apparent correlation between the parity numbers of 
the litters into which mothers used in the present study were born and average fetal 
weight in the litters subsequently produced by these mothers in this study.
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Due to the unexpected nature of the weight data in Figure 3.1 mentioned previously, the 
quality of the in-house prepared diet, the 18% casein diet in particular, came into 
question.  The experiment was therefore run again on a new cohort of mice which 
received comparable 9% casein and 18% casein diets that had been bought in ready-made 
rather than made in-house.  An alternative remedy would be to have had the individual 
nutrient levels analysed for the in-house prepared diet.  However this option was deemed 
to be less cost effective and thus not pursued.
Figure 3.5 indicates that in terms of conceptus and fetus weight a similar pattern exists in 
the bought in diet as was observed when the diet was made in-house i.e. the 9% casein 
and switch diets appear to produce slightly heavier conceptuses and fetuses than the 18% 
casein diet (non significant for bought in diets).  However interestingly, the average 
conceptus and fetus weights produced at gestational day 17 are increased in all three 
dietary treatment groups when mice are fed the bought in diets compared to when the in-
house diet was used, (Table 3.1).  This lends support to the idea that something was 
missing or depleted in the original in-house made diets used previously.  It is also 
noteworthy that the 18% casein diet was closer to the 9% casein diet in terms of 
conceptus and fetus weights when the bought in diets were used, which also is more in 
line with the previous findings of Drs W. Kwong, and E.Ursell, University of 
Southampton- unpublished.3.4.3 Gestational day 17 weight data (bought in diet cohort)
There were no significant differences in the average weights of the gestational day 17 
tissue examined in this cohort of mice.  However the absence of changes in the weights 
recorded does not necessarily mean that programming hasn’t taken place in the tissues, as 
the dietary manipulation imposed on the pregnant mice was relatively mild (Nelson and 
Evans, 1953).  Indeed, there is a certain amount of conflicting evidence regarding the 
impact of a low protein diet on raw weights in rodents.  A number of studies have 
indicated changes in cardiovascular parameters in offspring in response to a diet low in 
protein experienced in utero in the presence or the absence of changes in measured birth 
weights in these offspring (Langley-Evans et al., 1996c; Kwong et al., 2000; Watkins et 
al., 2008). 
Litter size often had a significant negative effect on the weight data parameters measured 
in this study.  As the total litter size increased, conceptus, fetus, placenta and fetal liver 
weights were significantly lighter; this may reflect a restriction of growth in response to 
limited resources due to crowding.  It is important to note here that the maternal low 
protein diet has no significant effect on litter size itself in rodents (Langley-Evans, 2000; 
Watkins et al., 2008; Kwong et al., 2000; E. Ursell, University of Southampton- PhD 
thesis, 2004).
Recently in mice the maternal switch diet, as was used in my study, has been reported to 
result in a significant elevation of the birth weights of pups (Watkins et al., 2008).  Also in rats, the switch treatment was found to cause significant alternations in birth weight 
but here the change seen is in the opposite direction, i.e. a reduction in birth weight 
(Kwong et al., 2000).  However in my data set, the switch treatment did not result in any 
significant change in fetus weight at day 17 as might be expected from these birth weight 
results.  It is possible therefore that the day 17 window is just too early for adaptations to 
diet treatment to have manifested themselves as changes in growth that are seen by the 
altered weights at birth.  It may be that at day 18, changes in the weight of the gestational 
day 17 fetal tissues become evident. 
 
Moreover, the reported changes in birth weight in rodents as a consequence of 
manipulating protein content of maternal diets are often gender specific (Kwong et al., 
2000; Watkins et al., 2008).  In both the aforementioned studies the significant alterations 
in birth weight reported as a consequence of an equivalent to the switch diet treatment, 
was exclusive to female offspring.  As it is not possible to reliably identify fetal sex by 
anatomy at gestational day 17 the data set inevitably incorporates fetuses of both sexes 
together.  This may offer another explanation for the absence of significant alterations in 
weight at day 17 in response to the maternal switch diet in the present study.  However, 
as the previous aforementioned studies indicate that sex is an important factor in the 
response to dietary interventions during development, clearly it would have been more 
favourable to express the weight data on the basis of sex of the fetuses in the present 
study rather than group all the data for both sexes together.Despite the absence of changes in the weights of the fetuses examined here at day 17, 
biochemical analyses were undertaken to examine the fetal liver tissue for evidence of 
programming influences in the gene and protein expression profiles (Chapters 4 and 5 
respectively).Chapter 4
4.1 Introduction: Genomics Analysis of Maternal Diet Effect on Fetal Development
It is important to identify gene pathways and specific genes influenced by maternal 
dietary programming so that the mechanisms involved can be elucidated and understood. 
There is minimal data currently available documenting these effects, moreover there is 
currently no such information concerning the impact of the maternal switch diet on the 
fetus.  
Micro-array techniques provide a powerful approach to study global patterns of gene 
expression.  A number of studies have made use of this tool for transcript profiling during 
murine pre-implantation development/embryogenesis (Hamatani et al., 2004; Wang et al., 
2004; Zeng et al., 2004).  Moreover, micro-array technology has proved a useful tool in 
assessing the impact of environmental manipulations during early development on global 
gene expression.  Thus, the short-term effects of embryo culture have been elucidated in 
blastocyst stage embryos which has demonstrated alterations in the global pattern of gene 
expression, and indicated the sensitivity of several gene pathways to such early 
environmental programming influences (Rinaudo et al., 2004).  
Affymetrix micro-arrays have also been used to understand the mechanism for the impact 
of environmental insults in murine fetal liver (not related to compromised maternal diet), 
including maternal perfluorooctanoic acid (PFOA) exposure, which is known to cause growth deficits and mortality in murine neonates.  Following maternal PFOA exposure, 
the expression of a number of genes in the murine fetal liver at term, including those 
related to fatty acid catabolism, were found to be altered in response to this treatment 
(Rosen et al., 2007).
The aim of this chapter is to determine global gene expression patterns in gestational 
day 17 murine fetal liver as a function of maternal diet using GeneChip expression 
analysis probe arrays (Affymetrix) to better understand the genetic mechanisms involved 
in dietary programming of the fetus.
The GeneChip Mouse Genome 430 v2.0 Array (Affymetrix) is composed of 45,101 
probe sets which represent over 34,000 mouse genes.  Sequences used in the design of 
these arrays were selected by Affymetrix from GenBank, dbEST and RefSeq.  Probe cells 
are specific areas on the probe array surface that contain hundreds of thousands to 
millions of copies of a given oligonucleotide probe sequence attached to the array surface 
to which single stranded labeled ‘target’ may bind.  The oligonucleotides on the surface 
of the probe array are called probes because they interrogate or ‘probe’ the sample. 
Eleven oligonucleotide probes (DNA probe cells) constitute one probe set and are used 
to measure the level of transcription of each mRNA sequence represented on the array, 
(Figure 4.1).Figure 4.1: Design of probe sets on the Mouse Genome 430 2.0 arrays (provided by 
Dr. Geoff Scopes, Affymetrix).
All the DNA probe cells for a particular mRNA sequence are made to a similar piece of 
sequence close to the 3’ end.  Each DNA probe cell contains complementary sequence to 
the part of the mRNA reference sequence it represents.  Individual probe cells belonging 
to each probe set are distributed out evenly over the array.  For every probe cell 
containing perfect match oligo sequences, there is an adjacent probe cell containing 
mismatched oligo sequences which differ only by a single base (Figure 4.2).  These act as 
controls for the specificity of target binding.  Housekeeping/control genes are present on 
each array and include GAPDH, beta-actin, transferrin receptor and pyruvate 
carboxylase.      
          Figure 4.2: Fluorescence intensity image of perfect match (PM) oligo sequences and 
mis match (MM) oligo sequences (from Dr. Geoff Scopes, Affymetrix).
4.2 Materials & Methods
Refer to Chapter 2 on Generic Methods, sections 2.1 Experimental Design, 2.2 Animal 
Treatments, 2.3 Recovery of Conceptuses, and 2.4 Collection of gestational day 17 tissue.
4.2.1 Recovery of conceptuses 
During the gestational day 17 dissections described in Chapter 3, the central conceptus in 
each uterine horn was identified as a potential candidate for use in the genomics analysis. 
The central conceptus was selected in order to avoid extreme positions in the uterine 
horns where fetal growth may be more variable due to the nature of the uterine horn 
Reference sequenceblood supply.  The blood supply to fetuses in each uterine horn in the mouse comes from 
offshoots of a main loop artery which is fed from both the top and the bottom ends.  In 
such a system, the pressure of blood is greatest in the top and bottom offshoots, 
decreasing in the offshoots towards the middle of the horn.  Thus, larger fetuses are often 
found at either end of the horns than in the middle.  However, the topmost fetus is often, 
particularly in crowded horns, supplied by one limb of a bifurcated offshoot of which the 
other limb supplies the ovary.  Therefore, this fetus is on average smaller than its 
neighbours in crowded horns (McLaren and Michie, 1960).  The central conceptus in a 
uterine horn was easily identifiable where there were an odd number of conceptuses; 
where there was an even number, the central conceptus nearest the oviduct end of uterus 
was taken to be the centre.
As average fetus weight was significantly affected by position in the uterine horn in the 
bought-in diet data set in Chapter 3, this further supports the work undertaken to keep 
uterine position as constant as possible when selecting potential fetal candidates for 
down-stream analyses.
4.2.2 Collection of gestational day 17 tissue 
Excised tissues from central conceptuses were incubated individually in ‘RNA later’ 
stabilisation reagent (QIAGEN, UK) immediately following dissection and placed on ice 
and then stored in the reagent overnight at 2-8
oC.  Each tissue was completely submerged 
in a minimum of ten volumes of RNA later per milligram of tissue.  The following day, tissues were removed from the RNA later and were blotted dry and transferred to -80
oC 
until required.  
4.2.3 PCR genotyping of fetuses
To keep biological variation in the genomics analysis to a minimum, I decided that the 
genomics analysis would be conducted on tissue from one sex of fetus only (males); thus, 
PCR genotyping of the central fetus in each uterine horn selected as a potential candidate 
for the genomics analysis was carried out to ascertain sex.  This was undertaken using 
DNA extracted from fetal tail tissue (DNeasy Tissue Kit, QIAGEN UK).  In addition, in 
order to standardise the immediate environment experienced by each central fetus in 
utero, the sexes of the nearest neighbours in each horn were also determined by the same 
method.  Thus, a central male fetus was only considered as a candidate for the micro-
array if at least one of its immediate neighbours was also a male. 
The sex of the neighbouring fetuses is important information to have as hormones from 
one fetus can influence the physiology and behavioural development of contiguous 
fetuses in the mouse due to the close proximity in which fetuses line the uterine horns 
(vom Saal, 1981).  By selecting male fetuses for the genomics analysis with a maximum 
of one female neighbour it was intended that the impact of hormones from nearest 
neighbours of the opposite sex would be minimised.  Two different primer pairs (Kunieda 
et al., 1992; see below) for distinct regions of the mouse Y chromosome were used as a check for the presence of male DNA in the samples.  These primer pairs are specific for 
the sex-determining region of Y (Sry) and the Zinc-finger region of Y (Zfy) genes.  
Y chromosome primer sequences:
A third ‘micro-satellite’ primer pair (Kunieda et al., 1992) specific for a locus of the 
mouse X-chromosome, the X-inactivation centre (DXNds3) (i.e. common to both sexes) 
was also used, namely NDS3 and NDS4 as follows:
X chromosome primer sequences:
A micro-satellite contains di-, tri- or tetra- nucleotide repeats in the DNA of the type 
(CA)n or (CCA)n, where n is typically between 10-30+.  Here, the micro-satellite locus 
confirms the presence of PCR product in the reaction.  It is used as a check for DNA 
extraction efficiency, and is a check that DNA has been added to the PCR reactions.The conditions adopted for the PCR thermal cycling reactions are as specified in 
(Kunieda et al., 1992).  PCR reactions in 0.5ml PCR tubes were overlaid with mineral oil 
and were incubated using a Hybaid thermal reactor.  Table 4.1 shows the reagents used 
per cycling reaction.  The thermal cycling protocol for the PCR genotyping is also 
shown; after the last cycle, samples were held at 72
oC for 10 minutes.  
Reagent          Volume
10 x Buffer (Invitrogen) 4.5 µl
dNTPs (10 mM each) 1 µl  
MgCl2 (50 mM) 1.5 µl
Primer (forward) (40 pmol/µl) 1 µl
Primer (reverse) (40 pmol/µl) 1 µl
DNA (~80 ng) variable
Di H2O variable
Total volume 45 µl
10 x Taq Master-mix 5 µl
Table 4.1: Example of reagents used per cycling reaction (master-mixes were made 
to increase accuracy).
94
oC Denaturation (60 secs) 
                                
  60
oC Annealing (150 secs)   x 30 cycles
  
72
oC Extension (150 secs)                           (Thermal cycling procedure)      Primers pairs for DXNds3 and Sry could be run together in a multiplex system while the 
primer pair for Zfy was run in a separate reaction.  Despite optimisation, it was not 
possible to run all three sets of primers in multiplex and decipher the products reliably. 
In addition, as a positive control, DNA extracted from male and female adult tissue was 
always run alongside the DNA from the fetal tails being genotyped.
4.2.4 DNA electrophoresis and visualisation
PCR products were mixed with 6x loading dye and run alongside a 100 base-pair ladder 
(Invitrogen) on a 1.6% agarose gel for effective separation of multiplexed reactions, 
made with buffer 5 x Tris-Borate-EDTA (TBE), 1% Ethidium Bromide, and run in 5x 
TBE buffer at 120V for 1 hour.  Gel photographs were taken using Alpha Imager 
technology (Alpha Innotech Corporation).  For female DNA, no bands should be evident 
for the Y-chromosome region products; a band for the micro-satellite product only should 
be observed.  For male DNA there should be bands evident for all three products i.e. Sry, 
Zfy and the micro-satellite product DXNds3.  Expected PCR product sizes are as follows: 
DXNds3 product 244bp; Sry product 147bp; Zfy product 217bp.
4.2.5 DNA sequencing of PCR products: (Sanger ‘dideoxy’ method)
In order to confirm PCR product identity independently of product size, DXNds3 and the 
Zfy gene were sequenced.  It was not possible to successfully sequence the Sry PCR 
product.  PCR products were purified using QIAquick PCR purification kit (QIAGEN, UK) in preparation for sequencing.  The concentration of DNA recovered from the 
column was assessed by running a small amount in a 1% agarose gel alongside a low 
mass ladder (Invitrogen).
Sequencing (Beckman Coulter CEQ 8000 DNA analysis system)
100 fmols of template was used for the cycling step per sequencing reaction.  A ratio of 
40:1 primer to template was used in cycling reactions, for instance 4 pmols of primer was 
used where 100 fmols (i.e. 0.1 pmols) was added to the reaction.  The Beckman Coulter 
Quick-start kit was used which supplies a master-mix of dye-tagged dNTPs, the 10x 
Buffer, and Taq Polymerase (Table 4.2).
Reagent        Volume
DNA (100 fmols)        variable
Di H2O              variable
Primer (4 pmol/µl) 1 µl
Beckman Coulter Mastermix 8 µl
Total volume 20 µl
Table 4.2: Reagents per sequencing reaction.  (Forward and reverse primers added 
to separate reactions).
Samples were transferred to a Tetrad DNA Engine for cycling.  A two-step thermal 
cycling protocol was adopted for sequencing DXNds3: 96
oC for 20 seconds (denaturation), then 60
oC for 4 minutes (annealing and extension).  This was repeated for 
thirty cycles.  This protocol could be adopted because the melting temperatures (T
M) of 
the NDS primers are ~5
oC higher than the extension temperature of 60
oC.  Following 
cycling, reactions were cleaned-up by ethanol precipitation.  (For protocol see Beckman 
Coulter CEQ 8000 handbook).  After bench drying, pellets were re-suspended in Sample 
Loading Solution (Beckman Coulter) transferred to a 96 well plate, overlaid with mineral 
oil and read by the Beckman Coulter CEQ 8000.
4.2.6 Experimental design
Twelve fetal liver samples were selected for the genomics analysis from male fetuses that 
had been centrally positioned within their respective uterine horns.  Four biological 
replicates from each of three dietary treatment groups were probed with the micro-arrays 
(one chip per sample).  
4.2.7 Total RNA extraction from fetal liver tissue 
Total RNA was extracted from ~20 mg slices of RNA-preserved day 17 fetal liver 
samples in an RNase-restricted environment (RNeasy Mini Kit, QIAGEN, UK).  
RNA samples were snap frozen on dry ice and stored at -80
oC.  Trial total RNA 
extractions using TRIzol reagent (Invitrogen) and chloroform followed by purification 
with RNeasy Mini Kit (QIAGEN, UK) were also attempted, but the RNeasy method 
alone produced much better RNA yields.4.2.8 Qualitative analysis of total RNA extracted from fetal liver tissue 
Total RNA quality extracted from fetal livers was assessed using the Agilent 2100 
Bioanalyser with the RNA 6000 Nano Assay Kit (Agilent Technologies).  The Agilent 
2100 Bioanalyzer provides a platform that uses a fluorescent assay involving 
electrophoretic separation to evaluate RNA samples qualitatively.  It measures the 
amount of fluorescence as the RNA sample is pulsed through a micro-channel over time. 
The Agilent Bioanalyzer software creates a graph called an electropherogram which 
diagrams fluorescence over time.  Smaller molecules are pulsed through the separation 
channel more quickly than larger ones and will therefore appear on the left side of the 
electropherogram.  For each sample the software creates a gel image to accompany the 
graph.
4.2.9 One-Cycle Target Labelling Assay (Affymetrix)
For more details of protocols, see Appendix I.
Poly-A-tailed Bacillus subtilis transcripts were spiked directly into total RNA samples to 
act as positive controls to monitor the target labeling process (Poly-A RNA Control Kit, 
Affymetrix).  The poly-A RNA controls (lys, phe, thr, and dap) are Bacillus subtilis 
genes that are obviously not present in the eukaryotic samples.  They are synthesised in 
vitro and the polyadenylated transcripts are premixed at staggered dilutions.  The 
concentrated Poly-A Control Stock was serial diluted on ice with Poly-A Control Dil Buffer in non-stick RNase free microfuge tubes (Ambion) and spiked directly into 5 µg 
of each of the RNA samples to achieve the final dilutions.  These controls were then 
amplified and labelled together with the samples.  Monitoring the intensities of these 
controls on the arrays helps to monitor the labelling process independently of the RNA 
quality of the starting material.
                        
One-Cycle cDNA Synthesis
In the first strand cDNA synthesis reaction, 5 µg total RNA (target) per sample (with 
spiked-in poly-A RNA controls) was reverse transcribed using an Oligo(dT) Primer 
containing a T7 polymerase promoter binding site.  RNase H-mediated second strand 
cDNA synthesis followed (One-cycle cDNA Synthesis Kit, Affymetrix, Figure 4.3).Figure 4.3: Part one of One-Cycle Target Labelling for 1-15 µg total RNA 
(GeneChip Expression Analysis Technical Manual, Affymetrix, 
http://www.affymetrix.com).
Newly synthesised double-stranded cDNA was cleaned up at room temperature using 
spin columns and buffers (Sample Cleanup Module, Affymetrix).  The average volume of 
eluate recovered after cleanup was 12µl.  Cleaned-up, double-stranded cDNA samples 
were stored at -80
oC.In Vitro     Transcription (IVT) Reaction     
The purified, double-stranded cDNA served as a template for the IVT reaction for the 
synthesis of complementary RNA.  The in vitro transcription reaction (IVT) was carried 
out in the presence of T7 RNA Polymerase and a biotinylated nucleotide analog/ 
ribonucleotide mix for complementary RNA (cRNA) amplification and biotin labelling 
(IVT Labeling Kit, Affymetrix), (see top of Figure 4.4).  IVT reactions were incubated 
for 16 hours at 37
oC using a Tetrad thermal cycler.
 
Figure 4.4: Part two of One-Cycle Target Labelling for 1-15 µg total RNA 
(GeneChip Expression Analysis Technical Manual, Affymetrix).Biotinylated cRNA was cleaned up at room temperature using spin columns and buffers 
(Sample Cleanup Module, Affymetrix).  Purified cRNA was subsequently stored at 
-80
oC.
Quantification of cRNA yield
Spectrophotometric analysis was used to determine the cRNA yields (1 absorbance unit 
at 260 nm equals 40 µg/ml RNA).  The A260/A280 ratio was close to 2.0 for all purified 
RNA samples (acceptable levels).  A280 represents protein content in a sample.
For quantification of cRNA when total RNA was the starting material, adjusted cRNA 
yields were calculated to reflect carryover of unlabeled total RNA.  (See Appendix I for 
formula).
4.2.10 cRNA fragmentation
cRNA ranges in length from 50-3000 bases and larger transcripts often contain secondary 
structure which can interfere with hybridisation and increase the opportunity for non-
specific cross-hybridisation to the probe oligos attached to the array.  The labeled cRNA 
makes a better target for oligo arrays once it has been fragmented to an optimal size of 
50-200 bases long.  This is because the structures of the fragmented targets are less 
complex which helps improve their specificity (Agilent Technologies, Application Note).20 µg cRNA per sample was fragmented in a 40µl reaction to give a final concentration 
of 0.5 µg/µl cRNA in the fragmentation reaction (Sample Cleanup Module, Affymetrix). 
The fragmentation buffer breaks down full length cRNA by metal-induced hydrolysis to 
produce RNA fragments ranging in size from ~35 - 200 bases (average fragment size 
~100bps).  
4.2.11 Target (cRNA) hybridisation to probe arrays
Fragmented labelled cRNA from each sample was hybridized to individual “GeneChip 
Mouse Genome 430 2.0” Arrays (Affymetrix).  Hybridisation cocktails were prepared at 
room temperature using Hybridisation, Wash and Stain Kit, Affymetrix; Eukaryotic 
Hybridization Control Kit, Affymetrix.  Hybridization cocktails were heated at 99
oC for 5 
minutes and then at 45
oC for 5minutes using a Tetrad thermal cycler.  They were then 
centrifuged for 5 minutes at maximum speed in a micro-centrifuge to collect any 
insoluble material from the hybridization mixture.  Meanwhile, each array was 
equilibrated at room temperature and then wet with 200 µl of Pre-Hybridization Mix by 
filling it with a micropipettor through one of the rubber septa.  Filled probe arrays were 
incubated at 45
oC for 10 minutes with rotation in a Hybridization Oven 640 (Affymetrix). 
Arrays were then removed from the hybridisation oven and the pre-hybridization mix was 
extracted.  Finally, array cartridges were refilled with 200 µl clarified hybridization 
cocktail and incubated in the hybridization oven at 45
oC for 16 hours with rotation at 60 
rpm.4.2.12 Washing and staining of hybridized probe arrays
The Fluidics Station 450 (Affymetrix) was used to wash and stain the probe arrays and 
was operated using GeneChip Operating System (GCOS) software, Affymetrix.  Before 
inserting the probe arrays into the fluidics station modules, the lines of the fluidics station 
were primed with the wash buffers A (non-stringent) and B (stringent) to prepare it for 
use (Hybridization, Wash & Stain Kit, Affymetrix).  Hybridized probe arrays were 
removed from the oven and the hybridization cocktails were extracted.  Array cartridges 
were then filled with 250 µl Wash Buffer A: Non-Stringent Wash Buffer.  At each of the 
fluidics station modules, three 1.5 ml vials containing aliquots of 600 µl of each of Stain 
Cocktail 1 (Streptavidin Phycoerythrin (SAPE) Stain Solution) and Stain Cocktail 2 
(Biotinylated anti-streptavidin antibody solution) and 800 µl of Array Holding Buffer 
were positioned in the module sample holder.  Stain Cocktail 1 is light-sensitive so was 
transferred into an amber vial (Hybridisation, Wash & Stain Kit, Affymetrix).  
Probe arrays were inserted into the modules of the fluidics station.  The needle levers 
were then engaged to snap needles into position and to start the run, (Figure 4.5).Figure 4.5: A module of the fluidics station (GeneChip Expression Analysis 
Technical Manual, Affymetrix).
The antibody amplification protocol used to control the washing and staining of the probe 
arrays can be found in Appendix I.  (Note: streptavidin is a protein that binds with high 
affinity to the biotin-labelled cRNA target).  
4.2.13 Probe array scanning
Each of the twelve hybridized probe arrays stained with the streptavidin phycoerythrin 
conjugate were then scanned in turn using the GeneChip Scanner 3000 (Affymetrix). 
The amount of light emitted at 570 nm is proportional to the bound target at each location 
on the probe array.  Phycoerythrin, a commonly-used bright fluorescent dye, is a light 
Needle lever
Probe array cartridge
Cartridge lever
Position of three vials in sample holderharvesting protein isolated from cyanobacteria and red algae.  It has a strong emission 
peak at 575 +/- 10 nm.
4.2.14 Data analysis
The raw data file generated from the GeneChip scanner console was the .DAT image. 
This was a pixelated image of the probe array analyzed for probe intensities.  .CEL files 
represent single (average) intensity values for each probe cell.  Thus a .CEL file 
represents a non pixelated image whereby multiple pixel intensities are condensed to give 
one value for every probe cell.  .CHP files are the text files generated from .CEL file 
data, and contain qualitative and quantitative analysis for each probe set as well as data 
quality assessment information.  Finally, report files were generated from the .CHP file 
data to provide data quality information.
Data files generated were initially analyzed with the GeneChip Operating System 
(GCOS) software (Affymetrix) for quality control purposes.  Other quality monitoring of 
the data was carried out using Expression Console (Affymetrix) (with thanks to Dr. Geoff 
Scopes, Affymetrix).  Downstream analyses of .CEL file data were conducted using three 
separate software applications; Array Assist (Stratagene) (with help from Dr. Geoff 
Scopes, Affymetrix) and GeneSpring (Agilent) (with help from Dr. Nat Street, University 
of Southampton) and also dChip (a publicly available software package, Li and Wong, 
2001) (in collaboration with Dr. Tom Papenbrock, University of Southampton), to 
identify genes/probe sets apparently sensitive to programming by maternal diet.  The analyses attempt to reveal differences in levels of expression between the dietary 
treatments.
4.2.14.1 Array Assist analysis parameters
Significance analysis (unpaired t-tests) for comparison of gene expression levels between 
pairs of dietary groups was carried out using after the data was filtered for Present-Absent 
calls to remove the genes called as absent across all samples, and so reduce noise.  After 
filtering, the number of probe sets involved in the analysis was reduced from 45101 to 
29641.  
Gene lists were produced for probe sets that were at least 1.4 fold different between diet 
groups, with a p-value of <0.05.  Three independent comparisons between the diet groups 
were made: 9% casein v 18% casein, switch v 18% casein and switch v 9% casein (here, 
the 9% casein group was the baseline for the comparison).
4.2.14.2 GeneSpring analysis parameters
For this analysis, the level of stringency was such that for a probe set to avoid being 
filtered out it must have been called as “present” in at least 3 out of 4 arrays per treatment 
group and it must also be changing by at least 2 fold in expression between treatments 
being compared.  In generating the gene lists the data was filtered by experimental treatment group; the 9% casein group and the switch group were each compared in turn 
to the 18% casein (control) group.
4.2.14.3 dChip analysis parameters
dChip, a publicly available software package (Li and Wong, 2001) was used to normalise 
and analyse the Affymetrix .CEL file data and for subsequent class comparison analysis 
between diet treatments (‘classes’).
The class comparison tool in dChip enables one to specify a number of filtering criteria.
Two different sets of filtering criteria, termed high and low stringency were used for the 
class comparisons to identify differential expression of probe sets (genes) between 
classes/diet groups, and to eliminate signal noise.  
High stringency criteria for inclusion of a probe set were as follows.  The threshold for 
the lower bound of the 90% confidence interval for fold change was set at 1.6.  We can 
therefore be 95% confident (median of confidence interval) that probe sets identified as 
being differentially expressed between groups represent differences of at least 1.6 fold. 
In addition, an absolute minimum expression value, equal to 
1/10 of the mean level of 
expression of all genes on every chip, was selected to exclude very small expression 
values from the analysis which may lead to misleading fold change information.  The 
average expression value of genes on all chips after normalisation was found to be ‘89’, 
thus the absolute expression value was set to 8.9.  Finally, the p-value (ANOVA) to assess likelihood of there being no significant difference in expression for a particular 
probe set between classes had to be 0.05 or less.  Only probe sets that met these criteria 
were included on candidate lists generated from the class comparisons.  
The low stringency comparison criteria were identical to the above, except that the lower 
bound of the 90% confidence interval for fold change was set at 1.4.
In order to control for multiple testing error, multiple (50) random permutations were 
made for each class comparison to determine the false discovery rate (FDR) in each case. 
The number of false discoveries generated empirically from non-meaningful comparisons 
was determined and the non-meaningful gene lists were used to give an indication of the 
average number of candidates that might be generated by chance due to multiple testing. 
This gives us an insight into the level of error that may be present in gene lists produced 
from the meaningful class comparisons.  The average number of probe sets reportedly 
differentially expressed based upon the arbitrary comparisons obtained empirically was 
expressed as a percentage of the number of probe sets apparently differentially expressed 
when actual class comparisons were made.  This gives a percentage for false discoveries 
specifically based upon those samples involved in each actual class comparison.
Gene ontology enrichment analysis was performed on lists of candidate genes generated 
from the class comparisons in order to find biological meaning and clues about the 
transcriptional response to treatments.  Enrichment analysis is most effective when 
carried out on a large pool of candidates as it is used to determine gene ontologies that are over-represented relative to an appropriate background.  The gene ontology tools used 
to identify enriched/over-represented categories on a given gene list were Gene Ontology 
Tree Machine (GOTM) http://bioinfo.vanderbilt.edu/gotm and the Database for 
Annotation, Visualisation and Integrated Discovery (DAVID) 
http://david.abcc.ncifcrf.gov/.  In order to generate a background list against which the 
candidates on the gene lists could be compared, the background was defined as the 
Affymetrix chip used in the study i.e. Mouse 430v2.0 Array.  The representation of probe 
sets was thus equivalent between the background and the gene lists analysed for 
enrichment.
To identify enriched categories of probe sets for a given candidate list
+, the gene ontology 
tools group similar probe sets from the list into categories and compare the observed 
number found in each category to the calculated number of probe sets expected to be 
present in each category based on the background list.  If the observed value is greater 
than the expected value the category is said to be enriched in the gene list being analysed. 
Based on the observed and expected numbers an enrichment factor (R) is calculated; the 
higher the number of observed probe sets relative to the number expected for a given 
category, the greater the enrichment of that category in the gene list being analysed.  For 
all enrichment factors, the p-value to assess the likelihood of there being no true 
enrichment was p<0.01.
+Probe sets on a given gene list were separated into those that were up-regulated and 
those that were down-regulated and analysed separately for enrichment.4.3 Results
4.3.1 Genotyping of centrally positioned fetuses and the immediate neighbours by 
PCR 
Figure 4.6 is a representative photograph of PCR products run on an agarose gel.  It 
shows the sexes of six fetuses collected for genotyping from an 18% casein diet fed 
mother (three fetuses from each horn of the uterus).  Known adult male DNA: ‘m liv’ 
shows bands for all three PCR products as expected, and known adult female DNA ‘f liv’ 
shows just one band in the first lane at ~244 bp which is indicative of the DXNds3 
product from the X-chromosome primer pair NDS3/NDS4, as expected.
          
Figure 4.6: DNA electrophoresis. ‘M’ refers to a 100 base-pair size marker ladder 
(Invitrogen).  ‘m-liv’ refers to the positive control male liver tissue and ‘f-liv’ refers 
to known female liver tissue. ‘RC’ refers to reagent control (i.e. no DNA added to 
the reaction).
Zfy
    DXNds3
       Sry
600 bpsThe fetuses are denoted by their uterine position references L3, L4, L5 etc.  For each 
fetus there are two lanes on the gel.  The first lane for each fetus represents a reaction 
containing NDS and SRY primers in multiplex and the second lane represents a reaction 
containing the ZFY primers only.  For fetus ‘L3,’ there are two bands at the 
corresponding sizes to DXNds3 (244 bp) and Sry (147 bp) in the first lane, and there is 
one band corresponding to the size of Zfy (217 bp) in the second lane, hence it is 
concluded that this fetus is male.  Conversely, for fetus ‘L4,’ there is one band only 
evident at ~244bp (DXNds3) in the first lane, and there is no band evident in the second 
lane, hence it may be concluded that this fetus is female.  Table 4.3 shows potential fetal 
candidates identified by PCR genotyping that met the genotyping criteria for the micro-
array samples as laid out in section 4.2.3.Table 4.3: Results from PCR genotyping: fetuses are denoted by their uterine 
position references e.g. R3, L2.  Male fetuses with a maximum of one female 
neighbour (see number in brackets) are shown.  The numbers in red indicate the 
corresponding horn litter size for each fetus.   
The fetuses listed in Table 4.3 all refer to male fetuses with a maximum of one female 
nearest neighbour fetus.  Results not shown include where the central fetus was female or 
where there were two females neighboring a central male fetus.
Of the twenty-nine male fetuses listed in Table 4.3, the twenty-one which had one female 
neighbour (and therefore also one male neighbour) were selected for RNA extraction and 
qualitative analysis (see section 4.3.4).  These are the samples with a (1) in brackets after 
      L4 (1) 7 L4 (1) 9
  R3 (1) 5   L3 (0) 7 R5 (0) 8
R4 (1) 8 R2 (0) 5 L4 (1) 7 R2 (1) 5 R4 (0) 8
9-n22 9-n20 9-n19 9-n17 9-n16
  L5 (1) 8     L3 (0) 5
L4 (1) 7 R3 (0) 5     L2 (1) 5
R3 (1) 7 R2 (1) 5 R2 (1) 4 R5 (1) 9 R5 (1) 9
18-n18 18-n20 18-n14 18-n11 18-n10
L3 (1) 5        
L2 (1) 5   L5 (1) 9   R4 (0) 6
R3 (1) 6 L3 (1) 6 L4 (0) 9 R5 (1)10 R3 (1) 6
sw-n22 sw-n20 sw-n12 sw-n11 sw-n10
Litter/mother referencesthe fetal reference in Table 4.3.  Thus, for each dietary treatment there are five possible 
mothers (biological replicates) with at least one fetus available which had a single female 
neighbour.  Quality RNA from one fetal liver sample from each of four biological 
replicates per treatment is required for the genomics analysis study.
4.3.2 Sequencing of PCR products 
Confirmation of the identity of the band at ~244 bp as DXNds3 is achieved from 
analyzing the sequence generated from NDS4 (reverse primer) shown in Figure 4.7. 
Figure 4.7: Sequence retrieved with the NDS4 (reverse) primer using Beckman 
Coulter CEQ 8000 The DXNds3 product is rich in GT/CA base repeats in its middle region, which made it 
difficult to sequence the entire product.  Regions with long strings of repeats often cause 
secondary structure to form during amplification and prevent the DNA polymerase 
making the complete product.  As shown in Figure 4.7, the sequence is read successfully 
up until the highly repeated region beginning around base 90.  At this point the sequence 
degenerates and thereafter it is no longer possible to gain any useful sequence data. 
However, upon blasting this sequence (NCBI, BLAST), 73 bases out of 244 matched the 
known sequence for the X-inactivation centre (DXNds3) and hence it can be assumed 
with reasonable confidence that the primers are amplifying the appropriate product.
The sequence retrieved from the reverse primer ZFY12 confirms that the Zinc-finger 
region of the Y-chromosome was also amplified successfully (Figure 4.8).
Figure 4.8: Sequence obtained with the ZFY12 (reverse) primer using the ABI377 
sequencing system4.3.3 Qualitative analysis of total RNA using Agilent Bioanalyser
Figure 4.9: Gel of ribosomal RNA bands for 28S and 18S subunits shows high 
quality non-degraded total RNA. 
Figure 4.10: Electropherogram of clearly defined 18S and 28S ribosomal RNA 
peaks.
DNA contamination? Marker peakFigures 4.9 and 4.10 respectively are representative examples of the gel images and 
electropherograms produced for four trial total RNA samples of fetal liver (~200 ng RNA 
loaded per sample).  The electropherogram shows clearly defined 18S and 28S ribosomal 
RNA subunit peaks with low inter-peak noise, and minimal low molecular weight 
contamination.  The distinctive marker peak is detectable at the left hand side of the trace 
in Figure 4.10.  It is possible that there is genomic DNA contamination present within the 
samples as indicated by the small bump just after the 28S ribosomal peak on the 
electropreogram.  The peak ratios achieved for the trail samples were all between 2.4-2.6. 
A peak ratio of around 2.0 is desirable (i.e. the 28S ribosomal RNA subunit should be 
present with approximately twice the intensity of the 18S ribosomal RNA subunit).  This 
indicates that the sample handling and preparation and the RNA extraction procedure 
employed were effective at maintaining good quality total RNA with minimal 
degradation.
4.3.4 Qualitative analysis of total RNA extracted from the twenty-one selected male 
fetal liver samples
In the selection of the final twelve fetal liver RNA samples for the micro-array 
experiment it was also important to take account of the following variables:
-the RNA quality of fetal liver samples
-horn and total litter sizes from which fetuses were taken  Figure     4.11:     Representative electropherogram of the total RNA quality of one of the 
21 selected fetal liver samples showing low baseline, minimal low molecular weight 
noise, low inter-peak noise, well defined 18S and 28S peaks, 28S/18S ribosomal peak 
area ratio 2:1 with 28S peak taller than 18S peak.
Figure 4.11 is an electropherogram of the total RNA of one of the twenty-one selected 
fetal liver samples that were assessed for RNA quality using the Agilent Bioanalyser. 
The electropherograms for most of the twenty-one samples resembled this graph.  
28S 18S
MarkerF   igure 4.12:     Electropherogram example of total RNA quality from one of the 21 
selected fetal liver samples showing apparent degradation (this sample was 
discarded from the selection on the basis of poor RNA quality).
Figure 4.12 was an exception and shows poor quality RNA with moderate degradation. 
Consequently this sample was excluded from the selection.
4.3.5 Final sample selection of fetal liver RNA 
From the twenty-one male fetuses selected from Table 4.3, twelve fetal liver samples 
were chosen to be used in the micro-array study.  The final twelve fetal samples were 
selected on the basis of total RNA quality (28S/18S peak ratios for the selected twelve 
samples were between 1.5 and 2.1), as well as on the sizes of the litters from which the 
fetuses were taken (see Table 4.4).  
28S peak
Low molecular 
weight noiseMeans        (7.75/14.5)                                       (7.75/13.5)                                            (7.75/11) 
Table 4.4    :    References of the final twelve male fetal liver samples selected for 
genomics analysis, four biological replicates per dietary treatment group.  Numbers 
in red indicate the horn litter size and the total litter size respectively from which 
each fetus came.
As described in Chapter 3, (section 3.3.1.2) the total size of the litter (i.e. total number of 
conceptuses in both uterine horns) from which a conceptus is taken has a significant 
negative effect on the weight of the conceptus, fetus, placenta and fetal liver when 
measured at day 17.  In addition, left horn litter size had a significant negative effect on 
left horn fetus weights (p= 0.000) and on left horn placenta weights (p=0.025) in the 
same cohort of samples.  Similarly, right horn litter size had a significant negative effect 
on right horn fetus weights (p=0.000).  Note that horn (i.e. left or right) did not have a 
significant effect on the weight data at day 17.
In view of the above, and in order to minimize any potential effects of litter size on the 
genomics analysis, the total and in particular, the horn litter sizes of fetuses were taken 
into account when selecting the final fetal samples for the micro-array study so that these 
parameters could be kept as constant as possible between the dietary treatments.  Mean 
total litter size and mean horn litter size for the final twelve samples selected are shown at 
9% 
casein Horn/total
28s/18s 
ratio
18% 
casein Horn/total
28s/18s 
ratio Switch Horn/total
28s/18s 
ratio
9-n16 L4  9/17   2.1 18-n10 R5  9/14  2.0 SW-n10 R3  6/10 1.5
9-n17 L4 7/12     2.1 18-n11 R5  7/13  2.0 SW-n11 R5  10/11 1.6
9-n19 L4 7/16   1.7 18-n20 L5  8/13       1.9 SW-n12 L5  9/10 2.1
9-n22 R4 8/13 2.0 18-n18 R3  7/14  1.6 SW-n20 L3  6/13 2.0the bottom of Table 4.4.  It was possible to standardize the average horn litter sizes across 
all treatment groups in the samples, however total litter sizes were more variable.  
4.3.6 Comparison of total RNA yields (µg) from final fetal liver samples 
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Figure 4.13: Average RNA yield (µg/mg) from fetal liver tissue for final 12 micro-
array samples.  (n = 4 livers per group).
Figure 4.13 indicates that the average amount of RNA extracted from fetal liver tissue 
(µg/mg) was broadly similar between dietary treatments for the twelve selected samples. 
There was a large amount of variation around the means due to the low number of 
replicates in each dietary treatment group (n = 4).4.3.7 Adjusted cRNA yields
Yields of biotinylated cRNA recovered after clean up were above average.  The yields 
ranged from ~49 µg to ~85 µg across all samples, (Table 4.5).
9-16 L4 60.84   18-10 R5 85.42   SW-10 R3 71.81
9-17 L4 49.60 18-11 R5 59.03   SW-11 R5 83.31
9-19 L4 82.20 18-20 L5 48.81   SW-12 L5 57.72
9-22 R4 67.75 18-18 R3 57.34   SW-20 L3 64.00
Table 4.5: Adjusted cRNA yields (µg) for the twelve micro-array samples
4.3.8 Monitoring cRNA fragmentation
Figure 4.14 is a representative example of an electropherogram produced with the newly 
fragmented cRNA.  Migration of the fragmented cRNA at ~25 seconds correlates with an 
average fragment size of above 25 bps (migrates at 22.5 seconds) but below 200 bps 
(migrates at about ~29 seconds).  Average cRNA fragment size was estimated as ~90 bp 
in all samples, similar to expected.Figure 4.14: Example electropherogram of fragmented cRNA.  Peak height relates 
to quantity of fragmented cRNA.  Only 38.5 ng of fragmented cRNA was loaded 
here, hence the small cRNA peak reflects the small quantity of cRNA fragments 
loaded.  Note the change of fluorescence scale (y-axis) compared to previous 
electropherograms which explains large marker peak here.
4.3.9 Scanned probe array images
Figures 4.15 to 4.18 show some images obtained from the GeneChip Scanner 3000 
(Affymetrix).  Images are of scanned probe arrays and show raw (.DAT file) data and 
averaged (.CEL file) data.  By eye, all the .DAT files showed a high degree of similarity 
to one another amongst the chips for twelve samples which is desirable (i.e. no gross 
differences in staining/fluorescence were apparent at this stage).
Marker peak (25 bps)
cRNA fragmentsFigure 4.15: Raw .DAT file image of a scanned probe array generated from the 
GeneChip Scanner 3000.
The B2 Oligo serves as a positive hybridisation control and it is used by the GCOS 
software to place a grid over the image.  Grid alignment is indicated by a checkerboard 
pattern at each corner of the array, and the pattern of intensities on the borders as well as 
by the central cross (Figure 4.16).    
Figure 4.16: Zoomed in example .DAT file image from a scanned probe array of 
pixel intensities in each probe cell.  Here, the central cross on the array formed by 
the Oligo B2 indicates that the grid has been correctly aligned for image analysis. 
This was the case for all twelve scanned arrays.
.CEL files were generated from the .DAT file data.  .CEL files contain a single intensity 
value for each probe cell delineated by the grid (Figure 4.17, 4.18).
Control 
Oligonucleotide B2 is 
indicated by the 
central cross Feature/probe cellFigure 4.17: Example .CEL file image from a scanned probe array.  Single (average) 
intensity values for each probe cell are calculated here.                       
Figure 4.18: Zoomed in example .CEL file image
4.3.10 Data quality control parameters (GCOS)
Before conducting downstream analyses of array data, the quality of the array images was 
assessed using the GCOS software (Affymetrix).  From the report files (generated 
from .CHP file data), a number of quality control parameters were assessed using the 
poly-A controls, hybridization controls and house keeping/control probe sets. 
For the purposes of reliable array-array comparison, a global scaling strategy was 
employed.  Thus, the average signal intensity of all the arrays was set to a default Target 
Signal (TGT) value of 500.  The key assumption here is that a relatively small subset of transcripts will be changing amongst the arrays being analyzed.  In this case, since the 
majority of transcripts will not be changing amongst samples, the overall intensities of 
the arrays should be similar.  The overall intensity for each array is determined and 
compared to the target intensity value in order to calculate an appropriate scaling factor to 
make the different arrays comparable.  The resulting scaling factors should be similar 
amongst all arrays, i.e. within two or three-fold of one another, as larger discrepancies 
here may indicate significant assay variability or sample degradation leading to noisier 
data (personal communication from Dr. Geoff Scopes, Affymetrix).  
Overall Intensity x Scaling Factor = Target Intensity
For all twelve arrays, the scaling factors were within 2 fold of one another, the range of 
scaling factors for all the samples was between 3.792 and 5.137.
The number of probe sets called as “present” relative to the total number of probe sets on 
the array is shown as a percentage.  The percentage detected should be similar amongst 
the replicates in each treatment (Table 4.6).  Very low percent present can indicate poor 
sample quality.
Replicate 9% casein 18% casein switch
 1 50.30% 48.30% 48.80%
 2 46.80% 49% 47.10%
 3 47.40% 50.40% 51.20%
 4 50.50% 49.10% 49.60%
Table     4.6:     The percentage of probe sets called as “present” in samples from each 
dietary treatment showed similarity amongst replicates. Table 4.6 indicates that around 50% of probe sets were detected across all samples in 
each of the three treatment groups which indicate there is a relatively high expression 
profile, (personal communication from Dr. Geoff Scopes, Affymetrix).  Thus, the probe 
arrays contained genes which were relevant and appropriate for the samples used.
The poly-A RNA controls are internal control genes used to monitor the target labeling 
process for each sample and should be called “present” with increasing signal values in 
the order of lys, phe, thr, dap.  In all cases, the poly-A controls were all present and were 
generally called in the expected order of detection although some minor exceptions were 
present at the lower end of detection.
The hybridisation controls bioB, bioC, bioD and cre (1.5pM, 5pM, 25pM and 100pM 
respectively) were spiked into the hybridization cocktail and hence are independent of 
RNA sample preparation, and thus can be used to measure sample hybridization 
efficiency on the expression arrays.  BioB is at minimum level of assay sensitivity and 
hence may not always be called present.  However BioC, BioD and cre should always be 
called “present” with increasing signal intensity.  For all twelve arrays used, BioC, BioD, 
and cre were detectable with increasing intensity.  Furthermore, BioB was also detectable 
on all of the arrays indicating that the detection was as good as it could be within the 
limitations of the assay.
Finally, the internal control genes on each array, β-actin and GAPDH, were used to 
indicate RNA sample and assay quality.  Signal values of the 3’ probe sets for actin and GAPDH are compared to the signal values of the corresponding 5’ probe sets.  The ratio 
of the 3’ probe set to the 5’ probe set is usually no more than 3.0.  The Affymetrix 
expression assay used has a strong 3’ bias because this is where transcription started (in 
IVT reactions).  Anti-sense cRNA was transcribed from the sense strand of the double-
stranded cDNA via the T7 promoter.  A higher 3’ to 5’ ratio indicates degraded RNA or 
inefficient transcription of the double-stranded cDNA or biotinylated cRNA.  For all 
twelve arrays, actin and GAPDH were detected and the 3’/5’ ratios for both genes were 
close to 1.0 in all cases.  This indicates that RNA samples were of sufficient quality (non-
degraded) and the cDNA synthesis and cRNA labelling assays worked optimally for all 
samples producing full-length transcripts.
4.3.11 Quality control monitoring with Expression Console
Expression Console is able to confirm many of the quality control measures that were 
analysed in GCOS, as well as provide some novel qualitative analyses of the array data 
gathered.  Micro-array signals were normalised and quantified using Micro-array 
Analysis Suite 5.0 (MAS 5.0), Affymetrix before examining the Expression Console 
metrics.0
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Figure 4.19: Comparison of Scale Factors (SF) across all micro-array samples.
Figure 4.19 confirms the GCOS results for this metric.  The sample references denote the 
array samples in the three treatment groups as shown in Table 4.7.
Diet treatment: 9% casein 18% casein switch diet
Sample References: 1 3 6
  8 4 7
  9 17 12
  16 18 13
Table 4.7: Sample references of the twelve micro-array samples and the dietary 
treatment groups to which they belong.0
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Figure 4.20: Background average intensity across all micro-array samples.  Figure 4.20 indicates that there were no extreme outliers in terms of the background level 
of fluorescence detected on the arrays across all diet groups.
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Figure 4.21: The percentage of probe sets called as “present” in each micro-array 
fetal liver sample. 
Again, Figure 4.21 confirms the GCOS analysis of this parameter i.e. approximately 46-
50% of the probe sets on the micro-array are detected in the fetal liver samples.0
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Figure 4.22: 3` to 5` ratios of housekeeping genes GAPDH and β-Actin across all 
micro-array samples.
Figure 4.22 indicates that the 3` to 5` ratios for the house keeping genes are close to 1.0 
across all array samples which confirms the results obtained from GCOS.
Using the Expression Console software, a Pearson Correlation plot was generated from 
the .CEL file data.  Figure 4.23 and Table 4.8 indicates the strength of the correlations of 
signals amongst samples of the same treatment group and between samples in different 
treatment groups.Figure 4.23: (Overleaf) Pearson’s Correlation plot showing the correlations in 
signals amongst all samples after analysing the .CEL files normalised with the MAS 
5.0 algorithms.  The strength of correlation between any two samples is indicated by 
the sliding colour scale from red (perfect correlation, 1.0) to dark blue (weakest 
correlation coefficient, 0.985).Correlation 
coefficient 
sliding scaleMean of samples 17,18,3,4 (18% casein diet treatment) 0.9922988
Mean of samples 1,16,8,9 (9% casein diet treatment) 0.9917677
Mean of samples 12, 13, 6, 7 (switch diet treatment) 0.9899321
   
Mean of 18% casein samples Vs 9% casein samples 0.9907692
Mean of 18% casein samples Vs switch samples 0.9906570
Mean of 9% casein samples Vs switch samples 0.9902044
Table 4.8: Mean correlation coefficients of signals for array samples within and 
between treatment groups (MAS 5.0 normalised data).
Figure 4.23 and Table 4.8 indicate that all the array samples, from whichever treatment 
group, show a very high degree of similarity.  This suggests that there are no appreciable 
differences in the correlation coefficients within groups compared to between groups. 
Therefore, changes in expression that are due to treatment may be difficult to distinguish 
from background biological variation.
RMA normalisation algorithm
A Pearson Correlation plot and table of mean correlations was also created for 
correlations between the sample arrays when the .CEL files were analysed using the 
RMA algorithm (see Appendix I).  In general, the strength of these correlations appeared 
to be stronger compared to that in Figure 4.23, where data were normalised with MAS 
5.0 algorithm.  However, it is still the case that in general there does not seem to be much 
higher correlation coefficients of signals amongst samples of the same treatment group 
compared to between samples of different groups (see also Figure 4.24). Figure 4.24: RMA normalized log expression signal data compared to raw log 
expression signal data.  After RMA normalization, all twelve array samples are 
comparable and no real differences in expression signals are apparent overall.4.3.12 Downstream analysis using Array Assist (using RMA normalised data).
The .CEL file data were converted into expression levels and Principal Component 
Analysis was used to visualize the separation between the different treatment groups of 
samples when the array data had been normalised with the RMA algorithm.  However, 
there is not a clear-cut separation of samples into the three treatment groups, (Figure 
4.25).  Indeed, as described earlier many of the samples show a higher correlation 
between different diet groups than within groups of replicates.Figure 4.25: Principal Component Analysis Scores for array data when normalised 
with RMA.  The three dietary groups are identified by the different coloured 
shapes.  Ideally, there should be a good separation between the control group and 
the two treatment groups, but this is not the case.  In Figure 4.25, samples 1, 9 and 16 in the 9% casein diet group all look fairly closely 
related, but sample 8 is a strong outlier from this group on the opposite side of the plot. 
Similarly, for the 18% casein diet group samples 4, 17, and 18 are closely related but 
sample 3 is a strong outlier.  In the switch diet group samples 6, 7, 12 are fairly close to 
one another, but sample 13 is further away from its group.  Thus, it appears that samples 
3, 8 and 13 are outliers to their respective diet groups.  One possibility would be to 
exclude these outliers from the further analysis; however, this would also mean a loss of 
information.  Thus the analysis proceeded with all samples included.  
Table 4.9 displays the results of the significance analysis for each of three comparisons 
made between the diet groups.  The number of changed genes at different p-values, 
combined with different sized fold changes is shown for each comparison.  The bottom 
row of each comparison indicates the number of changed genes expected to arise by 
chance at each p-value, which is quite concerning.
Table 4.9: (overleaf) Results of differential expression analyses between pairs of diet 
groups (unpaired t-tests).  Key to nomenclature used in this table: T1 (9% casein), 
T2 (switch), Ctrl (18% casein), FC (Fold change).Using the least stringent criteria in Table 4.9, i.e. p<0.05 and fold change 1.1< (a very 
small change in expression), the results indicate that for the 9% casein v 18% casein 
comparison 1377 probe sets changed; for the switch v 18% casein comparison 992 probe 
sets changed and for the switch v 9% casein comparison 1964 probe sets were changed. 
Thus, it appears that the greatest number of changes in probe set expression was between 
the switch and 9% casein diet groups.  However, the expected number of changes 
identified by chance at this significance level was 1482!  If gene lists were produced of 
the probe sets identified in the first two comparisons using the above criteria they would 
include non-meaningful results as the numbers of probe sets identified by chance is 
greater than the number of probe sets identified as changing in each of these 
comparisons.  Using these criteria, only the switch v 9% casein comparison is likely to 
include meaningful probe sets changes, not generated by chance, but even then the rate of 
false discovery stands at 75%!
Despite the high likelihood of false discoveries, analysis was carried out to detect probe 
sets apparently changing between the diet groups with a fold change of 1.4< and a p-
value of <0.05, and gene lists were produced (Tables 4.10 to 4.12).  The gene lists 
indicate that the largest number of changes again results from the switch v 9% 
comparison.  For all comparisons the number of up-regulated genes was greater than the 
number down-regulated: 9% casein v 18% casein = 73 probe sets changed, 29 down; 44 
up; switch v 18% casein = 53 probe sets changed, 13 down, 40 up; switch v 9% casein 
227 probe sets changed, 109 down, 118 up.    
  Probe Set ID Gene Title p-value FC
1455869_at Calcium/calmodulin-dependent protein kinase II, beta 1.41E-06 (-)14.20
1431213_a_at RIKEN cDNA 1300007C21 gene ///  7.15E-05 (-)11.52
1436296_x_at Similar to dynein, axonemal, intermediate polypeptide 2 0.04 (-)3.51
1455773_at Phosphatidylinositol binding clathrin assembly protein 0.02 (-)2.32
1448406_at CREBBP/EP300 inhibitory protein 1 0.001 (+)2.31
1423257_at cytochrome P450, family 4, subfamily a, polypeptide 14 0.01 (+)2.23
1416460_at myo-inositol oxygenase 0.03 (-)2.21
1452975_at alanine-glyoxylate aminotransferase 2-like 1 0.02 (+)2.19
1458609_at Adult male bone cDNA, RIKEN full-length enriched library,  0.03 (+)2.17
1457458_at cDNA sequence BC057627 0.04 (+)2.10
AFFX-
18SRNAMur   0.02 (+)2.03
1438644_x_at COMM domain containing 9 0.03 (+)1.98
1438763_at dynein, axonemal, heavy chain 2 /// dynein heavy chain domain 3 0.01 (+)1.92
1429351_at kelch-like 24 (Drosophila) 0.01 (+)1.92
1436735_at NOL1/NOP2/Sun domain family 3 0.04 (+)1.86
1450459_at RIKEN cDNA 2010106G01 gene 0.05 (+)1.86
1451920_a_at replication factor C 1 0.05 (-)1.80
1451793_at kelch-like 24 (Drosophila) 0.01 (+)1.78
1419127_at neuropeptide Y 0.02 (+)1.75
1435378_at RIKEN cDNA 2210020M01 gene 0.03 (-)1.67
1425451_s_at chitinase 3-like 3 /// chitinase 3-like 4 0.03 (+)1.65
1419039_at cytochrome P450, family 2, subfamily d, polypeptide 22 0.02 (+)1.64
1421031_a_at RIKEN cDNA 2310016C08 gene 0.02 (+)1.63
1417273_at pyruvate dehydrogenase kinase, isoenzyme 4 0.03 (+)1.63
1423566_a_at heat shock protein 110 0.03 (-)1.62
1419764_at chitinase 3-like 3 0.01 (+)1.61
1416521_at selenoprotein W, muscle 1 0.01 (+)1.61
1449051_at peroxisome proliferator activated receptor alpha 0.02 (+)1.60
1423062_at insulin-like growth factor binding protein 3 0.03 (-)1.59
1426037_a_at regulator of G-protein signaling 16 0.02 (+)1.59
1428923_at protein phosphatase 1, regulatory (inhibitor) subunit 3G 0.02 (+)1.57
1434278_at X-linked myotubular myopathy gene 1 0.02 (-)1.54
1436795_at RIKEN cDNA 9630058J23 gene 0.01 (+)1.54
1436948_a_at RIKEN cDNA 6430550H21 gene 0.03 (+)1.54
1436355_at fatty acid desaturase domain family, member 6 0.01 (-)1.53
1419314_at tubulointerstitial nephritis antigen 0.04 (-)1.53
1418936_at v-maf musculoaponeurotic fibrosarcoma oncogene family,  0.04 (+)1.51
1437497_a_at heat shock protein 90kDa alpha (cytosolic), class A member 1 0.02 (-)1.51
1421163_a_at nuclear factor I/A 0.02 (+)1.50
1426743_at Dip3 beta 0.003 (+)1.49
1429530_a_at sphingomyelin phosphodiesterase 4 0.02 (-)1.48
1451355_at N-acylsphingosine amidohydrolase 3-like 0.03 (+)1.48
1458268_s_at insulin-like growth factor binding protein 3 0.02 (-)1.48
1453457_at RIKEN cDNA 2900070H08 gene 0.04 (+)1.48
1460328_at bromodomain containing 3 0.03 (-)1.48
1425993_a_at heat shock protein 110 0.04 (-)1.48
1417707_at RIKEN cDNA B230342M21 gene 0.03 (+)1.47
1421198_at integrin alpha V 0.03 (+)1.471441915_s_at RIKEN cDNA 2310076L09 gene 0.01 (+)1.47
1427347_s_at tubulin, beta 2a /// tubulin, beta 2b /// similar to tubulin, beta 3 0.01 (-)1.46
1434405_at RIKEN cDNA A730024A03 gene 0.01 (+)1.46
1428682_at zinc finger CCCH type containing 6 0.03 (+)1.46
1446807_at ubiquitin specific peptidase 8 0.03 (-)1.45
1428870_at nucleolar and coiled-body phosphoprotein 1 0.04 (-)1.45
1433772_at
stress 70 protein chaperone, microsome-associated, human 
homolog 0.003 (-)1.45
1424937_at RIKEN cDNA 2310076L09 gene 0.005 (+)1.44
1444036_at Protein phosphatase 2, regulatory subunit B (B56), alpha isoform 0.05 (+)1.43
1439516_at RIKEN cDNA 2610201A13 gene 0.02 (-)1.43
1453008_at RIKEN cDNA 2300002D11 gene 0.01 (+)1.43
1453080_at RIKEN cDNA 9130022K13 gene ///  0.03 (+)1.43
1424843_a_at growth arrest specific 5 0.03 (-)1.43
1450900_at expressed sequence AW011752 0.01 (+)1.43
1425632_a_at PQ loop repeat containing 2 0.02 (+)1.42
1437959_at zinc finger protein 324 0.02 (-)1.42
1456991_at Cobl-like 1 0.04 (+)1.42
1453954_a_at mitochondrial ribosomal protein S5 0.03 (-)1.42
1421260_a_at spermidine synthase 0.002 (-)1.42
1448277_at polymerase (DNA directed), delta 2, regulatory subunit 0.002 (-)1.41
1426657_s_at 3-phosphoglycerate dehydrogenase ///  2.58E-04 (-)1.41
1428869_at nucleolar and coiled-body phosphoprotein 1 0.04 (-)1.41
1421009_at radical S-adenosyl methionine domain containing 2 0.04 (+)1.41
1425503_at glucosaminyl (N-acetyl) transferase 2, I-branching enzyme 0.03 (+)1.40
1421002_at angiopoietin-like 2 0.01 (+)1.40
Table 4.10: Gene list of 73 probe sets identified as up or down-regulated in 
expression in the 9% casein treatment group relative to 18% casein control group. 
The +/- sign in the FC (fold change) column indicates the direction of the change in 
expression of that gene.  The largest fold change identified here is for probe set 
1455869 which represents the Camk2b gene.  This analysis suggests that Camk2b is 
heavily down regulated by the 9% casein treatment.Probe Set ID Gene Title p-value FC
1448406_at CREBBP/EP300 inhibitory protein 1 0.02 (+)1.98
1429809_at transmembrane and tetratricopeptide repeat containing 2 0.01 (-)1.44
1457484_at hypothetical D930050J11 9.53E-04 (+)1.42
1438644_x_at COMM domain containing 9 0.002 (+)2.60
1435378_at RIKEN cDNA 2210020M01 gene 0.04 (-)1.59
1436296_x_at Similar to dynein, axonemal, intermediate polypeptide 2 0.04 (-)3.59
1457458_at cDNA sequence BC057627 0.03 (+)2.23
1426737_at G1 to S phase transition 1 0.02 (-)1.46
1440443_at RIKEN cDNA E030016H06 gene 0.04 (+)1.90
1443852_at Transcribed locus 0.04 (+)1.51
1446160_x_at transmembrane protein 69 0.05 (+)1.48
1436944_x_at RIKEN cDNA 4933439C20 gene 0.02 (+)1.49
1435371_x_at carboxylesterase 3 0.05 (+)1.45
1442255_at RIKEN cDNA 5033414D02 gene 0.04 (+)1.73
1438508_at Jumonji domain containing 1B 0.02 (+)1.49
1436766_at LUC7-like 2 (S. cerevisiae) 0.05 (+)1.48
1421258_a_at pyruvate kinase liver and red blood cell 0.02 (-)1.42
1439319_at E74-like factor 1 0.04 (+)1.62
1429478_at RIKEN cDNA 6720463M24 gene 0.04 (+)1.82
1417079_s_at lectin, galactose-binding, soluble 2 0.02 (-)1.61
1451798_at interleukin 1 receptor antagonist 0.03 (-)1.46
1458505_at hypothetical LOC552901 0.01 (+)1.50
1436898_at
splicing factor proline/glutamine rich (polypyrimidine tract binding protein 
associated) 0.004 (+)1.48
1457605_at Ataxin 1 0.03 (+)1.45
1421869_at tripartite motif-containing 44 0.03 (-)1.54
1445402_at Adenosine kinase 0.03 (+)1.56
1420901_a_at hexokinase 1 0.03 (-)1.45
1438244_at nuclear factor I/B 0.02 (+)1.62
1443056_at Protein tyrosine phosphatase, receptor type, D 0.05 (+)1.45
1435163_at RIKEN cDNA 9030612M13 gene 0.01 (+)1.44
1445695_at Ataxin 1 5.25E-04 (+)1.62
1424737_at thyroid hormone responsive SPOT14 homolog (Rattus) 0.02 (+)1.64
1429701_at RIKEN cDNA 2410003J06 gene 0.03 (+)1.63
1442109_at   0.02 (+)1.82
1449556_at histocompatibility 2, T region locus 23 /// RIKEN cDNA C920025E04 gene  0.03 (-)1.41
1430404_at RIKEN cDNA 4833416J08 gene 0.05 (+)1.46
1440365_at Actin, beta, cytoplasmic 0.04 (+)1.43
1418604_at arginine vasopressin receptor 1A 0.03 (-)1.69
1446284_at metastasis suppressor 1 0.004 (+)2.02
1441988_at protein phosphatase 1K (PP2C domain containing) 0.05 (+)1.41
1417015_at Ras association (RalGDS/AF-6) domain family 3 0.01 (-)1.45
1429882_at RIKEN cDNA 2610005L07 gene 0.03 (+)1.55
1437862_at RIKEN cDNA 2600011C06 gene 0.04 (+)1.49
1457770_at solute carrier family 39 (zinc transporter), member 14 0.04 (+)1.50
1441653_at RIKEN cDNA D030022P06 gene 0.01 (+)1.52
1430622_at RIKEN cDNA 4833423F13 gene 0.04 (+)1.44
1427052_at acetyl-Coenzyme A carboxylase beta 0.02 (+)1.58
1443512_at Spermatogenesis associated 5 0.01 (+)1.421431096_at integrator complex subunit 8 0.03 (-)1.47
1450332_s_at flavin containing monooxygenase 5 0.02 (+)1.40
1438265_at   0.04 (+)1.41
1457554_at apolipoprotein B 0.01 (+)1.59
1451577_at zinc finger and BTB domain containing 20 0.02 (+)1.41
Table 4.11: Gene list of 53 probe sets identified as up or down-regulated in 
expression in the switch treatment group relative to 18% casein control group.  Probe Set ID Gene Title p-value FC (+/-)
1434062_at RAB GTPase activating protein 1-like 5.01E-04 1.55 down
1429809_at transmembrane and tetratricopeptide repeat containing 2 6.12E-04 1.78 down
1453365_at RAB GTPase activating protein 1-like 6.78E-04 1.40 down
1422833_at forkhead box A2 6.89E-04 1.43 up
1444406_at Mitogen-activated protein kinase kinase kinase kinase 3 7.82E-04 1.41 up
1457528_at solute carrier family 4, sodium bicarbonate cotransporter, member 7 8.38E-04 1.54 up
1422906_at ATP-binding cassette, sub-family G (WHITE), member 2 8.39E-04 1.40 down
1416286_at regulator of G-protein signaling 4 8.44E-04 1.86 down
1449252_at RIKEN cDNA 9030611O19 gene 9.42E-04 1.42 down
1422100_at cytochrome P450, family 7, subfamily a, polypeptide 1 0.002 1.53 up
1424864_at homeodomain interacting protein kinase 2 0.002 1.60 down
1437360_at protocadherin 19 0.002 1.51 down
1416521_at selenoprotein W, muscle 1 0.002 1.43 down
1449936_at RIKEN cDNA 8430419L09 gene 0.002 1.45 down
1415899_at Jun-B oncogene 0.002 2.56 down
1429882_at RIKEN cDNA 2610005L07 gene 0.002 1.62 up
1416913_at esterase 1 0.002 1.81 up
1427347_s_at tubulin, beta 2a /// tubulin, beta 2b ///  0.002 1.64 up
1456359_at peptidylprolyl isomerase domain and WD repeat containing 1 0.003 1.55 down
1444538_at Expressed sequence AL033314 0.003 1.55 up
1441653_at RIKEN cDNA D030022P06 gene 0.003 1.56 up
1426721_s_at TCDD-inducible poly(ADP-ribose) polymerase 0.003 1.74 down
1437878_s_at
coiled-coil domain containing 39 /// tetratricopeptide repeat domain 
14 0.003 1.41 up
1443512_at Spermatogenesis associated 5 0.003 1.43 up
1429433_at BAT2 domain containing 1 0.003 1.55 up
1431235_at   0.004 1.50 up
1427052_at acetyl-Coenzyme A carboxylase beta 0.004 1.62 up
1416460_at myo-inositol oxygenase 0.004 2.23 up
1417079_s_at lectin, galactose-binding, soluble 2 0.004 1.90 down
1430622_at RIKEN cDNA 4833423F13 gene 0.004 1.40 up
1424962_at transmembrane 4 superfamily member 4 0.004 1.49 down
1446284_at metastasis suppressor 1 0.004 1.89 up
1421163_a_at nuclear factor I/A 0.004 1.61 down
1439970_at WNK lysine deficient protein kinase 1 0.005 1.41 up
1443505_at Prokineticin 1 0.005 3.34 up
1449335_at tissue inhibitor of metalloproteinase 3 0.01 1.41 down
1438037_at hect domain and RLD 5 0.01 1.72 up
1448852_at regucalcin 0.01 1.45 up
1438763_at dynein, axonemal, heavy chain 2 /// dynein heavy chain domain 3 0.01 2.01 down
1451240_a_at glyoxalase 1 0.01 1.47 up
1440490_at
Membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 
6) 0.01 1.54 down
1440573_at Erbb2 interacting protein 0.01 2.44 down
1424108_at glyoxalase 1 0.01 1.42 up
1457554_at apolipoprotein B 0.01 1.59 up
1449005_at
solute carrier family 16 (monocarboxylic acid transporters), member 
3 0.01 1.45 down
1417231_at claudin 2 0.01 1.78 up
1418918_at insulin-like growth factor binding protein 1 0.01 1.45 down1459984_at melanoma inhibitory activity 3 0.01 2.00 up
1423663_at folliculin 0.01 1.41 down
1439933_at RIKEN cDNA B430316J06 gene 0.01 1.42 up
1419149_at serine (or cysteine) peptidase inhibitor, clade E, member 1 0.01 6.87 down
1450387_s_at adenylate kinase 3 alpha-like 1 0.01 1.64 down
1441228_at apolipoprotein L domain containing 1 0.01 1.45 down
1426037_a_at regulator of G-protein signaling 16 0.01 1.75 down
1421031_a_at RIKEN cDNA 2310016C08 gene 0.01 1.98 down
1416921_x_at aldolase 1, A isoform 0.01 1.47 down
1433831_at RIKEN cDNA 4833418A01 gene 0.01 1.52 down
1434278_at X-linked myotubular myopathy gene 1 0.01 1.69 up
1417766_at cytochrome b5 type B 0.01 1.49 up
1416667_at phenylalkylamine Ca2+ antagonist (emopamil) binding protein 0.01 1.51 up
1455186_a_at RIKEN cDNA 1190003J15 gene 0.01 1.59 up
1458268_s_at insulin-like growth factor binding protein 3 0.01 1.73 up
1431786_s_at RIKEN cDNA 1190003J15 gene 0.01 1.54 up
1452973_at protein phosphatase 1K (PP2C domain containing) 0.01 1.50 down
1427213_at 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 0.01 1.55 up
1438244_at nuclear factor I/B 0.01 1.48 up
1423062_at insulin-like growth factor binding protein 3 0.01 1.88 up
1419647_a_at immediate early response 3 0.01 1.68 down
1438663_at BAT2 domain containing 1 0.01 1.43 up
1439825_at deltex 3-like (Drosophila) 0.01 1.66 up
1441438_at glypican 6 0.01 1.47 up
1437355_at zinc finger, CCHC domain containing 5 0.01 1.42 down
1416895_at ephrin A1 0.01 2.33 down
1444036_at Protein phosphatase 2, regulatory subunit B (B56), alpha isoform 0.01 1.69 down
1449846_at eosinophil-associated, ribonuclease A family, member 2 0.01 1.41 up
1457760_at RIKEN cDNA A930004J17 gene 0.01 1.65 up
1419103_a_at abhydrolase domain containing 6 0.01 1.48 down
1442109_at   0.01 2.03 up
1441272_at   0.01 1.60 up
1423244_at RIKEN cDNA 9030012A22 gene 0.01 1.69 up
1434799_x_at aldolase 1, A isoform 0.01 1.47 down
1438167_x_at Folliculin 0.01 1.47 down
1442015_at RIKEN cDNA 2500002B13 gene 0.01 1.47 down
1451756_at FMS-like tyrosine kinase 1 0.01 1.45 down
1439038_at RIKEN cDNA 9130227C08Rik gene 0.01 1.52 down
1440461_at RIKEN cDNA 0910001A06 gene 0.02 1.46 up
1419039_at cytochrome P450, family 2, subfamily d, polypeptide 22 0.02 1.63 down
1454229_a_at exonuclease domain containing 1 0.02 1.41 down
1426805_at
SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, 0.02 1.86 up
1429351_at kelch-like 24 (Drosophila) 0.02 1.63 down
1445381_at   0.02 1.70 down
1441947_x_at cDNA sequence BC033915 0.02 1.56 down
1446007_at Bone morphogenetic protein 1 0.02 1.40 up
1448510_at ephrin A1 0.02 2.54 down
1418787_at mannose binding lectin (C) 0.02 2.76 up
1459687_x_at Cleavage and polyadenylation specific factor 6 0.02 1.41 up1457449_at Longevity assurance homolog 6 (S. cerevisiae) 0.02 1.46 up
1451798_at interleukin 1 receptor antagonist 0.02 1.64 down
1448340_at transmembrane protein 30A 0.02 1.54 up
1460052_at Acyl-CoA synthetase medium-chain family member 1 0.02 1.64 down
1430566_at RIKEN cDNA 4733401A01 gene 0.02 1.85 up
1454617_at arrestin domain containing 3 0.02 1.48 down
1459497_at Farnesyl diphosphate farnesyl transferase 1 0.02 1.42 up
1441102_at prolactin receptor 0.02 2.15 up
1418936_at
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F 
(avian) 0.02 1.79 down
1434025_at   0.02 1.42 down
1419322_at FYVE, RhoGEF and PH domain containing 6 0.02 1.40 down
1448009_at UDP-glucose ceramide glucosyltransferase-like 1 0.02 1.41 up
1426958_at ribosomal protein S9 /// similar to ribosomal protein S9 0.02 1.47 up
1420774_a_at RIKEN cDNA 4930583H14 gene 0.02 2.99 down
1437638_at serine/arginine repetitive matrix 2 0.02 1.55 up
1421830_at adenylate kinase 3 alpha-like 1 0.02 1.58 down
1426810_at jumonji domain containing 1A 0.02 1.43 down
1436538_at ankyrin repeat domain 37 0.02 3.21 down
1459141_at RIKEN cDNA 1810008I18 gene 0.02 1.62 up
1448792_a_at cytochrome P450, family 2, subfamily f, polypeptide 2 0.02 2.00 up
1438743_at cytochrome P450, family 7, subfamily a, polypeptide 1 0.02 1.87 up
1433604_x_at aldolase 1, A isoform 0.02 1.49 down
1427070_at RIKEN cDNA 5730407K14 gene 0.02 1.85 down
1438265_at   0.02 1.40 up
1428923_at protein phosphatase 1, regulatory (inhibitor) subunit 3G 0.02 1.56 down
1451355_at N-acylsphingosine amidohydrolase 3-like 0.02 1.61 down
1449347_a_at X-linked lymphocyte-regulated 4B /// 4A /// 4E 0.02 1.59 up
1437417_s_at glypican 6 0.02 1.48 up
1443838_x_at fatty acid desaturase 2 0.02 1.42 up
1458601_at RIKEN cDNA 8030447M02 gene 0.02 1.41 up
1434465_x_at very low density lipoprotein receptor 0.02 1.73 down
1442679_at Mitogen activated protein kinase kinase 4 0.02 2.21 up
1458832_at Growth hormone receptor 0.02 1.52 up
1420678_a_at interleukin 17 receptor B 0.02 1.40 down
1435866_s_at histone 3, H2a 0.03 1.56 down
1434958_at sacsin 0.03 1.43 up
1425632_a_at PQ loop repeat containing 2 0.03 1.41 down
1426356_at RIKEN cDNA 6330578E17 gene 0.03 1.48 down
1424794_at ring finger protein 186 0.03 1.51 down
1453189_at ubiquitin-conjugating enzyme E2I 0.03 1.73 up
1439173_at hook homolog 1 (Drosophila) 0.03 1.43 up
1459627_at Sterol-C4-methyl oxidase-like 0.03 1.44 up
1456974_at one cut domain, family member 1 0.03 2.75 up
1420934_a_at serine/arginine repetitive matrix 1 0.03 1.42 up
1453009_at carboxypeptidase M 0.03 1.99 down
1440926_at FMS-like tyrosine kinase 1 0.03 1.41 down
1442549_at muscleblind-like 3 (Drosophila) 0.03 1.45 up
1421076_at SERTA domain containing 3 0.03 1.74 down
1418662_at RIKEN cDNA 2210012G02 gene 0.03 1.81 down1453776_at RIKEN cDNA 5730407K14 gene 0.03 1.45 down
1441573_at Sex comb on midleg homolog 1 0.03 1.49 down
1435018_at RIKEN cDNA 5930434B04 gene 0.03 1.40 up
1421946_at C-reactive protein, pentraxin-related 0.03 1.44 up
1451261_s_at expressed sequence AW049765 0.03 1.51 up
1454904_at X-linked myotubular myopathy gene 1 0.03 1.61 up
1418028_at dopachrome tautomerase 0.03 1.58 up
1424737_at thyroid hormone responsive SPOT14 homolog (Rattus) 0.03 1.85 up
1416514_a_at
fascin homolog 1, actin bundling protein (Strongylocentrotus 
purpuratus) 0.03 1.50 down
1437862_at RIKEN cDNA 2600011C06 gene 0.03 1.56 up
1447046_at DnaJ (Hsp40) related, subfamily B, member 13 0.03 1.57 up
1440373_at
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1 (Hu 
antigen R) 0.03 1.41 up
1457635_s_at nuclear receptor subfamily 3, group C, member 1 0.03 1.44 down
1457357_at tousled-like kinase 2 (Arabidopsis) 0.03 1.43 up
1419523_at cytochrome P450, family 3, subfamily a, polypeptide 13 0.03 1.63 up
1460242_at CD55 antigen 0.03 1.42 down
1417273_at pyruvate dehydrogenase kinase, isoenzyme 4 0.03 1.61 down
1445695_at Ataxin 1 0.03 1.50 up
1426008_a_at solute carrier family 7 (cationic amino acid transporter, y+ system),  0.03 1.67 down
1448239_at heme oxygenase (decycling) 1 0.03 3.70 down
1418946_at ST3 beta-galactoside alpha-2,3-sialyltransferase 1 0.03 1.84 down
1418453_a_at ATPase, Na+/K+ transporting, beta 1 polypeptide 0.03 1.43 down
1453290_at high mobility group box 2-like 1 0.03 1.87 up
1450109_s_at ATP-binding cassette, sub-family C (CFTR/MRP), member 2 0.03 1.56 up
1457483_at AT rich interactive domain 5B (Mrf1 like) 0.03 1.41 up
1431170_at ephrin A3 0.03 1.75 down
1428141_at
golgi associated, gamma adaptin ear containing, ARF binding 
protein 2 0.03 1.41 down
1424148_a_at expressed sequence AW049765 0.03 1.49 up
1455904_at growth arrest specific 5 0.03 1.40 up
1458719_at Transcribed locus 0.03 1.42 up
1437218_at Fibronectin 1 0.04 1.73 up
1430165_at serine/threonine kinase 17b (apoptosis-inducing) 0.04 1.61 down
1419251_at epidermal growth factor receptor pathway substrate 15 0.04 1.44 down
1460328_at bromodomain containing 3 0.04 1.53 up
1439036_a_at ATPase, Na+/K+ transporting, beta 1 polypeptide 0.04 1.46 down
1425031_at Fukuyama type congenital muscular dystrophy homolog (human) 0.04 1.54 up
1440439_at Expressed sequence AI591476 0.04 1.42 up
1423828_at fatty acid synthase 0.04 1.54 up
1451577_at zinc finger and BTB domain containing 20 0.04 1.41 up
1453080_at RIKEN cDNA 9130022K13 gene /// 0.04 1.44 down
1442277_at choline kinase alpha 0.04 1.46 up
1424733_at purinergic receptor P2Y, G-protein coupled, 14 0.04 1.50 down
1451263_a_at fatty acid binding protein 4, adipocyte 0.04 1.41 down
1426812_a_at RIKEN cDNA 9130404D14 gene 0.04 1.44 down
1444330_at DNA segment, Chr 2, ERATO Doi 173, expressed 0.04 1.60 up
1457987_at RIKEN cDNA 6030458C11 gene 0.04 2.07 up
1418736_at
UDP-GalNAc:betaGlcNAc beta 1,3-galactosaminyltransferase, 
polypeptide 1 0.04 1.40 down1416432_at 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 0.04 1.45 down
1422797_at mitogen activated protein binding protein interacting protein 0.04 1.48 down
1416833_at kidney expressed gene 1 0.04 1.50 up
1455265_a_at regulator of G-protein signaling 16 0.04 1.45 down
1418370_at troponin C, cardiac/slow skeletal 0.04 1.43 down
1418813_at serine (or cysteine) peptidase inhibitor, clade A, member 5 0.04 2.04 up
1424273_at cytochrome P450, family 2, subfamily c, polypeptide 70 0.04 1.42 up
1429093_at DNA-damage inducible protein 2 0.04 1.53 up
1439255_s_at G protein-coupled receptor 137B ///  0.04 1.47 down
1439231_at   0.04 1.68 up
1418603_at arginine vasopressin receptor 1A 0.04 1.44 down
1418601_at aldehyde dehydrogenase family 1, subfamily A7 0.04 1.62 up
1456094_at ubiquitin specific peptidase 36 0.04 1.49 up
1422710_a_at calcium channel, voltage-dependent, T type, alpha 1H subunit 0.04 1.41 down
1437100_x_at proviral integration site 3 0.04 1.51 down
1448453_at
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-
isomerase 1 0.04 1.53 up
1424140_at galactose-4-epimerase, UDP 0.04 1.42 up
1448873_at occludin 0.04 1.54 down
1424981_at neurolysin (metallopeptidase M3 family) 0.04 1.45 down
1455818_at RIKEN cDNA 4930427A07 gene 0.04 1.43 up
1418835_at pleckstrin homology-like domain, family A, member 1 0.05 1.65 up
1415965_at stearoyl-Coenzyme A desaturase 1 0.05 1.54 up
1417388_at brain expressed X-linked 2 0.05 1.54 down
1429847_a_at RIKEN cDNA 4833418A01 gene 0.05 1.45 down
1435926_at RIKEN cDNA E030003F13 gene 0.05 1.41 up
1433837_at RIKEN cDNA 8430408G22 gene 0.05 1.60 down
1449233_at basic helix-loop-helix domain containing, class B, 8 0.05 1.42 up
1451456_at RIKEN cDNA 6430706D22 gene 0.05 1.45 up
1449047_at 2-hydroxyacyl-CoA lyase 1 0.05 1.54 up
1434486_x_at UDP-glucose pyrophosphorylase 2 0.05 1.46 down
1421198_at integrin alpha V 0.05 1.43 down
1417900_a_at very low density lipoprotein receptor 0.05 1.85 down
1428329_a_at intraflagellar transport 80 homolog (Chlamydomonas) 0.05 1.43 down
1450876_at complement component factor h 0.05 1.79 up
1416687_at procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 0.05 1.99 down
Table 4.12: Gene list of 227 probe sets identified as up or down-regulated in 
expression in the switch treatment group relative to 9% casein treatment group.  4.3.13 Downstream analysis using GeneSpring (using RMA normalized data).
Initial analysis of the data using GeneSpring suggested there was a considerable amount 
of biological variation amongst replicates from within the same diet group, thus making it 
difficult to distinguish changes in expression that are due to the diet treatment. 
Log signal intensity plots created from RMA normalized data are shown in Figures 4.26 
to 4.29; the vertical blue grid lines on the plots represent the four biological replicates 
within each of the diet groups.  If minimal biological variation in gene expression was 
present, the zigzagged lines on these plots would appear more linear across replicate 
samples from the same diet group.  Each coloured line on the grid represents the 
expression pattern of a single probe set/gene that appears to be changing in relation to 
diet under the analysis parameters selected (section 4.2.14.2).  The line colours are 
dictated by comparison to the level of expression in the 18% casein diet group for the 
particular gene (a sliding scale of line colour denotes the relative level of expression 
relative to the 18% casein diet).Figure 4.26: Data filtered for two-fold decreases in gene expression in the 9% casein 
diet treatment compared to the 18% casein diet treatment.  
Figure 4.27: Data filtered for two-fold increases in gene expression in the 9% casein 
diet treatment compared to the 18% casein diet treatment.  In Figure 4.27 there appears to be multiple genes following the same pattern of 
expression amongst the replicates within the diet groups being compared; this may be 
because these genes are all associated with a common pathway.  Notably, in this 
comparison, one sample from the 18% casein diet group appears to be markedly different 
in terms of probe set expression levels relative to the other three replicates within that 
group.
Figure 4.28: Data filtered for two-fold decreases in the switch diet treatment 
compared to the 18% casein diet treatment.Figure 4.29: Data filtered for two-fold increases in the switch diet treatment 
compared to the 18% casein diet treatment.
Gene lists were generated from the log signal intensity plots in Figures 4.26 to 4.29 
detailing the gene name/description of the genes identified as increasing or decreasing in 
expression in each of the treatment groups relative to the control group (Tables 4.13 to 
4.16).  However, no significant differences were up held in the level of probe set 
expression between the dietary treatments (ANOVA, p<0.05).Table 4.13: Gene list of 14 probe sets down-regulated in expression in the 9% casein 
treatment group relative to 18% casein control group.  Interestingly, the Camk2b 
gene was also identified as being down regulated in the 9% casein group relative to 
controls in the gene lists produced by analysis using Array Assist (section 4.3.12).  
9% casein (down)
Gene      Number pass      Description                     
1431213_a_at 4          RIKEN cDNA 1300007C21 gene; 
1455869_at 4          Calcium/calmodulin-dependent protein kinase II, beta (Camk2b), mRNA  82; G1/S transition of    
                                      mitotic cell cycle; protein amino acid phosphorylation; calcium ion transport; protein amino acid     
                                      autophosphorylation;
1436296_x_at 4          Transcribed locus
1452388_at 3          heat shock protein 1A  723 ; telomere maintenance; DNA repair; protein folding; response to 
                                     unfolded protein; response to heat;
1452318_a_at 3          heat shock protein 1B  723 ; telomere maintenance; inhibition of caspase activation; DNA repair; 
                                      protein folding; anti-apoptosis; response to unfolded protein; response to heat;
1457987_at 3          RIKEN cDNA 6030458C11 gene
1455773_at 3
1452705_at 3          expressed sequence AA415817        6520; amino acid metabolism;
1427126_at 3          heat shock protein 1B  723; telomere maintenance; inhibition of caspase activation; DNA repair; 
                                      protein folding; anti-apoptosis; response to unfolded protein; response to heat;
1418129_at 3          24-dehydrocholesterol reductase     188; inactivation of MAPK activity; cholesterol biosynthesis;   
                                      electron transport;
1416460_at 3          myo-inositol oxygenase     9992 ; cellular osmoregulation; membrane organization and biogenesis;   
                                      myo-inositol catabolism; inositol phosphate-mediated signaling;
1436823_x_at 3          hemoglobin Y, beta-like embryonic chain      6810 ; transport ; oxygen transport;
1436717_x_at 3          hemoglobin Y, beta-like embryonic chain      6810 ; transport; oxygen transport;
1433876_at 3          RIKEN cDNA 6430402H13 gene     7155; cell adhesion;Table 4.14: Gene list of 36 probe sets up-regulated in expression in the 9% casein 
treatment group relative to 18% casein control group.  This condition revealed the 
largest number of apparent gene expression changes of the comparisons that were 
made here.  However, there are a number of pancreatic transcripts identified in this 
list which may suggest an element of tissue contamination at the dissection stage.
9% casein (up)
Gene        Number pass        Description
1427451_a_at 4         cDNA sequence BC018473
1438763_at 3
1436240_at 3         RIKEN cDNA 1500010G04 gene (1500010G04Rik), mRNA
1438612_a_at 3         colipase, pancreatic 7586 ; digestion; lipid catabolism;
1437326_x_at 3         elastase 3B, pancreatic      6508 ; proteolysis;
1433459_x_at 3         protease, serine, 2              6508; proteolysis; digestion;
1431743_a_at 3         solute carrier family 4 (anion exchanger), member 1      6810; transport; ion transport; anion transport;
1435611_x_at 3         elastase 3B, pancreatic        6508; proteolysis; 
1435012_x_at 3         elastase 3B, pancreatic        6508; proteolysis;
1450689_at 3         protease, serine, 3 ; trypsinogen 16 ; similar to trypsinogen 12     6508; proteolysis;
1450459_at 3         RIKEN cDNA 2010106G01 gene 6508; proteolysis;
1458609_at 3         Adult male bone cDNA, RIKEN full-length enriched library, clone:9830162N06 product:unclassifiable, 
1454623_at 3         similar to Carboxypeptidase A2 precursor
1448406_at 3         CREBBP/EP300 inhibitory protein 1         122; negative regulation of transcription from RNA   
                                     polymerase II promoter;
1448220_at 3         chymotrypsinogen B1         6508; proteolysis; digestion;
1448107_x_at 3         kallikrein 6 6508; proteolysis; 
1448281_a_at 3         elastase 2 6508; proteolysis;
1448239_at 3         heme oxygenase (decycling) 1      6788; heme oxidation; response to stimulus;
1416523_at 3         ribonuclease, RNase A family, 1 (pancreatic)
1415954_at 3         trypsin 4 ; trypsinogen 16 ; RIKEN cDNA 1810049H19 gene       6508; proteolysis; 
1420774_a_at 3         RIKEN cDNA 4930583H14 gene
1417257_at 3         carboxyl ester lipase       16042; lipid catabolism; ceramide catabolism; cholesterol catabolism; fatty 
                                     acid catabolism; protein amino acid esterification; intestinal lipid catabolism;
1415837_at 3         kallikrein 6 6508 ; proteolysis; 
1415805_at 3         colipase, pancreatic 7586; digestion; lipid catabolism;
1415884_at 3         elastase 3B, pancreatic 6508 ; proteolysis; 
1415883_a_at 3         elastase 3B, pancreatic 6508 ; proteolysis;
1415777_at 3         pancreatic lipase related protein 1       6629 ; lipid metabolism; lipid catabolism;
1428062_at 3         carboxypeptidase A1 6508 ; proteolysis;
1425642_at 3         similar to centrosome protein cep290
1428359_s_at 3         RIKEN cDNA 1810010M01 gene
1428102_at 3         carboxypeptidase B1 (tissue) 6508; proteolysis;
1422434_a_at 3         RIKEN cDNA 2210010C04 gene 6508; proteolysis; digestion;
1421866_at 3         nuclear receptor subfamily 3, group C, member 1     6350; transcription; regulation of transcription, 
                                     DNA-dependent; glucocorticoid receptor signaling pathway;
1423257_at 3         cytochrome P450, family 4, subfamily a, polypeptide 14 6118; electron transport;
1422682_s_at 3         protease, serine, 3 ; trypsinogen 16; similar to trypsinogen 12        6508; proteolysis;
1421077_at 3         SERTA domain containing 3 6350; transcription; regulation of transcription, DNA-dependent;Table 4.15: Gene list of 10 probe sets down-regulated in expression in the switch 
treatment group relative to 18% casein control group.  
Switch (down)
Gene         Number pass     Description            
1427126_at 4        heat shock protein 1B  723; telomere maintenance; inhibition of caspase activation; DNA repair; 
                                    protein folding; anti-apoptosis; response to unfolded protein; response to heat 
1427127_x_at 4        heat shock protein 1B  723; telomere maintenance; inhibition of caspase activation; DNA repair; 
          protein folding; anti-apoptosis; response to unfolded protein; response to heat
1452388_at 4        heat shock protein 1A   723; telomere maintenance; DNA repair; protein folding; response to unfolded 
                                    protein; response to heat; 
1436296_x_at 4        Transcribed locus
1449526_a_at 3        glycerophosphodiester phosphodiesterase domain containing 3      6071; glycerol metabolism; 
1439483_at 3        expressed sequence AI506816
1419149_at 3        serine (or cysteine) peptidase inhibitor, clade E, member 1      45765; regulation of angiogenesis; 
1420491_at 3        eukaryotic translation initiation factor 2, subunit 1 alpha    6412; protein biosynthesis; regulation of 
          protein biosynthesis; regulation of translation; protein biosynthesis; 
1436538_at 3        Lrp2 binding protein
1455213_at 3        RIKEN cDNA 4930488E11 gene 7010; cytoskeleton organization and biogenesis; Table 4.16: Gene list of 12 probe sets up-regulated in expression in the switch 
treatment group relative to 18% casein control group.  
Switch (up)
Gene        Number pass      Description
1438644_x_at 4           COMM domain containing 9
1427451_a_at 4           cDNA sequence BC018473
1442679_at 3           Mitogen activated protein kinase kinase 4 (Map2k4), mRNA     165 ; MAPKKK cascade; protein 
                                       amino acid phosphorylation;
1457680_a_at 3           transmembrane protein 69
1446284_at 3           metastasis suppressor 1     7015 ; actin filament organization; actin filament polymerization; cell 
motility; cell adhesion; transmembrane receptor protein tyrosine kinase signaling pathway; 
microspike biogenesis; actin cytoskeleton organization and biogenesis; nervous system 
development; muscle development;
1450459_at 3           RIKEN cDNA 2010106G01 gene 6508; proteolysis;
1442109_at 3           Far upstream element (FUSE) binding protein 1 (Fubp1), mRNA       6350; transcription; regulation 
of transcription, DNA-dependent; phosphate transport;
1423866_at 3           serine (or cysteine) peptidase inhibitor, clade A, member 3K
1423556_at 3           aldo-keto reductase family 1, member B7      44255; cellular lipid metabolism;
1440443_at 3           RIKEN cDNA E030016H06 gene
1429478_at 3           RIKEN cDNA 6720463M24 gene
1419094_at 3           cytochrome P450, family 2. subfamily c, polypeptide 37 ; cytochrome P450, family 2, subfamily c, 
polypeptide 50 ; cytochrome P450    6118; electron transport;4.3.14 Downstream analysis using dChip
In order to obtain lists of candidate probe sets that appear to be differentially expressed, 
class comparisons were made of the expression of all individual probe sets between diet 
groups.  These comparisons were made for all three possible pair-wise combinations of 
the diet groups, i.e. switch and 9% casein; switch and 18% casein; 9% casein and 18% 
casein.  The 9% casein group may be seen as a type of control for the switch group, as the 
low protein treatment is maintained throughout gestation.
The class comparison tool in dChip (Li and Wong, 2001) was used with two different sets 
of comparison criteria- a ‘high’ and a ‘low’ stringency setting (see section 4.2.14.3).  
A positive average fold change for a probe set in a gene list generated from a class 
comparison indicates an up-regulation/higher level of expression of the probe set in the 
experimental diet group relative to the baseline diet group.  Likewise, a negative average 
fold change indicates a down-regulation/lower level of expression relative to the baseline 
group.  Percentage FDRs were analysed for each class comparison to give an indication 
of the reliability of the gene lists produced from the actual class comparisons versus 
random permutations of the samples between the two classes. 
4.3.14.1 Class comparison analyses using all samples in each treatment group
Results from the high stringency analyses are shown in Tables 4.18 to 4.20.  A summary 
of the high stringency results is given in Table 4.17.Class (treatment group) comparison  No. probe sets changed Median FDR
(probe sets)
switch v 9% casein 10 50% (5)
switch v 18% casein 6 50% (3)
9% casein v 18% casein 4 75% (3)
Table 4.17: Summary of class comparison results including all samples in each class, 
using the high stringency comparison criteria.  The numbers of apparently 
differentially expressed probe sets and the median FDRs are given in each case.
Affx probe set Gene information p-value
Fold 
change
1415899_at Junb: Jun-B oncogene 0.015699 -3.08
1416913_at Es1: esterase 1 0.000463 2.09
1417079_s_at Lgals2: lectin, galactose-binding, soluble 2 0.013999 -2.09
1417461_at Cap1: CAP, adenylate cyclase-associated protein 1 (yeast) 0.015394 2.45
1418787_at Mbl2: mannose binding lectin (C) 0.024216 3.14
1420774_a_at 4930583H14Rik: RIKEN cDNA 4930583H14 gene 0.046268 -3.79
1441573_at Scmh1: Sex comb on midleg homolog 1 0.030059 -2.31
1443505_at Transcribed locus 0.03639 3.28
1444330_at D2Ertd173e: DNA segment, Chr 2, ERATO Doi 173, expressed 0.026757 2.56
1457987_at 6030458C11Rik: RIKEN cDNA 6030458C11 gene 0.036347 2.94
Table 4.18: Candidate probe sets with apparent differential expression for switch 
versus 9% casein (baseline) class comparison using high stringency criteria.  The 
median FDR from random permutations of these samples was 50%.
Affx probe set Gene information p-value Fold Change
1438644_x_at Commd9: COMM domain containing 9 0.002046 2.75
1440443_at E030016H06Rik: RIKEN cDNA E030016H06 gene 0.030419 3.28
1442255_at Mm.132067.1 0.047928 3.22
1445826_at Ankrd17: ankyrin repeat domain 17 0.006859 2.18
1446284_at Mtss1: metastasis suppressor 1 0.003451 2.19
1457458_at Zc3h4: zinc finger CCCH-type containing 4 0.024002 2.66
Table 4.19: Candidate probe sets with apparent differential expression for switch 
versus 18% casein (baseline) class comparison using high stringency criteria. 
Median FDR was 50%. Table 4.20: Candidate probe sets with apparent differential expression for 9% 
casein versus 18% casein (baseline) class comparison using high stringency criteria. 
Median FDR was 75%. 
Across all class comparisons few probe sets were identified as apparently diet responsive 
and the apparent differential expression identified had a high likelihood of being due to 
chance, as indicated by the high FDRs.  The largest numbers of candidate genes were 
identified when the switch and 9% casein diet treatments were compared (Table 4.18), 
but even that comparison only yielded ten possible candidates.  
The average fold changes for the candidate probe sets identified in Tables 4.18 to 4.20 
were all more than 2-fold up or down, raising the possibility that some important 
candidate genes with slightly weaker fold changes may have been eliminated by the 
stringent filtering criteria.  Thus, further class comparison analyses were made using low 
stringency criteria (see section 4.2.14.3 for details).  Here, the lower bound of the 90% 
confidence interval for fold change had to be at least 1.4.  All other filtering criteria 
remained the same as before, and fifty random comparisons were made so that the FDR 
could be established for each class comparison.  Again, FDRs were determined 
empirically by class comparison on random permutations of sample allocation to classes. 
Affx probe set Gene information p-value
Fold 
change
1431213_a_at LOC100041156 /// LOC100041932 0.001615 -16.44
1448406_at Eid1: EP300 interacting inhibitor of differentiation 1 0.032715 2.67
1431220_at
LOC100040353 /// LOC100046169: similar to splicing 
coactivator subunit SRm300 ///  0.001555 2.27
1438763_at Dnahc2: dynein, axonemal, heavy chain 2 0.013813 2.48Table 4.21 summarises the findings from these reduced stringency analyses; the detailed 
results for each class comparison are shown in Tables 4.22 to 4.24.
Class comparison  No. probe sets changed Median FDR
(probe sets)
switch v 9% casein 35 37.1% (13)
switch v 18% casein 8 100% (8)
9% casein v 18% casein 9 88.9% (8)
Table 4.21: Summary of class comparison results including all samples in each class, 
using the low stringency comparison criteria.  The numbers of apparently 
differentially expressed probe sets and the median FDRs are shown.Affx probe 
set Gene information p-value
Fold 
change
1415899_at Junb: Jun-B oncogene 0.015699 -3.08
1416913_at Es1: esterase 1 0.000463 2.09
1417079_s_at Lgals2: lectin, galactose-binding, soluble 2 0.013999 -2.09
1417461_at Cap1: CAP, adenylate cyclase-associated protein 1 (yeast) 0.015394 2.45
1418787_at Mbl2: mannose binding lectin (C) 0.024216 3.14
1420774_a_at 4930583H14Rik: RIKEN cDNA 4930583H14 gene 0.046268 -3.79
1420934_a_at Srrm1: serine/arginine repetitive matrix 1 0.014744 1.97
1423062_at Igfbp3: insulin-like growth factor binding protein 3 0.012875 2.12
1426721_s_at Tiparp: TCDD-inducible poly(ADP-ribose) polymerase 0.030553 -1.83
1426805_at
Smarca4: matrix associated, actin dependent regulator of 
chromatin 0.042023 2.14
1434062_at Rabgap1l: RAB GTPase activating protein 1-like 0.000734 -1.62
1434278_at Mtm1: X-linked myotubular myopathy gene 1 0.009015 1.78
1438167_x_at Flcn: Folliculin 0.000896 -1.67
1438743_at Cyp7a1: cytochrome P450, family 7, subfamily a, polypeptide 1 0.02487 2.15
1429809_at Tmtc2: transmembrane and tetratricopeptide repeat containing 2 0.002183 -1.76
1429882_at 6820431F20Rik: RIKEN cDNA 6820431F20 gene 0.00617 1.76
1430566_at 4733401A01Rik: RIKEN cDNA 4733401A01 gene 0.022219 2.04
1438763_at Dnahc2: dynein, axonemal, heavy chain 2 0.018764 -2.32
1441272_at Matr3: Matrin 3 0.009433 1.89
1441573_at Scmh1: Sex comb on midleg homolog 1 0.030059 -2.31
1443505_at Transcribed locus 0.03639 3.28
1444036_at Transcribed locus 0.013603 -1.88
1444330_at D2Ertd173e: DNA segment, Chr 2, ERATO Doi 173, expressed 0.026757 2.56
1444538_at Mm.182679.1 0.022366 1.83
1445826_at Ankrd17: ankyrin repeat domain 17 0.012525 1.87
1446284_at Mtss1: metastasis suppressor 1 0.006739 1.89
1447258_at Mm.210555.1 0.002793 1.86
1453189_at Ube2i: ubiquitin-conjugating enzyme E2I 0.00708 2
1453776_at Snx21: sorting nexin family member 21 0.020045 -1.9
1454649_at Srd5a1: steroid 5 alpha-reductase 1 0.004672 1.7
1455933_at Tra2a: transformer 2 alpha homolog (Drosophila) 0.025982 2.06
1457554_at Apob: apolipoprotein B 0.001648 1.72
1457987_at 6030458C11Rik: RIKEN cDNA 6030458C11 gene 0.036347 2.94
1459734_at Mm.212401.1 0.003337 1.75
1459984_at Mia3: melanoma inhibitory activity 3 0.009647 2.13
Table 4.22: Candidate probe sets with apparent differential expression for switch 
versus 9% casein (baseline) class comparison using low stringency criteria.  The 
median FDR was 37.1%. Affx probe set Gene information p-value Fold Change
1438644_x_at Commd9: COMM domain containing 9 0.002046 2.75
1440443_at E030016H06Rik: RIKEN cDNA E030016H06 gene 0.030419 3.28
1442255_at Mm.132067.1 0.047928 3.22
1445695_at
0 day neonate lung cDNA, RIKEN full-length enriched 
library,  0.017914 1.86
1445826_at Ankrd17: ankyrin repeat domain 17 0.006859 2.18
1446284_at Mtss1: metastasis suppressor 1 0.003451 2.19
1457458_at Zc3h4: zinc finger CCCH-type containing 4 0.024002 2.66
1457554_at Apob: apolipoprotein B 0.000831 1.91
Table 4.23: Candidate probe sets with apparent differential expression for switch 
versus 18% casein (baseline) class comparison using low stringency criteria. 
Median FDR was 100%.
Affx probe set Gene information p-value Fold Change
1415777_at Pancreatic lipase related protein 1 0.032647 -2.45
1423114_at Ubiquitin-conjugating enzyme E2D 3  0.04101 -1.89
1423257_at Cyp4a14: cytochrome P450, 0.03825 2.35
1431213_a_at LOC100041156 /// LOC100041932 0.001615 -16.44
1448406_at EP300 interacting inhibitor of differentiation 1 0.032715 2.67
1429351_at Klhl24: kelch-like 24 (Drosophila) 0.023692 2.04
1431220_at LOC100040353 /// LOC100046169:  0.001555 2.27
1438763_at Dnahc2: dynein, axonemal, heavy chain 2 0.013813 2.48
1455773_at
0 day neonate kidney cDNA, RIKEN full-length enriched 
library,  0.04721 -2.55
Table 4.24: Candidate probe sets with apparent differential expression for 9% 
casein versus 18% casein (baseline) class comparison using low stringency criteria. 
Median FDR was 88.9%.
For the class comparison switch versus 9% casein, the low stringency criteria identifies a 
larger number of gene candidates as differentially expressed and there is a lower 
proportion of FDRs compared to when the higher stringency filtering criteria was adopted 
(Table 4.22).  However, when class comparisons were made for the other two possible 
combinations of diet group with the low stringency filtering criteria it became apparent that the FDRs were very high, and the number of probe sets identified did not increase 
markedly (Tables 4.23 and 4.24).  Thus, it is difficult to have any confidence in these 
gene lists.  
The lower stringency criteria only appear to improve upon the results obtained for the 
switch versus 9% casein class comparison.  For this comparison, a list of thirty-five 
probe-sets was produced, of which all are above the lower limit of the 90% confidence 
interval for 1.4 fold change (Table 4.22).  The smaller percentage FDR helps us to have 
more confidence in the reliability of candidates produced by the meaningful comparison. 
Thus, the gene list in Table 4.22 mostly contains candidates that are meaningful and truly 
changing in the class comparison, but also contains some candidates that are not and 
appear on the list by chance.
Of the thirty-five probe sets identified in Table 4.22 as apparently differentially 
expressed, twenty-four probe sets were expressed at a higher level in the switch group 
relative to the 9% group.  Up-loading these twenty-four probe sets into GOTM indicated 
that in terms of biological processes, enriched categories were growth, cellular lipid 
metabolism and steroid metabolism (Figure 4.30).Figure 4.30: GOTM tree produced for the twenty-four probe sets that were 
expressed at a higher level in the switch group relative to the 9% casein group from 
the gene list shown in Table 4.22.  Enriched categories are shown in red.  
Analysis of the tree in Figure 4.30, based on the twenty-four up regulated probe sets 
shown in Table 4.22, indicates that the enriched growth category is based on the two 
observed transcripts: Igfbp3: insulin-like growth factor binding protein 3 (1423062_at) 
and Smarca4: matrix associated, actin dependent regulator of chromatin (1426805_at). 
The expected number of transcripts for this category based on the background list was 
0.15, thus the enrichment factor (R) was 13.33.  The enriched steroid metabolism 
category (R= 20) is composed of two observed probe sets Cyp7a1: cytochrome P450, family 7, subfamily a, polypeptide 1 (1438743_at) and Srd5a1: steroid 5 alpha-reductase 
1 (1454649_at).  Finally, the enriched cellular lipid metabolism category (R=7.69) is also 
composed of probe set (1438743_at) and (1454649_at) as well as ApoB: apolipoprotein 
B (1457554_at).  In terms of cellular components the over-represented categories were: 
the endoplasmic reticulum (R= 8.7), vesicular fraction (R= 18.18) and microsomes (R= 
20). 
Similarly using DAVID, gene ontology analysis was carried out on the same twenty-four 
probe sets as in Figure 4.30 (Table 4.25).Table 4.25: DAVID gene ontology analysis of twenty-four probe sets expressed at a 
higher level in the switch group versus the 9% casein group (see Table 4.22).  
The DAVID analysis shown in Table 4.25 identifies two enriched categories: cellular 
metabolic process, and cellular lipid metabolic process.  These enriched categories 
include the same five probe sets as were identified the enriched GTOM categories for 
biological process in Figure 4.30, as well as a number of others.
Eleven of the probe sets in gene list in Table 4.22 were expressed at a lower level in the 
switch group relative to the 9% casein group; enrichment analysis carried out with 
GOTM (Figure 4.31).                                   
Figure 4.31: GOTM tree produced for probe sets that were expressed at a lower 
level in the switch group relative to the 9% casein group in the gene list shown in 
Table 4.22.  Enriched categories are shown in red.
Closer examination of the tree in Figure 4.31, based on the eleven down regulated probe 
sets in Table 4.22, indicates that in terms of biological process enriched categories are 
cell cycle (R= 11.76), regulation of cell cycle (R= 20) and the regulation of progression 
through cell cycle (R= 20).  All the enriched categories consist of the two probe sets, 
Junb: Jun-B oncogene (1415899_at) and Flcn: Folliculin (1438167_x_at).Too few probe sets were identified as being expressed at a lower level in the switch 
versus 9% casein class comparison in Table 4.22 for DAVID gene ontology analysis to 
be carried out on these candidates.
4.3.14.2 Hierarchical clustering analysis
In view of the fact that there are approximately 45,000 probe sets on the Mouse 430_v2 
chip used, and approximately 50% of the probe sets were detected and called as present 
in each of the samples across all the treatment groups (Table 4.6), relatively few probe 
sets appeared to be diet sensitive, even when the lower stringency analysis criteria was 
adopted for the class comparisons (see section 4.2.14.3).  One possible explanation for 
this is that responsiveness to maternal dietary treatment is being obscured by another 
factor, such as the presence of outlier samples within treatment groups (biological 
variation).  Thus, after obtaining expression values from the dChip model, high-level 
hierarchical clustering analysis (Eisen et al., 1998) was performed.  Unsupervised sample 
clustering using probe sets obtained by filtering* was used to identify the separation of 
samples between classes/treatment groups, so that unexpected clustering could be 
identified (Li and Wong, 2001) (Figure 4.32).  
*Clustering analysis was performed on the normalised expression of probe sets which 
had a coefficient of variation of 0.5< across all twelve samples from the three diet groups, 
and which had Affymetrix “present” calls in at least 20% of the twelve samples.  This excludes background probe set noise and prevents it from being incorporated into the 
cluster analysis. 
Figure 4.32: Cluster diagram for the 508 probe sets called as “present” in at least 
20% of the twelve samples and which have a coefficient of variation of 0.5< across 
all samples.  Different samples with similar probe set/gene expression profiles to one 
another are clustered together (on horizontal axis); different genes/probe sets with 
similar expression profiles to each other are clustered (on vertical axis).
Samples are coded as follows: N= 18% casein diet treatment, L= 9% casein diet 
treatment, E= switch diet treatment.  Red= higher, blue= lower expression of probe 
sets.Using the horizontal axis in Figure 4.32, outlier samples from within classes/treatment 
groups may be identified.  Whilst three out of the four samples in each of the three 
classes appear to cluster together, each class contains one member that did not cluster 
with the remainder of their group, indicating that these samples (N 3, L 8, and E 13) 
might be outliers.  Likewise, clustering analysis performed on the normalised expression 
of probe sets which had a coefficient of variation of 0.2< across all twelve samples from 
the three diet groups, and which had Affymetrix “present” calls in at least 20% of the 
twelve samples also produced similar results (Figure 4.33).  Interestingly, the same three 
samples were also identified as possible outliers in the analysis using Array Assist in 
section 4.3.12 (Figure 4.25).
In view of the concordant evidence presented above, further class comparisons were 
made excluding the presumed outlier samples N 3, L 8, and E 13 from their respective 
classes (refer to next section 4.3.14.3).                                         
      
Figure 4.33: Cluster diagram (cropped) for the 7475 probe sets called as “present” 
in at least 20% of the twelve samples and which have a coefficient of variation of 
0.2< across all samples.  Different samples with similar probe set/gene expression 
profiles to one another are clustered together on the horizontal axis.4.3.14.3 Class comparison analyses using three out of four samples from each 
treatment group/class
To examine the possibility of diet effects on global fetal liver gene transcription in the 
majority but not all, of the experimental fetuses, class comparisons were conducted with 
only the three most closely clustered samples in each treatment group (Figures 4.32, 
4.33).  Otherwise, these class comparisons were performed in the same way as those in 
section 4.3.14.1.  
Comparing the results summary for the high stringency analysis given in Table 4.26 with 
the summary given in Table 4.17 illustrates the effect of removing the outlier samples, as 
both tables display the results of class comparisons performed at the high stringency level 
(refer to section 4.2.14.3 for details).  The largest effect of removing outlier samples was 
on the switch versus 9% casein class comparison, where elimination of the respective 
outliers raised the returned probe set number from 10 to 136, with a lower percentage 
FDR of just 4.4%.  Conversely, the number of probe sets returned from the switch versus 
18% casein class comparison remained the same whether the respective outlier samples 
were included in the analysis or not.  For the 9% casein versus 18% casein class 
comparison, exclusion of the appropriate outlier samples resulted in an increase from 4 to 
26 probe sets obtained.  Refer to Appendix I, Tables AI.12 to AI.14 for the gene lists 
generated by each of the high stringency class comparisons summarised in Table 4.26, 
when outlier samples were excluded from the analyses.Class comparison  No. probe sets changed Median FDR
(probe sets)
switch v 9% casein 136 4.4% (6)
switch v 18% casein 6 100% (6)
9% casein v 18% casein 26 23.1% (6)
Table 4.26: Summary of class comparison results when excluding one outlier 
samples per class, using the high stringency comparison criteria.  The numbers of 
apparently differentially expressed probe sets and the median FDRs are shown. 
Outlier samples excluded from the class comparison analyses were: samples 3 (18% 
casein group), 8 (9% casein group), and 13 (switch group).
Further class comparison analyses excluding the outlier samples were made using low 
stringency criteria (see section 4.2.14.3).  Table 4.27 summarises the findings for the low 
stringency analyses; the gene lists generated from each class comparison are shown in 
Appendix I Tables AI.15 to AI.17.  Comparison of the results summarised in Table 4.21 
and Table 4.26 indicates the impact of removing the outlier samples from the class 
comparisons performed at low stringency.  Again, the largest effect of removing the 
outlier samples was seen for the switch versus 9% casein class comparison.  Elimination 
of the respective outliers from each class raised the number of probe sets returned from 
35 to 344!  In addition, the number of finds for the 9% versus 18% comparison increased 
from 9 to 76.  However, as was the case for the high stringency criteria, removal of the 
outliers did not markedly improve upon the number of probe sets returned for the switch 
versus 18% class comparison.Class comparison  No. probe sets changed Median FDR
(probe sets)
switch v 9% casein 344 4.9% (17)
switch v 18% casein 18 83.3% (15)
9% casein v 18% casein 76 23.7% (18)
Table 4.27: Summary of class comparison results when excluding one outlier 
samples per class, using the low stringency comparison criteria.  The numbers of 
apparently differentially expressed probe sets and the median FDRs are shown.  
Gene ontology analysis using GOTM (Figures 4.34 to 4.36) was performed on the gene 
list produced from the low stringency switch versus 9% class comparison excluding the 
outlier samples, (see gene list in Appendix I, Table AI.15).  This comparison returned the 
largest number of probe sets (344) and had a very low FDR (4.9%) which means we can 
be confident that the gene list generated for the comparison (Table AI.15) represents 
candidates that are truly changing.Figure 4.34: General overview of the GOTM tree produced for the 99 probe sets 
over expressed in the switch group relative to the 9% casein group from the gene list 
in Appendix I, Table AI.15 for the low stringency comparison when outliers were 
excluded from the analysis.  Enriched categories are shown in red.  Biological 
processes, molecular functions and cellular components all contained enriched 
categories.                 
Figure 4.35: Enlarged section of Figure 4.34 to illustrate the enriched categories 
(shown in red) of molecular function which include oxidoreductase activity (R= 
2.93), aldehyde reductase activity (R= 100) and iron ion binding (R= 4.5) for the 99 
probe sets over expressed in the switch group relative to the 9% casein group from 
the gene list in Appendix I, Table AI.15.Enriched categories in terms of molecular function are shown in the GOTM tree in Figure 
4.35 for the probe sets over expressed in the switch versus the 9% casein diet group (from 
gene list in Table AI.15 in Appendix I).  The most highly enriched of these categories 
was aldehyde reductase activity (R= 100).  This category is composed of three probe sets 
representing two genes; Akr1b3: aldo-keto reductase family 1, member B3 (aldose 
reductase) (1437133_x_at), (1456590_x_at) and Akr1b7: aldo-keto reductase family 1, 
member B7 (1423556_at).  In terms of cellular components, the enriched categories 
shown in the GOTM tree in Figure 4.34 are vesicular fraction (R= 8.51), endoplasmic 
reticulum (R= 3.4) and spliceosome complex (R= 11.54).
Figure 4.36 illustrates an overview of  the GOTM tree and enriched categories (shown in 
red) for probe sets down regulated in the switch group relative to the 9% casein group 
(from gene list in Table AI.15 in Appendix I).  Figure 4.36    :    General overview of the GOTM tree produced for the 245 probe sets 
down regulated in the switch group relative to the 9% casein group from the gene 
list in Appendix I, Table AI.15 for the low stringency comparison when outliers 
were excluded from the analysis.  Enriched categories are shown in red.  Biological 
processes, molecular functions and cellular components all contained enriched 
categories.
In Figure 4.36, in terms of molecular function, enriched categories include translation 
factor activity/ nucleic acid binding (R= 4.11) and nucleotide kinase activity (R= 13.64).
Enriched cellular components shown in the GOTM tree are related to the golgi apparatus 
(R= 3.09).4.4 Discussion 
4.4.1 Basis for experimental design regarding gender of fetuses
In an attempt to keep biological variation to a minimum, male fetuses only were used in 
the genomics analysis, and the gender of the nearest neighbours in utero was also 
monitored.  This is because secreted fetal hormones are thought to pass either through the 
amniotic fluid or uterine blood vessels to neighbouring littermates.  For instance, it has 
been observed that as a result of prenatal exposure to testosterone, female fetuses that 
were situated between two males in utero (‘2M females’) display a number of traits as 
adults that distinguish them from female fetuses which were next to two other females in 
the uterus (Figure 4.37).  
Figure 4.37: Schematic diagram of pregnant mouse uterus.  Fetuses develop within 
individual amniotic sacs in the uterine horns.  Positions of female fetuses are depicted in relation to male fetuses; e.g. ‘1M female’= a female fetus with one male 
neighbour and one female neighbour (vom Saal, 1981).
These traits include 2M females being less attractive to males, more aggressive to female 
intruders, marking of a novel environment at an increased rate, and having longer and 
more irregular estrous cycles (vom Saal and Bronson, 1978; vom Saal and Bronson, 
1980a; vom Saal and Bronson, 1980b).  Similarly, the adult behaviour of male mice is 
thought to be affected in a similar way by intrauterine estrogen secreted by the ovary and 
found in relatively high concentrations in female fetuses.  Males which develop in utero 
between two male fetuses (‘2M males’) tend to exhibit parental behaviour as adults when 
presented with newborn pups, whereas males that develop between two female fetuses 
often will kill the newborn.  Differential exposure to testosterone is not responsible for 
this as testosterone concentrations in blood and amniotic fluid of both these types of male 
fetuses do not differ (vom Saal, 1983).  4.4.2 Micro-array data analyses
The GCOS software and Expression Console metrics (Affymetrix) indicate that the 
micro-array data generated for the twelve fetal liver samples is of high quality.  However, 
a considerable amount of biological variation is present between samples from within the 
same diet group making it quite difficult to reliably identify genes that are changing due 
to diet treatment.
4.4.2.1 Array Assist analysis
By far the largest number of gene candidates was identified for the comparison between 
the switch and 9% casein diet groups (Table 4.12).  However, these analyses were all 
coupled with high FDRs which weaken the reliability of the gene candidates identified by 
the comparison of the treatments.
4.4.2.2 GeneSpring analysis
The GeneSpring analysis of the micro-array data identified a relatively large number of 
genes that appeared to be altered in expression in fetal liver by at least two-fold in 
response to dietary treatment.  However, none of the probe sets identified were 
significantly different the between dietary treatments (ANOVA at p<0.05).
The gene lists created using GeneSpring are grouped according to dietary treatment (9% 
casein or switch) relative to control (18% casein) and according to whether the change is 
an increase or decrease in the level of expression relative to the control treatment.  From these comparisons, the largest number of changes in gene expression relative to control 
was attributed to the 9% casein dietary treatment.  
Despite problems surrounding the validity and reliability of candidates included on the 
gene lists produced by the Array Assist and GeneSpring analyses, both analyses suggest 
that probe set 1455869_at may be heavily down-regulated in the 9% casein treatment 
group relative to the control 18% casein group (Tables 4.10 and 4.13).  As shown in the 
aforementioned tables, the Affymetrix annotation for this probe set at the time the gene 
lists were generated implicated it as representing the Camk2b gene.  
CaM kinases (calcium/calmodulin-dependent protein kinases) are important proteins as 
they catalyse phosphorylations on serine or threonine residues in selected proteins which 
mediate most of the actions of calcium in animal cells.  CaM-kinase II is a 
multifunctional CaM-kinase found in all animal cells, but especially enriched in the 
nervous system, and has been implicated in some types of learning and memory in the 
vertebrate nervous system (Alberts et al., 1994).
However, closer investigation into this probe set (Ensembl) reveals that it is in fact 
located within an intron present in the Camk2b gene; hence the probe set is not directed 
against the mRNA for Camk2b.  Indeed, the probe set sequence hits the mouse genome in 
348 locations, one of which is within the Camk2b gene, in 46 separate sites throughout 
the genome, and thus it would appear to be a repeated element.  Moreover, blasting this 
probe set (NCBI) reveals that the sequence the probe set best matches encodes for a viral poly-protein.  Thus, the Camk2b gene is just one of numerous elements possessing 
integration sites for a retrovirus.  Affymetrix has since updated the annotation for this 
probe set and no longer attributes it to Camk2b mRNA.
4.4.2.3 dChip analyses
Due to the difficulties with high probability for false discoveries with the Array Assist 
and GeneSpring analyses further analysis of the data was undertaken using an alternative 
software package, dChip.  
Class comparison analyses using all samples in each treatment group
The biological effect on transcription appeared to be the greatest for the switch versus 9% 
casein class comparison using the low stringency criteria (Table 4.22).  This reflects a 
meaningful difference between these classes, but the reason for this was not clear.  One 
would expect that, if diet was the main contributor the other class comparisons may also 
show a similar report, but they do not.  Thus, some other factor/s in the dataset may be 
overshadowing the dietary treatment effect here.
Enrichment analyses were only performed on the gene list in Table 4.22 produced from 
the low stringency switch versus 9% casein class comparison.  This was due to the small 
number of probe sets returned for the other comparisons, at both stringencies, and the 
difficulties with the associated high FDRs.  The GOTM tree shown in Figure 4.30 indicates that genes involved in growth, steroid 
metabolism and cellular and lipid metabolism are expressed more highly in the switch 
group relative to the 9% casein group.  One interesting candidate gene upon which the 
enriched cellular lipid metabolism category in Figure 4.30 was based is ApoB.  ApoB is 
expressed more highly in fetal livers of fetuses from the maternal switch diet group than 
in those from the 9% casein group.  APOB protein levels are positively correlated with 
coronary heart disease and are a strong predictor of risk of myocardial infarction 
(McQueen et al., 2008).  Indeed, mice over-expressing the ApoB gene have an increased 
level of low-density lipoprotein (LDL) also termed “harmful cholesterol” and decreased 
levels of high density lipoprotein (HDL) (“beneficial cholesterol”) (McCormick et al., 
1996).  However, ApoB heterozygous knockout mice containing only one functional 
copy of the ApoB gene show the opposite effect, being resistant to diet-induced plasma 
hypercholesterolemia (Farese Jr et al., 1995).  This information, together with the 
observation that the ApoB gene is more highly expressed in my switch group relative to 
my 9% casein group, is consistent with findings in rodents that male offspring from 
switch fed mothers tend to develop cardiovascular risk factors i.e. raised systolic blood 
pressure (relative to 18% casein offspring) (Watkins et al., 2008; Kwong et al., 2000) and 
may represent a tentative mechanism through which post natal defects in cardiovascular 
function are programmed before birth, possibly due to increased circulating LDL 
cholesterol associated with raised hepatic ApoB expression in the fetus.
Furthermore, the GOTM tree shown in Figure 4.31 indicates that genes for cell cycle; cell 
cycle regulation and regulation of progression through cell cycle are expressed at a lower level in the switch group relative to the 9% casein group.  The Folliculin (Flcn) gene is an 
interesting candidate being one of two genes upon which all of the aforementioned 
enriched categories in Figure 4.31 were based.  There are three probe sets representing 
Folliculin transcript on the Mouse 430_v2 arrays used in this study, one of which 
appeared diet-sensitive in this class comparison.  FLCN is a tumour suppressor protein 
encoded for by the BHD gene, with otherwise unknown function.  Homozygous loss of 
BHD may initiate renal tumorigenesis in the mouse (Baba et al., 2008).  Indeed, patients 
with Birt-Hogg-Dubé (BHD) syndrome have germ line mutations in the BHD tumor 
suppressor gene that are associated with an increased risk for kidney cancer.  FLCN may 
interact with the energy- and nutrient-sensing 5'-AMP-activated protein kinase-
mammalian target of rapamycin (AMPK-mTOR) signaling pathways (Baba et al., 2006). 
Targeted BHD knockout leads to activation of Akt-mTOR pathways in the kidneys and 
increased expression of cell cycle proteins and cell proliferation (Baba et al., 2008).  
In fetuses from the switch diet group, the Flcn probe set was expressed at lower levels 
than in those from the 9% casein group, which may indicate increased cell proliferation is 
taking place in the tissues of the switch fetuses, coupled with activation of mTOR 
signaling.  This hypothesis might lend support to the elevated birth weights of pups born 
to switch fed mothers relative to pups born to 9% casein or 18% casein fed mothers in the 
mouse (Watkins et al., 2008) and may suggest an elevation of the fetal growth trajectory 
takes place in these fetuses during gestation. The dChip analysis of the micro array data thus far had indicated that relatively few 
probe sets in the fetal liver were diet sensitive.  It is possible that the reason for this is that 
the maternal dietary treatment is a mild intervention which does not manifest itself as a 
vast number of transcriptional changes at this stage in hepatic fetal tissue.  However, it 
was also possible that some other factor in the dataset was obscuring the diet response 
from being observed in its entirety.  To this end, hierarchical clustering analysis was 
performed to examine the tightness of the dataset, with a view to potential excluding 
outliers in the biological replicates.  
Class comparison analyses using only the three most closely related (clustered) samples 
from each treatment group
Table 4.27 shows that when outlier samples 3, 13 and 8 were excluded from the data and 
class comparisons were re run at low stringency, the greatest benefit was seen in the 
switch versus 9% casein comparison.  When the switch and 9% casein outlier samples 
were removed from the respective classes the returned number of probe sets returned for 
this comparison rocketed to from 35 to 344, with a very low FDR (4.9%).  
The GOTM trees in Figures 4.34 and 4.36 produced from the list of candidates given in 
Table AI.15 indicate that a larger number of probe sets were down regulated in the switch 
versus 9% casein comparison, than were up regulated.  The most highly enriched 
category of probe sets that were over expressed in the switch group relative to the 9% 
casein was for aldehyde reductase activity (Figure 4.35).  This category comprised three probe sets representing two genes in aldo-keto reductase family 1 (Akr); Akr1b3: 
member B3 (aldose reductase) and Akr1b7: member B7.
Aldo-keto reductases (AKRs) catalyze NADPH-dependent reduction of various aliphatic 
and aromatic aldehyde and ketones.  Aldehyde reductase (AKR1A) and aldose reductase 
(AKR1B) have been extensively investigated, and the gene regulation of AKR1B has 
been noted to be heavily influenced by the hyperglycemic state and high glucose 
ambience in various culture systems.  AKR1B catalyzes the conversion of glucose to 
sorbitol with a coenzyme, NADPH (Danesh et al., 2003).  Thus over-expression of this 
gene may result in disturbed glucose metabolism which might have implications for 
stabilizing blood sugar in the pathobiology of diabetes mellitus.
The reason why the switch versus 9% casein comparison alone was so strongly affected 
by the removal of the outlier samples appeared to be a mystery.  Indeed, it would be 
expected that, if diet was the main contributor the other class comparisons may also show 
a similar report in the absence of biological variation confounding the results, but they 
did not.  This raised the question as to whether some other factor unrelated to maternal 
diet treatment or to biological variation within groups was driving the difference between 
the switch and 9% casein classes.  Indeed, this unknown factor may also help to explain 
the reason for the main branching of the twelve samples into a group of five and a group 
of seven observed in the clustering analyses (Figure 4.38).                          
Figure     4.38:     Samples cluster broadly into two branches composed of a group of five 
samples and a group of 7 samples, (Figure taken from the hierarchical clustering 
analysis across all samples for 7475 probe sets with a coefficient of variation of 0.2 
or more, shown in Figure 4.33).
Table 4.28 illustrates that the main branching of samples into a group of five and a group 
of seven appears to be due to a significant difference in the total litter sizes of the ‘5’ 
group and the ‘7’ group (p= 0.0189).  Horn litter size was not significantly different in 
either group.  
In order to minimize the potential effects of litter size on the genomics analysis, the total 
and in particular, the horn litter sizes of fetuses were taken into account when selecting 
the twelve fetal samples so that these parameters could be kept as constant as possible 
between the dietary treatments.  The horn litter size was standardised across all litters 
from which samples were selected and thus the effects of local crowding in the uterus 
were controlled for (average horn litter size for all diet groups was 7.75 fetuses).  Total 
litter size was standardised as far as possible but compromises were made in this 
parameter, and thus the average total litter sizes varied from 11 for the switch group to 
14.5 for the 9% casein group.Horn litter size was standardised in preference to total litter size due to information 
relating to the blood supply to fetuses in crowded uterine horns in the mouse.  Blood 
supply comes from offshoots of a main loop artery which is fed from both the top and the 
bottom ends of the uterine horns.  However, in crowded horns, growth of fetuses in the 
horn may be more variable because some of the fetuses may be supplied by one limb of a 
bifurcated offshoot of which the other limb supplies the ovary (McLaren and Michie, 
1960).    
Table 4.28: The main branching of samples into a group of 5 and a group of 7 
shown in relation to the horn and total litter sizes of the samples.
Table 4.28 indicates that the total litter size from which fetal samples were harvested for 
micro-array analysis has a significant effect on probe set expression and thus explains the 
division of samples into a group of five and a group of twelve.  Also this may explain 
13 8 18-20 L5 N_17
10 6 Sw-10 R3 E_6
10 9 Sw-12 L5 E_12
11 10 Sw-11 R5 E_7
12 7 9-17 L4 L_8
14 7 18-18 R3 N_18
13 8 9-22 R4 L_16
17 9 9-16 L4 L_1
13 6 Sw-20 L3 E_13
P = 0.0189 P = 0.916 “5” v “7” ANOVA
13 7 18-11 R5 N_4
14 9 18-10 R5 N_3
16 7 9-19 L4 L_9
Total litter size Horn litter size Sample ref Array codewhy the switch versus 9% class comparison produces more differentially expressed 
candidates when the outlier samples 13 and 8 are removed.  After removal of these 
outliers the average total litter sizes for the three 9% casein samples versus the three 
switch samples become more different to one another; average total litters size after 
outlier exclusion are 10.3 for the switch group compared to 15.3 for the 9% casein group.
Thus, the switch group has a smaller total litter size than the 9% casein group before 
removal of outliers and removal of outliers widens the gap.  Hence, rather than the 
maternal diet, it appears that the total stress on the mother, as reflected by the total 
number of fetuses she must support, is the driving force for the differences in gene 
transcription between the switch and 9% casein classes.  Gene expression differences 
may still be generated by the manipulation of maternal diet, but in this case it is not 
possible to elucidate this effect separately from the effect of the maternal capacity to 
support a large litter.  Further, as the 9% casein group had the larger total litter sizes 
which might have resulted in intra-uterine growth restriction due to a limited access to the 
mother’s resources/nutrients in the blood, it makes it difficult to distinguish whether 
effects on gene expression are related to the low protein manipulation or the larger litters 
as both parameters may have a similar effect on growth.
The strength of the effect of total litter size on probe set expression is indicated by a 
Peason’s correlation test which indicates that the expression of 356 probe sets out of the 
7475, which have a coefficient of variation of 0.2< across all samples (Figure 4.33) 
correlate to total litter size (p<0.01).  (The mean FDR based on multiple random 
allocations of total litter size information to samples was 20%).  Hence, the apparent effect of total litter size on probe set expression represents a true correlation between 
these parameters.   
In summary, initial analyses of the micro-array data using dChip highlighted some 
interesting candidates at the level of transcription that appeared to offer, in part 
explanations for mechanisms of programming of post natal phenotypes in response to 
maternal diet for the switch versus 9% class comparison.  However, further analysis of 
the class comparisons suggested that a factor unrelated to diet might be driving the 
differences in gene expression, particularly between the switch and 9% classes.  Thus, it 
appears that the mother’s capacity to support her litter is sensed by individual fetuses in 
the uterus, and indeed this seems to manifest in alterations in fetal heptic gene expression. 
4.4.2.4 Analyses overview
The downstream analyses described in section 4.4.2.1 to 4.4.2.3 all indicated that the 
level of biological variation in the data set made drawing comparisons between treatment 
groups more challenging.  The biological variation between fetal liver samples of the 
same treatment group may be explained in a number of ways.  For instance, the MF1 
strain used in this study is an out bred stock which inevitably shows a measure of genetic 
variability.  This may well have caused major differences in the response to 
environmental conditions, including maternal dietary restriction, between the 
experimental fetuses.  Furthermore, the mice were housed under non specific-antigen free 
conditions in a non-barrier biomedical facility.  Thus, the incidence of sub-clinical infection/inflammation in some animals is a possibility and may be another factor 
affecting the response to environmental manipulation.
Other explanations for the biological variation between replicates may be related to the 
developmental model used in this study; variability in the stage of fetal liver development 
at day 17 could not be controlled amongst replicates.  Similarly, as gestational day 17 
murine fetal liver does not have clearly defined lobes, as in the adult, there was no way to 
standardise the anatomical portion of liver tissue selected for the genomics analysis 
amongst different fetuses.  In terms of the tissue dissections, there is a possibility that 
some contamination of the hepatic tissue may have occurred from closely associated 
tissues in any number of samples to a greater or lesser extent (suggested in Table 4.14, of 
GeneSpring analysis) although every care was taken to preclude this.
As micro-arrays are largely explorative tools, it is important that candidates which appear 
to be differentially expressed are confirmed by means of another method, such as real-
time PCR, before any firm conclusions are drawn.  Unfortunately, it was not possible to 
validate any of the micro-array candidates due to time constraints.  However, it may 
prove difficult to show relatively small fold changes in gene expression conclusively 
amid a background of high variability within treatments using this type of technique.Chapter 5
5.1 Introduction: Effect of Maternal Diet on Fetal Protein Expression
The glucocorticoid system of receptors and enzymes mediate directly the action of the 
glucorticoids.  Glucocorticoids have been widely implicated in mammalian fetal growth 
control (Bertram and Hanson, 2002; Reinisch et al., 1978; Novy and Walsh, 1983; 
Ikehami et al., 1997) and in organ maturation in utero (Thompson et al., 2004; Liggins, 
1994; Cole et al., 1995; Langley-Evans, 2001).  In addition, glucocorticoids have a 
variety of physiological roles in mammalian fetal tissues such as blood pressure control 
(Tangalakis et al., 1992; Benediktsson et al., 1993; Lindsay et al., 1996; Langley-Evans, 
1997b), regulation of salt-water homeostasis, immunological responses and metabolism 
(Bertram and Hanson, 2002).
Evidence suggests that the glucocorticoid system is sensitive to nutritional modulation 
during pregnancy (Langley-Evans et al., 1996a; Langley-Evans, 1997b; Bertram et al., 
2001; Kwong et al., 2007; Lillycrop et al., 2005; Lillyccrop et al., 2007; Burdge et al., 
2007).  Thus, the glucocorticoid system was selected as an interesting target to study the 
effects of the maternal low protein diet in the fetus, with a view to understanding 
potential mechanisms for programming of adult cardiovascular and metabolic diseases 
such as hypertension and type 2 diabetes mellitus as outlined in the DOHAD hypothesis.5.1.1 Glucocorticoid receptor
The GR is an intracellular steroid hormone receptor belonging to the super-family of 
nuclear hormone receptors (Mangelsdorf et al., 1995; Funder, 1996).  Two 
phenotypically distinct isoforms of GR have been identified in humans: GRa, (the 
predominant physiological isoform) and GRβ (Hollenberg et al., 1985) of molecular 
weight 94 kDa and 90 kDa, respectively (Oakley et al., 1996).  Rodent GR cDNAs that 
have been identified are homologues of the human GRa isoform, (Danielsen et al., 1986). 
The GRa isoform is organised into defined domains.  It has an N-terminal domain which 
is concerned with activation of target genes, a central DNA-binding domain involved in 
interactions with DNA sequences of target genes and a C-terminal domain for ligand 
(glucocorticoid) binding (Oakley et al., 1996) (Figure 5.1).  
Figure 5.1: Structure of the human GR-a and β genes and proteins; functional sub-
domains of the a-isoform are also stated (Bamberger et al., 1996).In the absence of glucocorticoid, GRa is located predominantly in the cytoplasm of cells 
as part of a multi-protein complex (Oakley et al., 1996).  Cognate hormone binding 
induces a conformational change in GRa which leads to dissociation from the heat shock 
complex and concomitant hyper-phosporylation of GR.  Nuclear localisation signals 
within the C-terminal domain are unmasked and receptor molecules, with glucocorticoid 
bound, translocate to the nucleus (Bamberger et al., 1996).
5.1.2 Enzymatic modulation of glucocorticoid action
11-beta hydroxysteroid dehydrogenase (11β HSD) is a microsomal enzyme complex 
associated with endoplasmic reticulum responsible for catalysing the inter-conversion of 
active cortisol and biologically inactive cortisone (Mahesh and Ulrich, 1960).  Hence, the 
11β HSD family of enzymes play a critical role in controlling local tissue concentrations 
of glucocorticoids (Edwards et al., 1996) and glucocorticoid exposure to the GR (Draper 
and Stewart, 2005).  The enzyme complex is composed of two distinct components, one 
of which catalyses oxidation (the 11β-dehydrogenase) and the other responsible for 
reduction (the 11-oxoreductase) (Lakshmi and Monder, 1985a).
The proportions of the different enzyme components present vary between different 
tissues, e.g. in the rat, the liver is the major site of action of 11β HSD type 1 and hence in 
this tissue reduction usually exceeds oxidation (Lakshmi and Monder, 1985b).The aim of this chapter was to quantify protein expression of the Glucocorticoid Receptor 
(GR) and 11β hydroxysteroid dehydrogenase (11β HSD) in fetuses at day 17 of gestation 
as a function of maternal diet.
5.2 Materials & Methods 
Refer to Chapter 2 for Generic Methods on Experimental Design (section 2.1), Animal 
Treatments (section 2.2), Recovery of Conceptuses (section 2.3), and Collection of 
gestational day 17 tissue (section 2.4).
5.2.1 Collection of gestational day 17 tissue and total protein extraction
During the gestational day 17 dissections described in Chapter 3, tissues from the nearest 
neighbours on either side of the central conceptus in each horn were collected, snap 
frozen in liquid nitrogen and stored at -80
oC for protein analysis.  For analysis of the 11β 
HSD type 1 enzyme and the GR, the fetal liver was used as this organ is the target tissue 
for these proteins.  
Day 17 fetal liver tissue was homogenised in 1% weight per volume of the strong anionic 
detergent, sodium dodecyl sulphate (SDS) in PBS (extraction buffer) using a motorised 
homogeniser, PowerGen 125 (Fisher Scientific).  SDS denatures proteins and gives them 
net negative charges proportional to their masses.  10 µl of extraction buffer was used per 
mg of tissue.  The resultant lysate was heated at 100 
oC for 10 minutes and centrifuged at 10,000 g for 10 minutes at 4 
oC.  The supernatant was removed from the pellet and 
assessed for total protein content.
    
5.2.2 Protein assay
Calculation of total protein content in samples was made using the DC Lowry Protein 
Assay (BIORAD, UK).  Four serial dilutions of samples were prepared in 1% SDS-PBS 
as well as four serial dilutions of 2 mg/ml Bovine Serum Albumin (BSA) protein 
standard, which were assayed alongside samples to generate a standard curve from which 
total protein content could be related to light absorbance.  Light absorbance was read at 
630 nm.  As a result, the concentration of total protein in all sample lysates was 
calculated.
5.2.3 Gel electrophoresis (SDS-PAGE)
To each sample lysate, 4 x NuPAGE LDS sample buffer (Invitrogen) and 0.05M DTT 
(reducing agent to break the covalent disulphide bonds in proteins) were added and 
samples were heated at 100
oC for 3 minutes.  A known quantity (µg) of total protein from 
each sample lysate was loaded into the wells of a 1.0 mm pre-cast 4-12% BIS-TRIS 
polyacrylamide SDS gel (Invitrogen) alongside a protein standard marker (Precision Plus 
Protein Standards, All blue, BIORAD, UK).  Gels were run in 20 x NuPAGE (MOPS) 
SDS running buffer (Invitrogen) diluted with deionised H2O.  NuPAGE Anti-oxidant 
(Invitrogen) was added to the running buffer in the inner part of the gel tank to maintain proteins reduced by DTT in a reduced state and prevent re-oxidation of the –SH groups 
on cysteine amino acids that are juxtaposed in space during the gel electrophoresis.  Gels 
were run for ~1 hour at 200 volts (maximum current).  Following gel electrophoresis, 
proteins were electro-blotted from the gel onto low fluorescence Immobilon-FL PVDF 
(0.45 µm) membranes (Millipore) overnight (16 hours) in transfer buffer (Appendix II) at 
300 mA with maximum voltage.
Pre-treatment of the PVDF is required before transfer of proteins from the gel: the 
membrane was wet in 100% methanol for 15 seconds, soaked in deionised water for 2 
minutes and finally placed in transfer buffer to equilibrate for at least 5 minutes. 
Post-transfer, the PVDF membranes were rinsed in deionised water and bench dried on 
Whatman 3MM paper, for 2 hours at room temperature.
5.2.4 Protein detection
Abundance of the target protein is quantified as a percentage of the abundance of 
appropriate non-diet sensitive loading controls also present in the target tissues.  For 11β 
HSD type 1 (34 kDa,) and GR (94 kDa), Actin (42 kDa) was used as such a control.  
5.2.5 Western blotting
PVDF membranes were re-wet i.e. by soaking in 100% methanol and rinsed in double-
distilled water before being incubated in PBS only.  Prepared membranes were then blocked for 1 hour in PBS-5% non-fat milk powder on a moving surface to prevent non-
specific antibody binding.  Primary antibodies specific for proteins of interest were then 
diluted in blocking buffer and incubated with membranes overnight at 4
oC on a moving 
surface.  Primary antibodies used included: Rabbit polyclonal anti-11β HSD1 {Cayman 
Chemical, USA}; Mouse monoclonal anti-Actin {Sigma Aldrich, USA}; Rabbit 
polyclonal anti-Actin {Sigma Aldrich, USA}; Rabbit polyclonal anti-GR {Santa-Cruz 
Biotechnology, USA}.  After incubation with primary antibody, membranes were given 4 
x 5 minute washes in PBS, with gentle shaking to remove any unbound antibody, and 
then incubated for 1 hour with appropriate fluorescently-labelled secondary antibodies 
diluted in blocking buffer and protected from the light (Goat anti-Rabbit 680 nm 
{Molecular Probes, UK}; Goat anti-Mouse 778 nm {Rockland, USA}).  Membranes 
were then given 4 x 5 minute washes in PBS with gentle shaking, before being scanned 
using the Licor Odyssey infra-red imaging system (680 nm tagged antibodies give a red 
signal when scanned, 778 nm tagged antibodies give a green signal).  Membranes were 
scanned with the default intensity setting (+ 5.0) for both 680 nm and 778 nm channels 
unless otherwise stated.
5.2.6 Densitometry
Integrated density values (IDVs) were obtained from the Odyssey infrared imaging 
system (Licor Biosciences), enabling quantification of the signal intensities of bands 
representing the target proteins present in each sample.  Rectangular boxes were fitted around the perimeter of each band and IDVs were automatically calculated for the area 
inside the boxes (Figure 5.2).
Figure 5.2: Example of IDV calculation.  The bands for actin are quantified here by 
fitting boxes to the bands and recording the automated integrated density value 
produced for each signal.  
5.2.7 Signal correction using gel standards
For the final GR and 11β HSD type 1 experiments, the same standard sample of fetal 
liver was loaded once onto every gel in each experiment to act as a gel standard to control 
for any variations in the blotting process of the different membranes within either 
Actinexperiment.  All the samples within each experiment were then corrected by comparison 
to this standard sample in order to make sure all blots were comparable with one another. 
5.2.8 Design of final experiments
The protein expression of six different fetal livers (from six different mothers) from each 
dietary group was analysed.  Each sample lysate was loaded a total of three times across 
different gels and in different positions on each gel.  The average expression of the 
protein of interest relative to actin from each of the three loadings of one lysate was then 
taken as a representative level of expression of the protein relative to actin for that fetal 
liver sample.  The fetal liver samples from each dietary group were coded A-F and then 
loaded in parallel across each gel.  An example layout of samples is shown in Figure 5.3. 
          9A   18A SWA   9B   18B SWB   9C   18C   SWC
Figure 5.3: Example of layout of samples across a gel.  The different diets are loaded 
in parallel in all cases.  In this example, fetal samples A-C from the three dietary 
groups are each loaded once on the gel.5.3 Results
5.3.1 Initial antibody optimisation 
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Figure 5.4: Detection of 11β HSD type 1 in gestational day 17 fetal liver.
M= Protein Standard Marker (BIORAD, Precision Plus).  20, 40 and 80 µg total 
protein loaded as shown.  Primary antibody conditions used: 1:250 (shown in 
figure), 1:500 and 1:1000 conditions produced no detectable bands (not shown), 
secondary antibody concentration 1:10,000 in all cases.  
Figure 5.4 shows that at 20 µg and 40 µg, faint but well defined bands representing 11β 
HSD type 1 are evident at ~37 kDa using a primary antibody concentration of 1:250.  At 
80 µg, the lane appears overloaded at this antibody concentration.  Higher primary 
antibody concentrations between 1:30 and 1:100 were also trialled with the same 
secondary antibody conditions but did not produce such satisfactory bands for 11β HSD 
type 1 due to signal saturation.
50kDa
37kDaIn order to distinguish reliably between the signals for 11β HSD type 1 (~34 kDa) and 
actin (42 kDa) when the blots are double-labelled for quantification, a Mouse anti-actin 
primary antibody was trialled so that a different fluorescently-labelled secondary 
antibody (Goat anti-Mouse 778 nm) could be used to produce a signal for actin at a 
different wavelength to that produced for 11β HSD type 1 (i.e. at 778 nm rather than 680 
nm).
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Figure 5.5: Detection of Actin in gestational day 17 fetal liver (as a loading control 
for 11β HSD type 1).  M= Protein Standard Marker (BIORAD, Precision Plus).
20, 40 and 80 µg total protein loaded as shown.  Primary antibody conditions used: 
Mouse anti-actin 1:500 (not shown) 1:300 (right three wells); 1:200 (left three wells). 
In all conditions 1:10,000 secondary antibody concentration was used.
Figure 5.5 shows that the 1:200 concentration of primary antibody produces a well 
defined band for actin detectable at ~42 kDa with 20 µg of total protein loaded (see 
circled band in Figure 5.5).To further optimise the signals for 11β HSD type 1 and actin at a loading of 20 µg of total 
protein the primary antibody conditions for both proteins were manipulated (Figure 5.6).
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Figure 5.6: Primary antibody concentrations used to optimise the signals of 11β 
HSD type 1 and actin at 20 µg of total protein loaded- see bands in circles.  Left 
circle, Mouse anti-actin 1:200 and Rabbit anti-11β HSD1 1:250 - as tried previously, 
Middle circle, Mouse anti-actin 1:150 and Rabbit anti-11β HSD1 1:200, Right circle, 
Mouse anti-actin 1:100 and Rabbit anti-11β HSD1 1:150.  In all cases, appropriate 
secondary antibodies were used at concentrations of 1:10,000.
As a result of the above optimisation results, the antibody conditions selected were those 
for the right hand circle shown in Figure 5.6.  At these antibody concentrations loading 
20 µg of total protein enables both proteins to be clearly and independently visualised 
without overloading.
Figure 5.7 indicates that the glucocorticoid receptor is present and detectable in day 17 
fetal liver.  Subsequent optimisation of the GR signal indicated that lower amounts of 
total protein loaded, i.e. <10 µg, produced a crisper signal with minimal non-specific 
bands using the same antibody conditions.  
  37kDa 
Actin
11β HSD type 1Figure     5.7:     Detection of GR in gestational day 17 fetal liver.  10, 20, 40, 80 µg total 
protein loaded as indicated.  Primary antibody concentration 1:250, secondary 
antibody concentration 1:10,000.
Figure 5.8 shows that, as was the case for GR, the lower amount of total protein loaded 
produces a more defined, less saturated band for Rabbit anti-actin.
Figure 5.8: Detection of Actin in gestational day 17 fetal liver (as a loading control 
for GR).  10 and 20 µg of fetal liver total protein loaded; primary antibody 1:250 
Rabbit anti-actin, secondary antibody 1:10,000.  
A summary of the above antibody optimisations is given in Figure 5.9.
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Actin
  M    10     20    40     80Detection of 11β HSD type 1 protein in the fetal liver at 20- 40 µg total protein using 
1:250 dilution of primary antibody, secondary antibody dilution 1:10,000 (Figure 5.4).
Detection of actin in the fetal liver (using a Mouse anti-actin primary antibody) at 20 µg 
total protein using 1:200 dilution of primary antibody, secondary antibody dilution 
1:10,000 (Figure 5.5)
20 µg total protein selected as the amount with which to optimise anti-11β HSD type 1 
and Mouse anti-actin antibody concentrations further. 
Double-labelling of 11β HSD type 1 and actin using different fluorescently-tagged 
secondary antibodies with 20 µg total protein loaded (Figure 5.6). Optimal signal 
detection was at the following primary antibody dilutions: Mouse anti-actin 1:100, anti-
11β HSD type 1 1:150.
Detection of GR protein in the fetal liver at 10 µg total protein using 1:250 dilution of 
primary antibody, secondary antibody dilution 1:10,000 (Figure 5.7)
Detection of actin in the fetal liver (using a Rabbit anti-actin primary antibody) at 10µg 
total protein using 1:250 dilution of primary antibody, secondary antibody dilution 
1:10,000 (Figure 5.8)
Double-labelling of GR and actin with 10 µg total protein loaded (Figure 5.10).  Primary 
antibody dilutions: Rabbit anti-actin 1:250, anti-GR 1:250.
Figure 5.9: Summary of initial antibody optimisation of signals from target proteins 
in the fetal liver
In summary, the initial antibody optimisations for the proteins of potential study indicate 
that GR and 11β HSD type 1 are present and detectable in day 17 fetal liver tissue.  The 
optimum amount of total protein loaded and optimum antibody dilutions found for GR 
and for 11β HSD type 1 according to the degree of detection is shown in the following 
Table 5.1.  Total protein (µg) Primary antibody  Secondary antibody 
GR 10 1 in 250 1 in 10,000
Actin 10 1 in 250 1 in 10,000
       
11β HSD type 1 20 1 in 150 1 in 10,000
Actin 20 1 in 100 1 in 10,000
Table 5.1: Summary of optimum amount of total protein and optimum antibody 
concentrations for detection of target proteins
5.3.2 Linear signal detection for GR and Actin
Prior to commencing experiments, several attempts were made to identify a linear range 
of detection for both GR and Rabbit anti-actin signals.  To optimise the conditions so that 
a linear phase of both proteins could be detected, integrated density values were taken for 
each protein in blots where doubling amounts of total protein had been loaded under 
various antibody conditions.  In the linear phase of signal detection it is expected that 
with a doubling of total protein loaded, the IDVs for the proteins being detected should 
also approximately double.  Note that, for double labelling the optimal amount of total 
protein loaded must be equivalent for both proteins.  Thus, antibody conditions were then 
varied in an attempt to bring ranges of detection in parallel (Table 5.2). 2.5 µg  5 µg  Ratio  10 µg  20 µg Ratio
GR (9% casein) 0.74 1.49  2.01 6.44 ---------
GR (18% casein) 0.99 2.08  2.10 8.13 ---------
GR (switch) 0.91 1.71  1.88 6.57 ---------
           
ACTIN (9% casein) 0.25 1.31  5.24 10.63 19.36 1.82
ACTIN (18% casein) 0.41 1.26  3.07 9.74 18.21 1.87
ACTIN (switch) 0.80 1.02  1.28 13.94 24.48 1.76
Table 5.2: IDVs for anti-GR and Rabbit anti-actin signals and the IDV signal ratios 
across increasing amounts of total protein loaded.  Primary antibodies: 1:250 
(Rabbit anti-GR; Rabbit anti-actin), secondary antibody 1:10,000 (blots not shown). 
Note; the 2.5 and 5 µg lanes were loaded on a different gel to the 10 and 20 µg lanes, 
thus the 5 µg and 10 µg IDVs are not directly comparable so ratios were not 
calculated.
Table 5.2 shows that between 2.5 and 5 µg of total protein, the signal for GR in all the 
diet lysates is approximately doubling.  Although this was not the case for actin, here the 
signal for the three diet lysates appears closer to a doubling between 10 and 20 µg of total 
protein loaded.  Therefore further optimisation was required to bring the linear range of 
both proteins in line with one another.
As the IDVs for 2.5 µg actin loaded shown in Table 5.2 are relatively low, the following 
primary antibody dilutions were used in an attempt to boost the signal for actin, again 
with 2.5 and 5 µg total protein loaded: 1:200, 1:150, 1:120, 1:100, 1:50 (all with 1:10,000 
secondary antibody concentrations).  The best results were achieved using the 1:150 
primary antibody dilutions; IDVs for this blot are shown in Table 5.3. 2.5 µg  5 µg Ratio
ACTIN (9% casein) 0.83 1.50 1.81
ACTIN (18% casein) 0.87 1.08 1.24
ACTIN (switch) 0.89 ---------
Table 5.3: IDVs obtained for actin signal with 1:150 Rabbit anti-actin primary 
antibody (blot not shown), and the IDV signal ratios obtained.
Table 5.3 shows a slight improvement in linearity for the actin signal between 2.5 and 
5 µg total protein loaded compared to that shown for actin in Table 5.2.  However, as the 
detection spectrum with the Licor scanner is extremely sensitive it will be able to reliably 
detect changes in signal which are outside a broadly linear part of the signal detection for 
a particular protein.  This means that it is no longer necessary to first find linear ranges of 
proteins being immuno-blotted when using this detection system (Personal 
communication from Licor Odyssey Technical Services).  Therefore, the amount of total 
protein loaded and the antibody dilutions for the GR and actin were selected according to 
the degree of detection of the bands rather than the degree of linearity obtained for each 
protein.  Thus, conditions selected for further experiments into GR expression in fetal 
liver were as follows: anti-GR 1:250 primary antibody (1:10,000 secondary), anti-actin 
1:250 primary antibody (1:10,000 secondary); 10 µg total protein loaded (Figure 5.10).        
                 
Figure 5.10: M= Protein Standard Marker (BIORAD, Precision Plus). 
10 µg of fetal liver total protein loaded; primary antibody dilutions: 1:250 Rabbit 
anti-GR; 1:250 Rabbit anti-actin; secondary antibody 1:10,000.  
5.3.3 Experimental: negative antibody controls
Use of secondary antibodies Goat anti-Rabbit 680, Goat anti-Mouse 778 in the absence of 
primary antibodies for 11βHSD type 1, GR and Actin resulted in clean blots, (Figure 
5.11).  The faint bands present at 25 kDa result from the anti-Mouse 778 secondary 
antibody binding the light chains of mouse antibody present in the sample of mouse 
tissue lysate.
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Figure 5.11: Negative primary antibody control.  M= Protein Standard Marker 
(BIORAD, Precision Plus).  20 µg total protein from fetal liver lysate was loaded in 
each lane.  Blot incubated with secondary antibodies only: Goat anti-Mouse 778, 
Goat anti-Rabbit 680, each at a dilution of 1:10,000.  Membrane scanned at 
intensity + 5.5 for both channels.
5.3.4 Sample selection 
Six fetal liver samples were selected from each dietary treatment group (one per litter).
In terms of the sex of the fetuses from which fetal livers used in this study were 
harvested, PCR genotyping showed that at least 50% of the fetal livers in each of the 
dietary groups came from male fetuses.  (The samples selected for protein analysis were 
nearest neighbours in the uterus to the central fetuses identified in the day 17 dissections 
in Chapter 3, bought in diet cohort.  The nearest neighbours had their sexes determined as 
Light chains of native mouse 
antibody (25 kDa).
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M   20    20    20described in Chapter 4, section 4.2.3).  Horn litter size and total litter size were not 
significantly different between the dietary groups from which fetal livers were selected 
for protein analysis (Figure 5.12).  
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Figure 5.12: Total and horn litter sizes from which fetal livers were selected for 
protein analysis.  
Figure 5.13 shows the comparison between the dietary groups in terms of amounts of 
total protein extracted per tissue weight.  The amount of total protein extracted per 
milligram of fetal liver tissue was not significantly different between the dietary groups.  0
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Figure 5.13: Comparison of average amount of total protein extracted between the 
dietary groups from fetal liver tissues selected for protein analysis.
For continuity, and to enable valid comparisons to be drawn, the same fetal liver lysates 
were used in both western blotting Experiments 1 and 2.
5.3.5 Experiment 1: Quantification of level of expression of glucocorticoid receptor 
in gestational day 17 fetal liver in relation to maternal diet.
An example of a blot from the experiment to determine the level of expression of the GR 
protein in samples of fetal liver from each of the dietary treatments is shown in Figure 
5.14.Figure 5.14: Experiment 1: analysis of GR expression levels in fetal liver in relation 
to maternal diet.  M= Protein Standard Marker (BIORAD, Precision Plus).
S= Standard fetal liver sample (same sample loaded onto all gels).  Fetal liver lysates 
from each dietary treatment were loaded in parallel as indicated, (9% casein, 18% 
casein and switch/sw).  10 µg total protein was loaded in each well, primary 
antibody dilutions: 1:250 Rabbit anti-GR; 1:250 Rabbit anti-Actin; secondary 
antibody 1:10,000.  Note; for the final experiment membranes were all scanned with 
the following intensities: L 2.0 (Actin) and + 1.5 (GR).    
Figure 5.15 displays the results from this experiment.  It illustrates that the level of 
protein expression of GR in fetal liver is significantly increased in the switch dietary 
treatment group compared to the control (18% casein) group (p<0.05). 
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Figure 5.15:  Protein expression of GR relative to Actin in day 17 fetal liver in 
respect to maternal diet. *p=0.03, one-tailed two sample t-test, n= 6 livers per 
treatment group.
Importantly, the level of average actin expression alone in the fetal livers did not change 
significantly between the diets (Figure 5.16). 
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Figure 5.1    6:     Raw IDV averages for actin in the fetal livers from each of the 
maternal dietary groups.
5.3.6 Experiment 2: Quantification of level of expression of 11β HSD type 1 in 
gestational day 17 fetal liver in relation to maternal diet.
An example of a blot from the experiment to determine the level of expression of the 11β 
HSD type 1 protein in samples of fetal liver from each of the dietary treatments is shown 
in Figure 5.17.Figure 5.17: Experiment 2: analysis of 11b HSD type 1 expression levels in fetal liver 
in relation to maternal diet.  S= Standard fetal liver sample (same sample loaded 
onto all gels).  Fetal liver lysates from each dietary treatment were loaded in parallel 
as indicated (9% casein, 18% casein and switch/sw).  20 µg total protein loaded, 
primary antibody dilutions: 1:150 Rabbit anti-11b HSD 1; 1:100 Mouse anti-Actin; 
secondary antibodies 1:10,000.  Note; for the final experiment membranes were all 
scanned with the following intensities: + 1.5 (Actin) and + 5.5 (11b HSD type 1).    
Figure 5.18 shows the results from this experiment and indicates that there is a significant 
reduction in the level of expression of the 11β HSD type 1 protein in the fetal liver in 
response to the switch diet relative to controls (p<0.05).  Decreased 11β HSD type 1 
expression in the fetal liver may result in a lower availability of active glucocorticoid in 
the fetus.
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Figure 5.18:  Protein expression of 11β HSD type 1 relative to Actin in day 17 fetal 
liver with respect to maternal diet. *p=0.026, one-tailed two sample t-test, n= 6 
livers per treatment group.
   *
 p<0.055.4 Discussion 
The results obtained from the experiments to determine the level of protein expression of 
GR and 11β HSD type 1 in the fetal liver in relation to maternal diet suggest that the 
switch diet is sufficient to invoke changes in the expression of both these proteins in the 
fetal liver, but that the low protein diet maintained throughout pregnancy does not induce 
any significant changes relative to controls.  The increased expression of GR in fetal 
livers from fetuses of switch diet fed mothers suggests that there may be a heightened 
level of glucocorticoid action in these livers, due to the increased receptor availability. 
Decreased 11β HSD type 1 expression in the exact same tissues suggests there may be a 
lower abundance of the active form of the glucocorticoid hormone in these switch fetal 
livers compared with the control group.
The decreased expression of 11β HSD type 1 may be a compensatory response to the 
increased GR expression present in the switch group fetal livers because, as described 
previously in rodents and in humans, increases in active glucocorticoid in utero may 
result in alterations to growth (Reinisch et al., 1978; Novy and Walsh, 1983) and changes 
to blood-pressure control and thus propensity to cardiovascular disease (Benediktsson et 
al., 1993; Lindsay et al., 1996; Edwards et al., 1993; Langley-Evans, 1997a,b).
Although the data collected for the 9% casein diet treatment here do not mirror the 
findings documenting significantly raised hepatic GR mRNA expression relative to 
controls in rat offspring as a result of maternal low protein fed throughout gestation (Lillycrop et al., 2005; Lillycrop et al., 2007) these studies did not examine expression at 
the protein level as mine did.  However, the results I obtained showing elevated GR 
protein expression in the switch treatment group does support other more closely related 
work using mouse liver tissue from 28-week old offspring from mothers fed the same 
switch diet as was used in my experiments.  This has shown DNA methylation of the GR 
promoter was significantly decreased relative to controls (Lillycrop, K, Watkins, A, 
Fleming, T; unpublished data).  Such hypomethylation may result in less restriction of the 
promoter’s activity and elevated expression of the GR gene.  This idea lends support to 
the raised protein expression of GR in the fetal liver of fetuses from switch fed mothers 
shown in the protein analysis data above.  It may be that in the fetus too there is this 
alteration to the methylation status of the promoter for the GR gene, which may in turn 
contribute to raise expression of the gene and thus the GR protein levels.  The elevated 
GR protein expression profile in the fetal liver is also supported by a trend towards raised 
GR gene expression in mouse day 17 fetal livers (although only female fetuses were 
analysed) from a switch dietary treatment relative to controls measured by Real-time 
PCR (Lillycrop, K, Watkins, A, Fleming, T; unpublished data).  
In both the aforementioned studies, in the 28 week post-natal murine liver of males and 
females and the female day 17 murine fetal liver, the Dnmt1 gene was found to be 
significantly elevated in the switch treatment group relative to controls (Lillycrop, K, 
Watkins, A, Fleming, T; unpublished data).  In contrast, previous work in the rat has 
indicated that Dnmt1 transcript expression is reduced in offspring in response to a 
maternal low protein diet throughout gestation (Lillycrop et al., 2007).  Thus, the maternal protein restriction throughout pregnancy versus the switch treatment may work 
through different epigenetic mechanisms in rodents.  It appears that the low protein diet 
throughout pregnancy leads to reduced capacity for methylation by Dnmt1 in the 
offspring, whereas the switch diet group seems to invoke an enhanced capacity for 
methylation by Dnmt1.  However, Dnmt1 is just one methyl transferase; expression of 
others may not necessarily reflect these patterns. 
A recent study in mice using the same maternal switch dietary treatment has found that 
the switch diet causes an elevation in recorded birth weight of pups at term (Watkins et 
al., 2008) indicating that there has been an up-regulation of fetal growth.  However, the 
increased level of hepatic glucocorticoid receptor expression found in the present study in 
the fetus at day 17 may indicate an increased action of glucocortoid in fetal tissues, which 
is known to have an inhibitory effect on fetal growth (Ikegami et al., 1997; Bertram and 
Hanson, 2002, Novy and Walsh, 1983).  Thus, the findings appear contradictory. 
Although in rats, it has been previously reported that the equivalent switch diet treatment 
results in a significant reduction of measured birth weights of pups at term (Kwong et al., 
2000) which may lend support to an attenuation of fetal growth taking place in late 
gestation.  However, the rat model may represent a slightly different mechanism in this 
species and thus the results obtained by Watkins et al, 2008 in the mouse may be more 
relevant to this study.  Although, as the effects on birth weight documented by Watkins 
et al, 2008 and also Kwong et al, 2000 are gender specific (the switch dietary treatment 
only resulted in a significant alteration of birth weight in female pups), and the present 
study incorporated fetuses of both sexes, these data may not be directly comparable to my study.  In hindsight, it would have been beneficial to know the level of target protein 
expression based on the sex of the fetuses in the present study so that gender-specific 
differences could be identified and more specific conclusions drawn.    
The depression in 11β HSD type 1 expression found in the fetuses from the maternal 
switch group might result in a reduction in the level of glucocorticoid action in the fetus 
and thus might lend support to there being an up-regulation of fetal growth, due to the 
reduction of a growth retarding influence in the form of active glucocorticoid, thus 
resulting in elevated birth weights at term.
If indeed the decrease in 11β HSD type 1 expression compensates for the elevation in GR 
expression, the net effect may be a slightly dampened expression of 11β HSD type 1 in 
the fetal liver, and hence a small reduced capacity of the fetus to transform inactive 
glucocorticoid into physiologically active forms.  This may manifest itself as a reduced 
capacity for glucocorticoid action in these fetuses.  In contrast to my findings at the 
protein level, increased levels of hepatic 11β HSD type 1 mRNA have been reported in 
female rat fetuses at late gestation in an equivalent of the switch diet group relative to 
controls (Kwong et al., 2007).  However, as mentioned earlier, my protein analysis of the 
fetal liver did not distinguish between fetal sexes comprehensively and thus may include 
fetal liver from both males and females in the analysis.  Thus, my results cannot be 
directly compared to reports of gender-specific changes.Programming responses are likely to be multi-factorial; glucocorticoids represent just one 
hormone of a pool of important signals in the fetus which are relevant for fetal growth 
and development.  Thus, these hormones alone cannot explain the bounds of fetal 
programming, but instead may explain a small part of the complex picture in the fetus in 
which adaptations to the environment in utero are made.
Further work
Further work on the GR protein might involve the selective detection of the 
phosphorylated form of the protein only.  This would enable specific analyses of the level 
of activated receptor to be made i.e. receptor that has bound its hormone ligand 
(Bamberger et al, 1996), and thus give a more specific indication of glucocorticoid 
presence in the tissue.  However, at the time of writing, the phospho-GR antibodies 
available were all raised against phosphorylations present on the human form of the GR 
protein (Serotec Database).  An additional possibility for further work on the 
glucocorticoid theme might involve analysis of the level of expression of the IGF-II 
protein in the same fetal liver tissues.  As IGF-II is a negative downstream target of 
glucocorticoids involved in stimulating fetal cell growth and differentiation (Fowden, 
2003), it may be that levels are reduced in those tissues where there is heightened 
glucocorticoid activity.  Indeed in the rat fetal liver, it has been reported that an 
equivalent to the maternal switch diet used in my study has resulted in reduced hepatic 
Igf2 gene expression in male fetuses (Kwong et al., 2006).Finally, further work might involve investigation of the protein expression/activity of 11β 
HSD type 2 in the placenta at day 17 to analyze the level of maternal glucocorticoid 
crossing the placenta and entering fetal circulation at this time.  Chapter 6
6.1 Introduction: The Influence of Pre-implantation Embryo Environment on Fetal 
Development 
Studies in a variety of animal models have demonstrated that the environment to which 
the early embryo is exposed has lasting implications for its later development.  A striking 
example of the sensitivity of the early embryo to its environment is documented by the 
phenomenon of Large Offspring Syndrome (LOS).  LOS has been illustrated in sheep and 
cattle after in vitro culture of embryos in the presence of serum.  The LOS phenotype is 
characterised by increased birth weight, increased muscle mass, cerebellar dysplasia, 
skeletal and facial malformations, and changes in the size and weight of internal organs. 
Furthermore, these animals die peri-natally (Thompson et al., 1995; Sinclair et al., 1999; 
Holm et al., 1996; Young et al., 1998).  Long-term effects of pre-implantation embryo 
culture and transfer documented in mice include adverse alterations to post natal 
behaviour, memory and growth (Ecker et al., 2004; Fernandez-Gonzalez et al., 2004) and 
elevated post natal blood pressure in female offspring (Watkins et al., 2007).  Similarly, 
in vivo manipulations to the pre-implantation embryo environment, mediated by altered 
maternal diet in rodents has demonstrated reduced blastocyst cell numbers in the short 
term, first within ICM (in early blastocyst) and later within both ICM and TE (in mid/late 
blastocyst), induced by a slower rate of cellular proliferation (Kwong et al., 2000) and 
altered birth weight, post natal growth and hypertension in the long term (Kwong et al., 
2000; Watkins et al., 2008).Thus, the pre-implantation stage of development represents an important window during 
which the embryo is sensitive to programming brought about through manipulations in its 
immediate environment.
Blastocyst stage embryo transfers were conducted at 3.5 days from low protein and 
control fed donor mothers to control fed pseudo-pregnant foster mothers, also at 3.5 days 
post plug in order to determine the influence of the in vivo low protein environment 
exclusively during the pre-implantation period.  Post-transfer, embryos were allowed to 
develop inside foster mothers until gestational day 17, when fetal growth was examined 
through weight analyses.
This experiment isolates the importance of the period during the pre-implantation 
window of embryo development (0-3.5 days) without altering uterine environment.  This 
is in contrast to the switch diet described in Chapter 2 which effects both maternal 
physiology and the embryo.  In this way it is possible to determine the relative maternal 
and fetal contributions for potential fetal programming in response to diet, and to 
investigate the potential for predictive adaptive responses (PARs) to be made by the 
embryo in response to its early environment (Gluckman and Hanson, 2004a, c).  6.2 Materials & Methods
Also refer to Chapter 2 on Generic Methods, sections 2.1 Experimental Design, 2.2 
Animal Treatments, 2.3 Recovery of Conceptuses, and 2.4 Collection of gestational day 
17 tissue.
 
6.2.1 Experimental design
Pseudo pregnant mothers fed a control (18% casein) diet since day of plug surgically 
received blastocysts from both low protein (9% casein) and control (18% casein) diet fed 
donor mothers.  Six blastocysts from a low protein diet fed donor were transferred into 
one horn of the pseudo pregnant uterus, and six blastocysts from a control diet fed donor 
were transferred into the other horn (Figure 6.1).  In this way it was intended that litters 
of up to twelve fetuses would be produced, representing average total litter sizes of 
naturally-mated females (see Chapter 3, Figure 3.2).  The transfer of blastocysts from 
18% casein fed donors, into the same foster mother as blastocysts from low protein (9% 
casein) diet donors acted as an internal control to account for the effects of the transfer 
procedure on the foster mother.  
To avoid horn bias the transfer of blastocysts of one diet type to either the left and right 
uterine horns was alternated during the experiment.  The order in which embryos of each 
diet were transferred was also alternated i.e. embryos from 9% casein diet fed donors were not always transferred before embryos from 18% casein diet fed donors and vice 
versa.
Figure 6.1: Schematic representation of the pseudo pregnant mouse uterus at 
blastocyst transfer; also the loaded transfer pipette.  Adapted from 
http://wheat.pw.usda.gov
Importantly, it is worth noting at this stage that trans-uterine migration does not appear to 
occur in mice (Rulicke et al., 2006).  Trans-uterine migration is the movement of 
embryos from one uterine horn into the other and is a phenomenon that has been 
described for animals of different species with a bicornuate type of uterus, as is present in 
the mouse.  The separation of the uterine body and the pre-vaginal portion of the uterine 
cervix into two canals by a septum seem to be the main reason for the absence of 
successful trans-uterine migration in mice (Rulicke et al., 2006).
18% casein embryos
9% casein embryos6.2.2 Stud vasectomies
Surgery was carried out under general anaesthesia following an intra-peritoneal injection 
of a Ketamine based anaesthetic (see Appendix III) to vasectomise ten 6-week old MF1 
studs which had been fed a standard chow diet from weaning.  After preparation of the 
skin area, the vasectomy was carried out by making a ventral incision at knee height, and 
locating the fat pad associated with the testis on either side.  The vas deferens were then 
located and cut and the ends cauterized.
Vasectomised males were housed individually, fed a standard chow diet and tap water ad 
libitum and allowed two weeks to recover from the procedure under standard conditions 
(refer to Chapter 2, section 2.2).  After recovery, mating commenced to generate pseudo 
pregnant females in which the signal of mating is sufficient to generate a uterus receptive 
to receiving embryos, in the absence of any fertilization.  
To check the effectiveness of the surgery before the experiment began, vasectomised 
males were allowed to mate two females each.  Plug-positive females were then observed 
for the following 21 days to ensure no weight gain, indicative of a pregnancy, was 
evident.6.2.3 Animal treatments
Plug-positive embryo donor females were fed either the 9% casein or 18% casein 
(control) diet from day of plug until day 3.5 of pregnancy, at which point they were 
culled and their embryos collected.  At 3.5 days, surgery took place in order to transfer 
embryos from the donors into 18% casein fed pseudo pregnant mothers at the equivalent 
stage of pseudo pregnancy.  After mating with vasectomised males, plug positive pseudo 
pregnant foster mothers were fed the 18% casein diet from day of plug until day 17 when 
they were sacrificed.  
6.2.4 Uterine dissection at day 3.5  
Pregnant embryo donor females were culled by cervical dislocation after 3.5 days 
gestation.  The uterus was dissected out by cuts made just posterior to the oviduct at the 
isthmus region of each uterine horn and a cut anterior to the cervix and was placed in 
saline warmed to 37 
oC.  Excess fat and mesometrial tissue was removed from the uterus 
at this point.
6.2.5 Embryo collection and short term culture
At 3.5 days post plug, embryos were flushed from each of the uterine horns of pregnant 
donors.  A needle puncture near the oviduct end of each uterine horn was made under a dissecting microscope and Hepes-buffered (H6 PVP) culture media (see Appendix III) 
pre-warmed to 37 
oC was flushed through and expelled with blastocysts at the cervix.  
Blastocyst stage embryos were selected and collected using a mouth pipette and 
transferred to ~20 µl drops of CO2 equilibrated T6 PVP culture media (see Appendix III) 
warmed to 37 
oC, covered with a layer of equilibrated mineral oil.  Blastocysts flushed 
from either horn of the donor uterus were pooled, as were blastocysts recovered from 
different donors of the same dietary treatment.  T6 PVP drops containing embryos were 
placed in a CO2 incubator at 37 
oC and gassed at 5% CO2 until required for transfer to a 
pseudo pregnant female.  To keep embryo culture time to a minimum, a ‘flush-transfer-
flush-transfer’ routine was adopted i.e. as soon as six embryos of one diet type were 
flushed and collected from the donor/s, these were transferred into the pseudo pregnant 
uterus before the donor/s of the other type of diet were flushed.
6.2.6 Embryo transfer surgery
Pseudo pregnant animals were given an intra-peritoneal injection of a Ketamine-based 
anaesthetic which incorporated analgesic (see Appendix III).  A maximum dose 
equivalent to 1% body weight was administered (weight vol 
-1).  The lower dorsal region 
of the mouse was shaved and the skin covered with iodine solution.  A small skin incision 
was made followed by an incision into the body wall over the region of the ovary.  The 
fat pad covering the ovary was located, clamped and rested across the mouse's back to 
hold the uterus in place (Figure 6.2).  Figure 6.2: Schematic showing how ovarian fat pad is easily visible and provides an 
anchor from which the delicate uterine horn may be accessed; taken from 
http://wheat.pw.usda.gov.
The uterus was located by easing the ovary, oviduct and part of the uterus out through the 
incision in the body wall.  Under a dissecting microscope, a puncture was made to the top 
of each uterine horn into the lumen of the uterus using a 25 gauge needle and embryos 
loaded in a fine flame-polished transfer pipette were expelled into each horn in turn 
(Figure 6.3).  Six embryos were transferred per horn with a small amount of T6 PVP 
(avoiding mineral oil from the culture).
Figure 6.3: Schematic of a loaded transfer pipette; taken from 
h   ttp://wheat.pw.usda.gov    .To minimise risk of infection, care was taken during surgery to keep instruments for 
cutting the skin separate from instruments used for working inside the mouse.  
All foster mothers were housed individually following surgery and were allowed to 
recover post-operatively in a quiet, warm room (~33 
oC) to minimise onset of 
hypothermia brought about by the anaesthesia (Bagis et al., 2004) and to aid recovery.
6.2.7 Recovery of conceptuses
On gestational day 17 (i.e. 14 days post-embryo transfer surgery), pregnant foster 
mothers were culled by cervical dislocation of the neck, and the uterus was dissected out 
and placed in ice cold PBS.  Conceptuses were dissected out of each of the uterine horns 
and weighed, and conceptus weights and horn litter sizes recorded.  
6.3 Results
Uterine horn litters from six different foster mothers for each of the embryo donor diet 
groups were collected at day 17, uterine horns containing just a single conceptus at day 
17 were excluded from the analysis as being anomalous. 6.3.1 Embryo development and horn litter sizes at day 17
Following the transfer of six embryos per uterine horn into the pseudo pregnant uterus, 
on average 3.5 conceptuses were recovered from a single uterine horn at day 17 for both 
types of diet embryos i.e. the average horn litter sizes were equivalent between diet 
groups.  As mentioned in Section 6.2.1, the design of this experiment was drawn up to 
enable conceptuses from both embryo diet treatments, to be recovered at day 17 in the 
same foster mother thus there would be an internal control for the effects of the transfer 
procedure on a particular foster mother.  However, only in 20% of foster mothers did two 
or more embryos develop successfully in both horns of the uterus.  In the majority of 
foster mothers the pregnancy was unilateral and restricted to just one of the uterine horns, 
despite both horns being transferred into (Table 6.1).
No. foster mothers with fetuses recovered from both 9% & 18% casein diet embryo donors 2
No. foster mothers with fetuses recovered from 9% casein diet embryo donors only 4
No. foster mothers with fetuses recovered from 18% casein diet embryo donors only 4
Total number of foster mothers pregnant at day 17 (with 2+ conceptuses per horn) 10
Table 6.1: Numbers of foster mothers where conceptuses were recovered at day 17 
in one or both uterine horns.  
6.3.2 Weight data at gestational day 17 after embryo transfer into 18% casein diet 
foster mothers at day 3.5
It appears that the dietary environment of the embryo <3.5 days has a significant effect on 
conceptus weight when measured at day 17.  Figure 6.4 indicates that the 9%-18% group (i.e. embryos from 9% casein diet fed donors transferred into 18% casein fed fosters) 
develop into significantly heavier conceptuses than the 18%-18% group (i.e. embryos 
from 18% casein diet fed donors transferred into 18% casein fed fosters).  
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     Figure 6.4:      Average conceptus and fetus weights after embryo transfer into 18% 
casein diet fed foster mothers, (*p =0.048) n= 6 mothers, 19-21 samples for each type 
of transfer.
Conceptus weight measured at day 17 indicates that embryos derived from 9% casein diet 
fed donor mothers give rise to larger conceptuses than embryos from 18% casein diet fed 
donors when both types of embryo develop within the same type of environment post 3.5 
days (p= 0.048).  However, when horn litter size is incorporated into the analysis, the 
effect of embryo donor diet on conceptus weight remains (p= 0.013) but there is a 
significant effect of horn litter size also (p= 0.024).  
   *
         p<0.05Similar patterns to that shown in Figure 6.4 were also observed in the fetus and a number 
of the other tissues examined, i.e. placenta and fetal kidneys, although not significant 
(Figures 6.5 and 6.6).  This indicates there may be a proportionate increase in growth of 
these components; the conceptus:placenta and fetal:placental weight ratios were 
unchanged between diet groups.
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Figure     6.5:     Average placenta, yolk sac and fetal liver weights after embryo transfer 
into 18% casein diet fed foster mothers.
No significant differences were found between embryo donor diets in terms of the 
average placenta, yolk sac and fetal liver and fetal kidney weights of conceptuses 
recovered from 18% casein diet fed foster mothers at day 17, (Figures 6.5, 6.6). 0
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Figure 6.6: Average fetal kidney weights after embryo transfer into 18% casein diet 
fed foster mothers.
6.3.3 Modifications to embryo transfer method
In an attempt to find ways to improve upon the pregnancy rate and average number of 
embryos recovered per horn, a number of modifications were implemented in a series of 
initial trials.  The first modification involved incorporating a day delay into the 
synchronicity of the developmental stage of the embryos being transferred (3.5 days) and 
the stage of pseudo pregnancy of the foster mother’s uterus.  Here, day 3.5 blastocysts 
were flushed from embryo donors as before but instead were transferred into foster 
mothers that were at 2.5 days of pseudo pregnancy.  In doing this it was intended to give 
embryos more chance to recover from the short term culture before the pseudo pregnant 
uterus was receptive to implantation at ~4.5 days post plug.  Other modifications to the 
method included increasing the number of embryos transferred into each uterine horn to ten so that even if only ~50% implanted and developed this would represent a more 
natural horn litter size.
A new cohort of twelve foster mothers was transferred into using this method, and the 
pregnancy rate increased (a pregnancy was counted as the presence of at least one fetus in 
the uterus).  However the average number of fetuses recovered per horn (of either diet) 
was just 
2.6/10 which represents a lower proportion of the total number transferred per horn 
than in the main experiment (data not shown).  This may indicate that the day delay helps 
with getting at least one embryo to implant and develop after transfer but there may still 
be problems with the method which restrict the number of embryos that are able to 
develop successfully post transfer.  
6.4 Discussion 
Comparison of conceptuses that have been transferred as embryos from 9% casein to 
18% casein diet fed mothers at day 3.5 with those transferred from 18% casein to 18% 
casein diet fed mothers, seeks to answer the question as to whether a restricted protein 
uterine environment for the first 3.5 days of development can programme embryos such 
that their development does not benefit from a normal maternal protein environment after 
this time.  If such conceptuses were comparable it may suggest that embryo fate is 
somewhat dependent on the maternal environment post 3.5 days and is not permanently 
programmed by the pre-implantation environment.  If, however the conceptuses showed 
differences it might indicate that 9% casein embryos have been programmed by the low protein uterine environment during the pre-implantation window and their development 
thereafter is largely independent of continued maternal environmental cues, as the 
developmental path has been determined.  Indeed it appears that the latter is the case in 
terms of the growth of the conceptus as a whole entity.   
Figure 6.4 showed that conceptuses that developed from 9% casein embryos were 
significantly heavier than those that developed from 18% casein embryos when each 
were transferred into 18% casein diet fed foster mothers at day 3.5, which may be an 
indication that over-compensatory modifications to growth occurred within the early 
embryo at the blastocyst stage.  This argument is supportive of an adaptation in 
embryonic development having taken place prior to day 3.5, which is then manifested 
itself as an increased weight phenotype at day 17 in the embryos from the 9% casein 
donors.  The significant difference in conceptus weight shown in Figure 6.4 in the 
absence of significant changes in the weights of component tissues: fetus, placenta, yolk 
sac, may suggest a cumulative effect of smaller changes to each component, notably the 
placenta, amounting to a significant change in conceptus weight.  Alternatively, a change 
in the volume of amniotic fluid surrounding the fetus may contribute to the difference in 
conceptus weight observed.  
As the significant effect of dietary treatment on conceptus weight was accompanied by a 
significant effect of horn litter size on conceptus weight, it is difficult to make 
conclusions about the relative impact of each factor on the resulting change in conceptus 
weight.  Furthermore, it is important to highlight that only 20% of the foster mothers contributed data at day 17 for both the 9% casein and 18% casein diet embryos.  The 
remainder of the data came from fosters mothers where only the 9% casein or the 18% 
casein embryos could be retrieved at day 17.  Thus, in the majority of cases there was no 
internal control.  However, this effect was evident equally in both diet treatments and 
therefore does not account for the change in weight gain observed.  
These data indicate that the initial low protein environment was sensed by the 9% casein 
embryos prior to their transfer and suggest these embryos increased their nutrient uptake 
or altered their metabolism to maximize use of all available nutrients in a restricted 
environment to protect future growth and development; once transferred to an 
environment of normal protein levels, such adaptations would have been inappropriate 
and thus may have caused embryos to overshoot the control (18% casein diet) conceptus 
weight at day 17.  This argument is supportive of the PARS hypothesis (Gluckman and 
Hanson, 2004 a, c) described previously in which the embryo ‘makes predictions’ about 
the environment in which it will develop and adapts its development accordingly.  The 
9% casein embryos may have been programmed by their protein restricted environment 
<3.5 days of development and thus made adaptations to enable themselves to best prepare 
for coping with a protein-restricted environment in the future, which were rendered 
inappropriate after the embryo transfer procedure into a non-restricted uterine 
environment.  
The 9%-18% transfer group is somewhat similar to the switching diet group (Chapter 2, 
section 2.1) in that the uterine environment experienced by the embryo changes from day 3.5 of gestation onwards.  However, in the present study the transition is more immediate 
and is independent of maternal physiology.  Birth-weight data in the mouse using a 
maternal low protein model has shown that weights of pups at term can be significantly 
elevated if the maternal diet was switched at day 3.5 from 9% casein to 18% casein. 
Although not an embryo-transfer model, this finding may lend support to the apparent 
changes in growth in utero found here, due to similarities in principle between the switch 
diet treatment and the 9%-18% transfer group in terms of the types of uterine 
environment experienced by the embryo during its in utero development.  Furthermore, 
parameters of post-natal health were also affected by the maternal protein diet during the 
pre-implantation period in this study (Watkins et al, 2008).
Extra embryonic lineages segregated at the blastocyst stage are likely to be contributors 
of pre implantation responses to maternal diet as they control the maternal-fetal nutrient 
transport capacity (Watkins et al., 2008).  The yolk sac (derived from blastocyst ICM) 
functions in part, in nutrition through endocytic uptake and lysosomal digestion of 
maternal proteins and delivery of release amino acids for fetal growth (Beckman et al., 
1998).  Indeed, yolk sacs from late gestation murine conceptuses exposed to a low protein 
environment in vivo have been studied and suggest that yolk sac function changes to 
promote an elevated rate of endocytosis in response to the low protein surroundings 
(Watkins et al., 2008).  Thus, the altered yolk sac function may represent a physiological 
adaptation to dietary conditions in utero, and provide a mechanism for the up regulated 
growth at term described in mice exposed to a maternal switch diet if the altered rate for 
endocytic uptake is programmed in the blastocyst by the environmental conditions experienced during the early pre implantation stage of embryo development.  Further, if 
this is the case it might offer some explanation for the elevated conceptus weight found in 
my study after embryo transfer. 
Further work 
Biochemical investigation of the tissues from the conceptuses produced by the embryo 
transfer procedure may reveal some explanations for the difference found in overall 
conceptus weight at gestational day 17.
Further investigation of this area might involve analysis of the conceptuses at a later stage 
of gestation, such as day 18.  It is possible that day 17 does not capture the time frame 
when the differences between the embryos from each type of donor are the most 
apparent.  As there was a consistent pattern of tissue weights for the different embryo-
donor diets across most of the tissues analyzed it is possible that a slightly later stage of 
development those differences would have become more marked and reflected the 
significant difference in conceptus weight described at gestational day 17.Chapter 7
General Summary
In this project I have examined the impact of maternal low protein diet on the subsequent 
development of the fetus.  I have collected data on gene and protein expression in day 17 
fetal liver and have also examined the growth phenotype of the fetus as a whole at day 17 
in response to a maternal dietary challenge.  A brief summary of my findings from the 
work in each of the aforementioned areas follows:
Genomics analysis data
The downstream analyses from all three of the programmes used to analyse the micro-
array data set (discussed in sections 4.4.2.1 to 4.4.2.3) indicated that the level of 
biological variation in the data set made drawing comparisons between treatment groups 
more challenging.  
In summary, initial analyses of the micro-array data using dChip highlighted some 
interesting candidates at the level of transcription that appeared to offer, in part 
explanations for mechanisms of programming of post natal phenotypes in response to 
maternal diet for the switch versus 9% class comparison.  However, further analysis of 
the class comparisons suggested that a factor unrelated to diet might be driving the 
differences in gene expression, particularly between the switch and 9% classes.  Thus, it 
appeared that it was the mother’s capacity to support her litter (determined by total litter size) more than her level of protein intake, which was sensed by individual fetuses in the 
uterus, and indeed this seems to manifest in alterations in fetal hepatic gene expression.  
Protein analysis data
The results obtained from the experiments to determine the level of protein expression of 
GR and 11β HSD type 1 in the fetal liver in relation to maternal diet suggest that the 
switch diet is sufficient to invoke changes in the expression of both these proteins in the 
fetal liver, but that the low protein diet maintained throughout pregnancy does not induce 
any significant changes relative to controls.  The increased expression of GR in switch 
fetal liver suggests that there may be a heightened level of glucocorticoid action in these 
livers, due to the increased receptor availability.  Decreased 11β HSD type 1 expression 
in the same tissues suggests there may be a lower abundance of the active form of the 
glucocorticoid hormone in these switch fetal livers compared with the control group.  The 
decreased expression of 11β HSD type 1 may thus be a compensatory response to 
increased GR expression.
Embryo transfer data
These data indicate that the initial low protein environment was sensed by the 9% casein 
embryos prior to their transfer and suggest these embryos adapted their nutrient uptake or 
altered their metabolism to maximize use of all available nutrients in the restricted 
environment to protect future growth and development; once transferred to an environment of sufficient protein levels, such adaptations would have become 
inappropriate and thus may have caused embryos to overshoot the control (18% casein 
diet) conceptus weight at day 17.  This argument is supportive of the PARS hypothesis 
(Gluckman and Hanson, 2004 a, c) described previously in which the embryo ‘makes 
predictions’ early on about the environment in which it will develop and adapts its 
development accordingly.  
Overall, the data I have collected show that switching the maternal diet from low to 
adequate protein at the end of the pre implantation period of embryo development has the 
most striking impact on fetal development observed at day 17; evidenced by elevated 
conceptus weight after natural mating (in house diet) and significantly altered hepatic 
expression of two glucocorticoid related proteins.  Furthermore, data collected from the 
embryo transfers performed at gestational day 3.5 support this idea; it appears that 
exposure to a low protein environment for the pre implantation period exclusively, 
programs the embryo to follow a different developmental pathway which is not reversed 
by subsequent exposure to an in utero environment of adequate nutrition after 3.5 days.AppendicesAppendix I
DNA Sequencing of PCR Products (Sanger ‘dideoxy’ method)
The Sanger chain termination method of DNA sequencing involves synthesis of a new 
DNA strand using a single stranded DNA template from the gene being sequenced. 
Synthesis of the new strand can be stopped at any of the four bases by adding the 
corresponding dideoxy (dd) derivative of the deoxyribonucleoside phosphates, e.g. by 
adding ddATP the synthesis terminates at an adenosine base.  The fragments are 
separated by electrophoresis according to their chain length and the dideoxy terminators 
are detected by fluorescence spectroscopy.  A computer generated printout of the 
corresponding base sequence from the bottom of the gel towards the top is produced.
Calculation of 100 fmols for 244 bp     DXNds3     product:    
330 (D) x (244 x 2) = 161040 Daltons
1 x 10 
-13 moles (100 x 1 x 10
-15) x 161040 D = Equivalent weight (g) i.e. 1.6 x 10
-8 g 
(16 ng)
16 ng of DXNds3 PCR product = 100 fmolsSequencing with ABI377 automated sequencer
Due to a number of technical difficulties with the Beckman Coulter system, the ABI377 
system was used as an alternative method for sequencing of the Zfy gene product.  The 
protocol for preparing sequencing reactions for the ABI system is similar to the Beckman 
Coulter system.  However the cycling sequencing chemistry used for the ABI377 
automated sequencer is BigDye Terminators.Detailed Affymetrix Methods
Target Labelling
Preparation of Poly-A RNA Controls for One-Cycle cDNA Synthesis 
 
Table AI.1: Final dilutions of Poly-A RNA controls in samples (GeneChip 
Expression Analysis Technical Manual, Affymetrix).
(Each probe array contains probe sets for the bacterial genes: lys, phe, thr, dap). 
First strand cDNA synthesis
For each sample, the total RNA, diluted poly-A RNA controls, and T7-Oligo(dT) Primer 
were mixed together in 0.2 ml thin walled PCR tubes.Table AI.2: RNA/T7-Oligo(dT) primer mix preparation for 1-8 µg RNA
(GeneChip Expression Analysis Technical Manual, Affymetrix).
Tubes were flick mixed, pulse centrifuged and incubated at 70
oC for 10 minutes, and then 
cooled for 2 minutes (minimum) at 4
oC.  A first strand master-mix was assembled on ice 
in a separate RNase-free tube, sufficient for all RNA samples.
Table AI.3: Components of first-strand master-mix per reaction (GeneChip 
Expression Analysis Technical Manual, Affymetrix).
To each RNA/Primer mix, 7µl of the first-strand master-mix was added to make a final 
volume of 19 µl.  Reactions were mixed and incubated at 42
oC for 2 minutes.  1 µl of 
Superscript II reverse transcriptase was then added to each reaction and reactions were incubated for 1 hour at 42
oC, and were then cooled for 2 minutes (minimum) at 4
oC. 
Second strand synthesis followed immediately.
Table AI.4: Summary of incubations for first strand cDNA synthesis reaction (one 
cycle only).  Heated lids were used to prevent evaporation.  All incubations were 
performed in a Tetrad thermal cycler.
Second strand cDNA synthesis
Sufficient second strand master-mix was prepared on ice for all samples in a separate 
tube.
Table AI.5: Components of second strand master-mix per reaction (GeneChip 
Expression Analysis Technical Manual, Affymetrix). To each first-strand synthesis reaction 130 µl of second strand master-mix was added to 
make a total volume of 150 µl.  These reactions were incubated for 2 hours at 16
oC. 
Finally, 2 µl of T4 DNA Polymerase was added to each sample and samples were 
incubated for 5 minutes at 16
oC.  After this incubation, 10 µl of 0.5M EDTA was added 
to each reaction.  Cleanup followed immediately. 
Table AI.6: Summary of incubations for one cycle second strand cDNA synthesis 
(using Tetrad thermal cycler).  
In Vitro     Transcription (IVT) Reaction     
11 µl of each of the double-stranded cDNA samples synthesised was added to each IVT 
reaction.  Reactions were assembled in 0.2 ml thin-walled PCR tubes at room 
temperature.  Sufficient IVT master-mix was prepared for all samples.  Reactions were 
incubated for 16 hours at 37
oC using a Tetrad thermal cycler.Table AI.7: Components of IVT master-mix per reaction (GeneChip Expression 
Analysis Technical Manual, Affymetrix).
Calculating an adjusted cRNA yield
Assuming an estimate of 100% carryover, the formula below was used to determine 
adjusted cRNA yields:
adjusted cRNA yield = RNAm – (total RNAi) (y)
RNAm = amount of cRNA measured after IVT (µg)
Total RNAi = starting amount of total RNA (µg)
y = fraction of cDNA reaction used in IVT
Formula for calculating adjusted cRNA yields (GeneChip Expression Analysis Technical 
Manual, Affymetrix).
11µlFor each cRNA sample the adjusted yield was calculated as above.  Adjusted cRNA 
concentrations were subsequently used for the cRNA fragmentation step.  Expected 
average yields of cleaned up cRNA are between 30-50 µg + (personal communication 
Geoff Scopes, Affymetrix).
cRNA Fragmentation Reaction
Table AI.8: Sample fragmentation reaction (GeneChip Expression Analysis 
Technical Manual, Affymetrix).
Fragmentation reactions were prepared on ice in 0.2 ml thin-walled PCR tubes and 
incubated for 35 minutes at 94
oC with a Tetrad thermal cycler.  Following the incubation, 
reactions were placed on ice and fragmented cRNA was subsequently stored at -80
oC.
Fragmentation of the cRNA was monitored with the Agilent 2100 Bioanalyser using the 
RNA 6000 Nano Assay Kit (Agilent Technologies) to determine whether the sample was 
of the length required for optimal micro-array performance.
Array format used 
Figure AI.1: RNA Ladder (Agilent Bioanalyser).  The marker peak and first 5 
ladder peaks define a correlation between migration time and sizing; the marker 
peak is set at a migration time of 22.5 seconds.
200bp
500bp Marker 
peak
(25bps)Target (cRNA) Hybridisation
Table AI.9: Hybridization cocktail for a single probe array; 30 µl of the 0.5 µg/µl 
fragmented labelled cRNA stock per sample was used.  Hybridization controls are 
ready made biotinylated and fragmented cRNA of bioB, bioC, and bioD from E. 
coli, and cre from P1 from bacteriophage premixed at staggered concentrations. 
Probes detecting these controls are present on the probe arrays.  Control Oligo B2 
was used to provide control and alignment signals for subsequent image analysis 
(GeneChip Expression Analysis Technical Manual, Affymetrix).Figure AI.2: Cartridge structure of the probe arrays (GeneChip Expression 
Analysis Technical Manual, Affymetrix).  The array chamber must be first vented 
through one of the septa before filling or draining.  The glass substrate consists of 
an array of oligonucleotides on its inner surface.
Washing and Staining of Hybridised Probe Arrays
The Fluidics Station Bleach Protocol was run prior to use of the Fluidics Station.  This 
involved running 500 ml 0.525% sodium hypochlorite solution through the station, 
followed by a rinse cycle with deionised water.  For bleach protocol, refer to GeneChip 
Expression Analysis Technical Manual, Affymetrix.                
Table AI.10: Antibody amplification fluidics protocol (GeneChip Expression 
Analysis Technical Manual, Affymetrix).  
Stain Cocktail 1Figure AI.3: MAS 5.0 normalized log expression signal data was similar for all 
twelve arrays across all treatments.   Figure AI.4: Pearson correlation plot showing the correlations in signals amongst all 
samples after analysing the .CEL files with the RMA algorithm.  All correlation are 
~0.985 and above.
Mean of samples 17,18,3,4 (18% casein diet treatment) 0.991335
Mean of samples 1,16,8,9 (9% casein diet treatment) 0.9910763
Mean of samples 12, 13, 6, 7 (switch diet treatment) 0.9927703
   
Mean of 18% casein samples Vs 9% casein samples 0.9914352
Mean of 18% casein samples Vs switch samples 0.99228
Mean of 9% casein samples Vs switch samples 0.9913881
Table AI.11: Mean correlation coefficients for array samples within and between 
treatment groups (RMA normalised data).Affx probe set Gene information Fold change p-value
1415773_at Ncl: nucleolin -2.57 0.001249
1415784_at Vps35: vacuolar protein sorting 35 -2.26 0.002003
1416157_at Vcl: vinculin -2.21 0.016113
1416180_a_at Rdx: radixin 3.56 0.004056
1416388_at Pip4k2c: phosphatidylinositol-5-phosphate 4-kinase, type II, gamma -1.89 0.001527
1416656_at Clic1: chloride intracellular channel 1 -2.17 0.000526
1416660_at Eif3s10: eukaryotic translation initiation factor 3, subunit 10 (theta) -2.1 0.010294
1416686_at Plod2: procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 -2.5 0.030153
1416691_at Gtpbp2: GTP binding protein 2 -1.98 0.003956
1416794_at Arl6ip2: ADP-ribosylation factor-like 6 interacting protein 2 -1.91 0.001552
1416837_at Bax: Bcl2-associated X protein -2.04 0.002074
1416913_at Es1: esterase 1 2.23 0.003057
1417238_at Ewsr1: Ewing sarcoma breakpoint region 1 -1.84 0.002141
1417576_a_at Otub2: OTU domain, ubiquitin aldehyde binding 2 -2.33 0.007124
1417900_a_at Vldlr: very low density lipoprotein receptor -2.68 0.000589
1418020_s_at Cpd /// LOC100046781: carboxypeptidase D /// similar to carboxypeptidase D -1.87 0.005103
1418231_at Lims1: LIM and senescent cell antigen-like domains 1 -2.04 0.013542
1418685_at Tirap: toll-interleukin 1 receptor (TIR) domain-containing adaptor protein 3.02 0.00666
1418787_at Mbl2: mannose binding lectin (C) 2.92 0.025395
1418946_at St3gal1: ST3 beta-galactoside alpha-2,3-sialyltransferase 1 -2.21 0.031563
1419029_at Ero1l: ERO1-like (S. cerevisiae) -1.94 0.02372
1419030_at Ero1l: ERO1-like (S. cerevisiae) -2.45 0.002844
1419098_at Stom: stomatin -2.86 0.000481
1419099_x_at Stom: stomatin -2.4 0.000538
1419256_at Spnb2: spectrin beta 2 2.75 0.031929
1420420_at Hao1: hydroxyacid oxidase 1, liver 1.88 0.019711
1420620_a_at Rnf13: ring finger protein 13 -1.84 0.000767
1420904_at Il17ra: interleukin 17 receptor A -2.26 0.005163
1420973_at Arid5b /// LOC100044968: AT rich interactive domain 5B (Mrf1 like) ///  2.45 0.00453
1421011_at Hsd17b11: hydroxysteroid (17-beta) dehydrogenase 11 -1.95 0.002402
1421077_at Sertad3: SERTA domain containing 3 -2.08 0.003372
1421534_at Dfna5h: deafness, autosomal dominant 5 homolog (human) -1.99 0.0133751421600_a_at Trim26: tripartite motif protein 26 -2.91 0.008922
1421839_at Abca1: ATP-binding cassette, sub-family A (ABC1), member 1 -1.96 0.002918
1421866_at Nr3c1: nuclear receptor subfamily 3, group C, member 1 -3.12 0.010773
1421890_at St3gal2: ST3 beta-galactoside alpha-2,3-sialyltransferase 2 -2.48 0.014365
1422102_a_at Stat5b: signal transducer and activator of transcription 5B -1.94 0.00265
1422512_a_at Ogfr: opioid growth factor receptor -2.01 0.002948
1422966_a_at Tfrc: transferrin receptor -2.17 0.028869
1422967_a_at Tfrc: transferrin receptor -4.25 0.031933
1423556_at Akr1b7: aldo-keto reductase family 1, member B7 3.12 0.00072
1423601_s_at Tcof1: Treacher Collins Franceschetti syndrome 1, homolog 2.1 0.020039
1423652_at Isca1: iron-sulfur cluster assembly 1 homolog (S. cerevisiae) -1.79 0.000272
1424684_at Rab5c: RAB5C, member RAS oncogene family 1.91 0.00641
1425457_a_at Grb10: growth factor receptor bound protein 10 -3.48 0.004811
1425515_at Pik3r1: phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) -2.45 0.032447
1425576_at Ahcyl1: S-adenosylhomocysteine hydrolase-like 1 -1.89 0.001966
1425617_at Dhx9: DEAH (Asp-Glu-Ala-His) box polypeptide 9 -2.84 0.002422
1425644_at Lepr: leptin receptor -3.33 0.00165
1425713_a_at Rnf146: ring finger protein 146 -2.12 0.007326
1425732_a_at Mxi1: Max interacting protein 1 -2.3 0.00104
1425803_a_at Mbd2: methyl-CpG binding domain protein 2 -1.9 0.000775
1426519_at
P4ha1: procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 
1 polypeptide -3.18 0.001533
1426576_at Sgms1: sphingomyelin synthase 1 -1.86 0.002219
1426805_at
Smarca4: SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily a, member 4 2.5 0.006415
1427070_at Snx21: sorting nexin family member 21 -2.55 0.033775
1427359_at Jhdm1d: jumonji C domain-containing histone demethylase 1 homolog D (S. cerevisiae) -2.23 0.004561
1427471_at
Fbxl3 /// LOC100044862: F-box and leucine-rich repeat protein 3 /// similar to Fbxl3 
protein -2.56 0.001351
1429492_x_at Ptdss2: phosphatidylserine synthase 2 -2.81 0.025099
1430692_a_at Sel1l: sel-1 suppressor of lin-12-like (C. elegans) -1.99 0.001872
1431030_a_at Rnf14: ring finger protein 14 -2.34 0.01264
1431170_at Efna3 /// LOC100046031: ephrin A3 /// similar to Ephrin A3 -4.17 0.03907
1431645_a_at Gdi2: guanosine diphosphate (GDP) dissociation inhibitor 2 -1.91 0.0017021432344_a_at Aplp2: amyloid beta (A4) precursor-like protein 2 -2.31 0.00582
1433491_at Epb4.1l2: erythrocyte protein band 4.1-like 2 -1.92 0.001775
1434020_at Pdap1: PDGFA associated protein 1 2.31 0.011171
1434357_a_at Kpnb1: karyopherin (importin) beta 1 -2.23 0.007152
1434370_s_at Faf1: Fas-associated factor 1 -1.84 0.003088
1434419_s_at Tardbp: TAR DNA binding protein -1.77 0.000683
1434465_x_at Vldlr: very low density lipoprotein receptor -1.91 0.000398
1437133_x_at Akr1b3: aldo-keto reductase family 1, member B3 (aldose reductase) 2.17 0.004414
1438743_at Cyp7a1: cytochrome P450, family 7, subfamily a, polypeptide 1 2.61 0.028814
1439120_at BC010304: cDNA sequence BC010304 -1.93 0.001818
1448009_at LOC100044322: similar to UDP-glucose ceramide glucosyltransferase-like 1 1.89 0.000855
1448127_at Rrm1: ribonucleotide reductase M1 -1.81 0.000918
1448239_at Hmox1: heme oxygenase (decycling) 1 -6.01 0.000075
1449051_at Ppara: peroxisome proliferator activated receptor alpha -2.03 0.004285
1449262_s_at Lin7c: lin-7 homolog C (C. elegans) -2.49 0.002731
1449341_a_at Stom: stomatin -1.92 0.00229
1449931_at Cpeb4: cytoplasmic polyadenylation element binding protein 4 -2.51 0.022915
1450006_at EG627557 /// Ncoa4: nuclear receptor coactivator 4 /// predicted gene, EG627557 -1.86 0.003071
1450007_at 1500003O03Rik /// LOC100048622: RIKEN cDNA 1500003O03 gene ///  -2.15 0.005709
1450104_at Adam10: a disintegrin and metallopeptidase domain 10 -1.96 0.001934
1450113_at Mpp5: membrane protein, palmitoylated 5 (MAGUK p55 subfamily member 5) -1.98 0.002464
1450368_a_at Ppp3r1: protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin B, type I) -2.24 0.023175
1450392_at Abca1: ATP-binding cassette, sub-family A (ABC1), member 1 -2.93 0.001511
1450703_at Slc7a2: solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 -2.75 0.014162
1451456_at 6430706D22Rik: RIKEN cDNA 6430706D22 gene 2.09 0.004218
1451658_a_at Polr3c: polymerase (RNA) III (DNA directed) polypeptide C -2.47 0.003352
1452315_at Kif11: kinesin family member 11 -2.13 0.001605
1452427_s_at Ptplad1: protein tyrosine phosphatase-like A domain containing 1 -2.24 0.000256
1452527_a_at P2rx4: purinergic receptor P2X, ligand-gated ion channel 4 -2.15 0.008256
1453604_a_at Hbs1l: Hbs1-like (S. cerevisiae) -2.15 0.001737
1454120_a_at Pcgf6: polycomb group ring finger 6 -2.28 0.048782
1454174_a_at C330007P06Rik: RIKEN cDNA C330007P06 gene -2.14 0.003745
1456080_a_at Serinc3: serine incorporator 3 -1.81 0.0077011456494_a_at AI451617 /// Trim30: tripartite motif protein 30 /// expressed sequence AI451617 2.97 0.011689
1460521_a_at Obfc2a: oligonucleotide/oligosaccharide-binding fold containing 2A -2.5 0.008642
1429413_at Cpm: carboxypeptidase M -2.89 0.001247
1429545_at
EG546265 /// F830028O17Rik /// LOC100044900 /// Ube2i: ubiquitin-conjugating enzyme 
E2I ///  2.75 0.00401
1429809_at Tmtc2: transmembrane and tetratricopeptide repeat containing 2 -1.92 0.002831
1430566_at 4733401A01Rik: RIKEN cDNA 4733401A01 gene 2.56 0.001863
1430697_at Ammecr1: Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis  2.72 0.004264
1430981_s_at Gpbp1: GC-rich promoter binding protein 1 -2.19 0.012382
1430984_at Azin1: antizyme inhibitor 1 -3.02 0.006748
1431061_s_at Peli1: pellino 1 -2.32 0.00346
1431197_at Arl6ip2: ADP-ribosylation factor-like 6 interacting protein 2 -2.26 0.000657
1431430_s_at LOC630539 /// Trim59: tripartite motif-containing 59 /// similar to mouse RING finger 1 -2.42 0.000373
1432304_a_at 9030624J02Rik: RIKEN cDNA 9030624J02 gene -2.46 0.005099
1433633_at Irf2bp2: interferon regulatory factor 2 binding protein 2 -2.3 0.01103
1436070_at Glo1: glyoxalase 1 2.18 0.005461
1437638_at Srrm2: serine/arginine repetitive matrix 2 2.12 0.036937
1438410_at Prtg: protogenin homolog (Gallus gallus) -2.33 0.006175
1438433_at Whdc1: WAS protein homology region 2 domain containing 1 2.78 0.008947
1442109_at Activated spleen cDNA, RIKEN full-length enriched library, clone:F830222N19 product: 2.82 0.002018
1443522_s_at Phip: pleckstrin homology domain interacting protein -2.25 0.003737
1444330_at D2Ertd173e: DNA segment, Chr 2, ERATO Doi 173, expressed 3.45 0.001175
1444436_at 9630030I15Rik /// Hsf2: heat shock factor 2 /// RIKEN cDNA 9630030I15 gene 2.83 0.001263
1446284_at Mtss1: metastasis suppressor 1 2.17 0.03126
1447063_at Sept14: septin 14 3.15 0.011794
1452906_at Meg3: maternally expressed 3 2.18 0.002968
1453009_at Cpm: carboxypeptidase M -2.54 0.002255
1453041_at Tmem16j: transmembrane protein 16J -2.39 0.001034
1453140_at 9030612M13Rik: RIKEN cDNA 9030612M13 gene 2.15 0.000222
1453189_at Ube2i: ubiquitin-conjugating enzyme E2I 2.31 0.008989
1453290_at Hmgb2l1: high mobility group box 2-like 1 3.11 0.006481
1453760_at Mier1: mesoderm induction early response 1 homolog (Xenopus laevis -2.66 0.016102
1454003_at Afg3l2: AFG3(ATPase family gene 3)-like 2 (yeast) -3.77 0.000099
1455876_at Slc4a7: solute carrier family 4, sodium bicarbonate cotransporter, member 7 2.58 0.0064641455933_at Tra2a: transformer 2 alpha homolog (Drosophila) 2.34 0.013907
1455998_at LOC667118: similar to Zinc finger BED domain containing protein 4 2.29 0.006551
1456596_at 6430550H21Rik: RIKEN cDNA 6430550H21 gene -3.53 0.001931
1457987_at 6030458C11Rik: RIKEN cDNA 6030458C11 gene 5.02 0.000052
1458609_at
14 days embryo liver cDNA, RIKEN full-length enriched library, clone:I530025F13 
product: -5.29 0.000046
1458685_at Garnl1: GTPase activating RANGAP domain-like 1 3.52 0.00907
1459734_at Mm.212401.1 1.93 0.002868
Table AI.12: Candidate probe sets with apparent differential expression for switch versus 9% casein (baseline) class 
comparison using high stringency criteria and excluding one sample outlier from each class.  Median FDR was 4.4%
Affx probe set Gene information Fold change p-value
1423556_at Akr1b7: aldo-keto reductase family 1, member B7 2.6 0.006555
1438644_x_at Commd9: COMM domain containing 9 2.69 0.011373
1452677_at LOC100044383 /// Pnpt1: polyribonucleotide nucleotidyltransferase 1 ///  3.03 0.032029
1435770_at Txndc13: thioredoxin domain containing 13 2.42 0.044705
1440443_at E030016H06Rik: RIKEN cDNA E030016H06 gene 3.68 0.004556
1457458_at Zc3h4: zinc finger CCCH-type containing 4 3.03 0.031387
Table AI.13: Candidate probe sets with apparent differential expression for switch versus 18% casein (baseline) class 
comparison using high stringency criteria and excluding one sample outlier from each class.  Median FDR was 100%Affx probe set Gene information Fold change p-value
1415773_at Ncl: nucleolin 1.96 0.002835
1415784_at Vps35: vacuolar protein sorting 35 1.94 0.002317
1416656_at Clic1: chloride intracellular channel 1 2.05 0.001959
1418129_at Dhcr24: 24-dehydrocholesterol reductase -3.45 0.013174
1419098_at Stom: stomatin 2.16 0.005589
1419099_x_at Stom: stomatin 2.21 0.003188
1420904_at Il17ra: interleukin 17 receptor A 2.16 0.005609
1421077_at Sertad3: SERTA domain containing 3 2.1 0.002635
1421600_a_at Trim26: tripartite motif protein 26 3.43 0.015389
1421866_at Nr3c1: nuclear receptor subfamily 3, group C, member 1 2.2 0.012703
1422797_at Mapbpip: mitogen activated protein binding protein interacting protein 1.93 0.002532
1422967_a_at Tfrc: transferrin receptor 2.48 0.040924
1425457_a_at Grb10: growth factor receptor bound protein 10 2.47 0.01139
1426519_at
P4ha1: procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 1 
polypeptide 1.98 0.004679
1431213_a_at LOC100041156 /// LOC100041932: -12.4 0.020197
1448239_at Hmox1: heme oxygenase (decycling) 1 4.7 0.00011
1450703_at Slc7a2: solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 2.21 0.020347
1438763_at Dnahc2: dynein, axonemal, heavy chain 2 2.8 0.013799
1444330_at D2Ertd173e: DNA segment, Chr 2, ERATO Doi 173, expressed -2.36 0.030702
1444436_at 9630030I15Rik /// Hsf2: heat shock factor 2 /// RIKEN cDNA 9630030I15 gene -2.35 0.006199
1447757_x_at Inpp5f: inositol polyphosphate-5-phosphatase F -2.36 0.013168
1452906_at Meg3: maternally expressed 3 -2.25 0.038167
1453290_at Hmgb2l1: high mobility group box 2-like 1 -2.55 0.013424
1454003_at Afg3l2: AFG3(ATPase family gene 3)-like 2 (yeast) 2.37 0.015738
1455773_at 0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630004N14 product -2.9 0.00904
1458609_at 14 days embryo liver cDNA, RIKEN full-length enriched library, clone:I530025F13 product 3.49 0.006039
Table AI.14: Candidate probe sets with apparent differential expression for 9% casein versus 18% casein (baseline) class 
comparison using high stringency criteria and excluding one sample outlier from each class.  Median FDR was 23.1%Affx Probe set Gene information Fold change p-value
1415771_at Ncl: nucleolin -1.59 0.000754
1415773_at Ncl: nucleolin -2.57 0.001249
1415784_at Vps35: vacuolar protein sorting 35 -2.26 0.002003
1415800_at Gja1: gap junction protein, alpha 1 -1.66 0.00127
1415810_at Uhrf1: ubiquitin-like, containing PHD and RING finger domains, 1 1.66 0.021671
1415957_a_at Rrp1: ribosomal RNA processing 1 homolog (S. cerevisiae) -1.93 0.031635
1415964_at Scd1: stearoyl-Coenzyme A desaturase 1 2.52 0.033312
1416157_at Vcl: vinculin -2.21 0.016113
1416162_at Rad21: RAD21 homolog (S. pombe) -1.62 0.003416
1416180_a_at Rdx: radixin 3.56 0.004056
1416388_at Pip4k2c: phosphatidylinositol-5-phosphate 4-kinase, type II, gamma -1.89 0.001527
1416514_a_at Fscn1: fascin homolog 1, actin bundling protein (Strongylocentrotus purpuratus) -1.77 0.00669
1416656_at Clic1: chloride intracellular channel 1 -2.17 0.000526
1416660_at Eif3s10: eukaryotic translation initiation factor 3, subunit 10 (theta) -2.1 0.010294
1416686_at Plod2: procollagen lysine, 2-oxoglutarate 5-dioxygenase 2 -2.5 0.030153
1416691_at Gtpbp2: GTP binding protein 2 -1.98 0.003956
1416794_at Arl6ip2: ADP-ribosylation factor-like 6 interacting protein 2 -1.91 0.001552
1416837_at Bax: Bcl2-associated X protein -2.04 0.002074
1416881_at LOC632101 /// Mcl1: myeloid cell leukemia sequence 1 ///  -1.58 0.006713
1416913_at Es1: esterase 1 2.23 0.003057
1417023_a_at Fabp4: fatty acid binding protein 4, adipocyte -1.76 0.013645
1417033_at Ube2g2: ubiquitin-conjugating enzyme E2G 2 -1.97 0.04656
1417079_s_at Lgals2: lectin, galactose-binding, soluble 2 -2.08 0.045964
1417238_at Ewsr1: Ewing sarcoma breakpoint region 1 -1.84 0.002141
1417388_at Bex2: brain expressed X-linked 2 -1.82 0.025224
1417576_a_at Otub2: OTU domain, ubiquitin aldehyde binding 2 -2.33 0.007124
1417707_at B230342M21Rik: RIKEN cDNA B230342M21 gene -1.94 0.035774
1417752_at Coro1c: coronin, actin binding protein 1C -1.9 0.035375
1417766_at Cyb5b: cytochrome b5 type B 1.78 0.013101
1417900_a_at Vldlr: very low density lipoprotein receptor -2.68 0.000589
1418020_s_at Cpd /// LOC100046781: carboxypeptidase D /// similar to carboxypeptidase D -1.87 0.005103
1418231_at Lims1: LIM and senescent cell antigen-like domains 1 -2.04 0.0135421418470_at Yes1: Yamaguchi sarcoma viral (v-yes) oncogene homolog 1 -1.98 0.016232
1418604_at Avpr1a: arginine vasopressin receptor 1A -2.28 0.023481
1418685_at Tirap: toll-interleukin 1 receptor (TIR) domain-containing adaptor protein 3.02 0.00666
1418787_at Mbl2: mannose binding lectin (C) 2.92 0.025395
1418889_a_at Csnk1d: casein kinase 1, delta -1.71 0.012703
1418898_at Lin7c: lin-7 homolog C (C. elegans) -1.67 0.013382
1418946_at St3gal1: ST3 beta-galactoside alpha-2,3-sialyltransferase 1 -2.21 0.031563
1419029_at Ero1l: ERO1-like (S. cerevisiae) -1.94 0.02372
1419030_at Ero1l: ERO1-like (S. cerevisiae) -2.45 0.002844
1419094_at Cyp2c37: cytochrome P450, family 2. subfamily c, polypeptide 37 2.25 0.015508
1419098_at Stom: stomatin -2.86 0.000481
1419099_x_at Stom: stomatin -2.4 0.000538
1419103_a_at Abhd6: abhydrolase domain containing 6 -1.74 0.009894
1419236_at Helb: helicase (DNA) B 2.28 0.019125
1419256_at Spnb2: spectrin beta 2 2.75 0.031929
1419322_at Fgd6: FYVE, RhoGEF and PH domain containing 6 -1.75 0.019566
1419382_a_at Dhrs4: dehydrogenase/reductase (SDR family) member 4 -1.73 0.009271
1420420_at Hao1: hydroxyacid oxidase 1, liver 1.88 0.019711
1420620_a_at Rnf13: ring finger protein 13 -1.84 0.000767
1420629_a_at Dnaja3: DnaJ (Hsp40) homolog, subfamily A, member 3 -1.78 0.006157
1420899_at Rab18: RAB18, member RAS oncogene family -1.77 0.005357
1420901_a_at Hk1: hexokinase 1 -1.74 0.0142
1420904_at Il17ra: interleukin 17 receptor A -2.26 0.005163
1420934_a_at Srrm1: serine/arginine repetitive matrix 1 2.04 0.01154
1420951_a_at Son: Son cell proliferation protein -1.8 0.014015
1420966_at
Slc25a15: solute carrier family 25 (mitochondrial carrier ornithine transporter), 
member 15 -1.82 0.019793
1420970_at Adcy7: adenylate cyclase 7 -1.79 0.015584
1420973_at Arid5b /// LOC100044968: AT rich interactive domain 5B (Mrf1 like) ///  2.45 0.00453
1421011_at Hsd17b11: hydroxysteroid (17-beta) dehydrogenase 11 -1.95 0.002402
1421013_at Pitpnb: phosphatidylinositol transfer protein, beta -1.75 0.022539
1421027_a_at Mef2c: myocyte enhancer factor 2C 2 0.024058
1421076_at Sertad3: SERTA domain containing 3 -1.87 0.010405
1421077_at Sertad3: SERTA domain containing 3 -2.08 0.0033721421156_a_at Dsc2: desmocollin 2 -1.82 0.015919
1421218_at Bche: butyrylcholinesterase -1.78 0.007625
1421491_a_at Tmem49: transmembrane protein 49 -1.57 0.004085
1421534_at Dfna5h: deafness, autosomal dominant 5 homolog (human) -1.99 0.013375
1421600_a_at Trim26: tripartite motif protein 26 -2.91 0.008922
1421830_at
Ak3l1 /// LOC100047616: adenylate kinase 3 alpha-like 1 /// similar to adenylate 
kinase 4 -1.77 0.025935
1421839_at Abca1: ATP-binding cassette, sub-family A (ABC1), member 1 -1.96 0.002918
1421845_at Golph3: golgi phosphoprotein 3 -1.63 0.006705
1421866_at Nr3c1: nuclear receptor subfamily 3, group C, member 1 -3.12 0.010773
1421890_at St3gal2: ST3 beta-galactoside alpha-2,3-sialyltransferase 2 -2.48 0.014365
1421895_at
Eif2s3x /// LOC100039419 /// LOC100048746: eukaryotic translation initiation 
factor 2, subunit 3, structural gene X-linked /// -1.9 0.003105
1421991_a_at Igfbp4: insulin-like growth factor binding protein 4 -1.55 0.003013
1422018_at Hivep2: human immunodeficiency virus type I enhancer binding protein 2 -2.02 0.011775
1422102_a_at Stat5b: signal transducer and activator of transcription 5B -1.94 0.00265
1422512_a_at Ogfr: opioid growth factor receptor -2.01 0.002948
1422627_a_at Mkks: McKusick-Kaufman syndrome protein -2.22 0.0245
1422755_at Btk: Bruton agammaglobulinemia tyrosine kinase -1.75 0.008119
1422797_at Mapbpip: mitogen activated protein binding protein interacting protein -1.76 0.007724
1422862_at Pdlim5: PDZ and LIM domain 5 -1.85 0.03874
1422966_a_at Tfrc: transferrin receptor -2.17 0.028869
1422967_a_at Tfrc: transferrin receptor -4.25 0.031933
1423048_a_at Tollip: toll interacting protein -1.69 0.005349
1423062_at Igfbp3: insulin-like growth factor binding protein 3 2.21 0.038342
1423064_at Dnmt3a: DNA methyltransferase 3A -1.76 0.010362
1423184_at Itsn2: intersectin 2 1.75 0.012928
1423266_at 2810405K02Rik: RIKEN cDNA 2810405K02 gene -1.92 0.010217
1423521_at Lmnb1: lamin B1 1.79 0.02712
1423556_at Akr1b7: aldo-keto reductase family 1, member B7 3.12 0.00072
1423601_s_at Tcof1: Treacher Collins Franceschetti syndrome 1, homolog 2.1 0.020039
1423652_at Isca1: iron-sulfur cluster assembly 1 homolog (S. cerevisiae) -1.79 0.000272
1423862_at
Plekhf2: pleckstrin homology domain containing, family F (with FYVE domain) 
member 2 -1.74 0.0110811423895_a_at Cugbp2: CUG triplet repeat, RNA binding protein 2 1.73 0.011248
1424084_at Rod1: ROD1 regulator of differentiation 1 (S. pombe) -1.7 0.012213
1424140_at Gale: galactose-4-epimerase, UDP 1.9 0.012023
1424474_a_at Camkk2: calcium/calmodulin-dependent protein kinase kinase 2, beta 1.7 0.029482
1424475_at Camkk2: calcium/calmodulin-dependent protein kinase kinase 2, beta 1.8 0.011321
1424684_at Rab5c: RAB5C, member RAS oncogene family 1.91 0.00641
1424724_a_at D16Ertd472e: DNA segment, Chr 16, ERATO Doi 472, expressed -1.75 0.047215
1424812_at BC017158: cDNA sequence BC017158 1.65 0.002773
1424937_at 2310076L09Rik: RIKEN cDNA 2310076L09 gene -1.82 0.01433
1424981_at Nln: neurolysin (metallopeptidase M3 family) -1.82 0.00436
1425330_a_at
LOC100048520 /// LOC666025 /// Ppm1b: protein phosphatase 1B, magnesium 
dependent, beta isoform ///  -1.59 0.002492
1425457_a_at Grb10: growth factor receptor bound protein 10 -3.48 0.004811
1425461_at Fbxw11: F-box and WD-40 domain protein 11 -1.86 0.00425
1425515_at
Pik3r1: phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 
alpha) -2.45 0.032447
1425576_at Ahcyl1: S-adenosylhomocysteine hydrolase-like 1 -1.89 0.001966
1425617_at Dhx9: DEAH (Asp-Glu-Ala-His) box polypeptide 9 -2.84 0.002422
1425644_at Lepr: leptin receptor -3.33 0.00165
1425713_a_at Rnf146: ring finger protein 146 -2.12 0.007326
1425732_a_at Mxi1: Max interacting protein 1 -2.3 0.00104
1425803_a_at Mbd2: methyl-CpG binding domain protein 2 -1.9 0.000775
1425932_a_at Cugbp1: CUG triplet repeat, RNA binding protein 1 -1.88 0.003809
1426037_a_at Rgs16: regulator of G-protein signaling 16 -1.98 0.045117
1426117_a_at Slc19a2: solute carrier family 19 (thiamine transporter), member 2 -1.73 0.003079
1426229_s_at Kras: v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog -1.94 0.014918
1426519_at
P4ha1: procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-
hydroxylase), alpha 1 polypeptide -3.18 0.001533
1426575_at Sgms1: sphingomyelin synthase 1 -1.77 0.014299
1426576_at Sgms1: sphingomyelin synthase 1 -1.86 0.002219
1426743_at
Appl2: adaptor protein, phosphotyrosine interaction, PH domain and leucine 
zipper containing 2 -1.6 0.014025
1426805_at
Smarca4: SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 2.5 0.0064151426837_at Metap1: methionyl aminopeptidase 1 -1.74 0.010894
1427070_at Snx21: sorting nexin family member 21 -2.55 0.033775
1427359_at
Jhdm1d: jumonji C domain-containing histone demethylase 1 homolog D (S. 
cerevisiae) -2.23 0.004561
1427471_at
Fbxl3 /// LOC100044862: F-box and leucine-rich repeat protein 3 /// similar to 
Fbxl3 protein -2.56 0.001351
1427483_at
Slc25a24: solute carrier family 25 (mitochondrial carrier, phosphate carrier), 
member 24 -1.84 0.009051
1427658_at Ctbs: chitobiase, di-N-acetyl- -1.72 0.002569
1428492_at Glipr2: GLI pathogenesis-related 2 -1.67 0.0065
1428662_a_at Hopx: HOP homeobox -1.68 0.002337
1428838_a_at Dck: deoxycytidine kinase -1.63 0.005373
1429239_a_at Stard4: StAR-related lipid transfer (START) domain containing 4 -1.92 0.007077
1429474_at Zadh1: zinc binding alcohol dehydrogenase, domain containing 1 -1.82 0.001921
1429492_x_at Ptdss2: phosphatidylserine synthase 2 -2.81 0.025099
1429533_at Immt: inner membrane protein, mitochondrial -1.92 0.010713
1429775_a_at
Gpr137b /// Gpr137b-ps /// LOC100044979: G protein-coupled receptor 137B /// 
G protein-coupled receptor 137B, pseudogene ///  -2.18 0.02574
1430019_a_at
EG434858 /// EG665646 /// Hnrnpa1 /// LOC100043855 /// LOC100044632 /// 
LOC654467: heterogeneous nuclear ribonucleoprotein A1 ///  -1.68 0.00805
1430533_a_at Ctnnb1: catenin (cadherin associated protein), beta 1 -1.77 0.012823
1430692_a_at Sel1l: sel-1 suppressor of lin-12-like (C. elegans) -1.99 0.001872
1431030_a_at Rnf14: ring finger protein 14 -2.34 0.01264
1431032_at Agl: amylo-1,6-glucosidase, 4-alpha-glucanotransferase -1.61 0.032597
1431170_at Efna3 /// LOC100046031: ephrin A3 /// similar to Ephrin A3 -4.17 0.03907
1431332_a_at Terf1: telomeric repeat binding factor 1 -1.87 0.016314
1431606_a_at Angel2: angel homolog 2 (Drosophila) -1.76 0.028326
1431645_a_at Gdi2: guanosine diphosphate (GDP) dissociation inhibitor 2 -1.91 0.001702
1431734_a_at Dnajb4: DnaJ (Hsp40) homolog, subfamily B, member 4 -1.58 0.001498
1431827_a_at Tlk2: tousled-like kinase 2 (Arabidopsis) -1.59 0.005797
1432344_a_at Aplp2: amyloid beta (A4) precursor-like protein 2 -2.31 0.00582
1433479_at 5730410I19Rik: RIKEN cDNA 5730410I19 gene -1.77 0.006193
1433480_at 2900010J23Rik: RIKEN cDNA 2900010J23 gene -1.7 0.002073
1433491_at Epb4.1l2: erythrocyte protein band 4.1-like 2 -1.92 0.0017751434020_at Pdap1: PDGFA associated protein 1 2.31 0.011171
1434062_at Rabgap1l: RAB GTPase activating protein 1-like -1.71 0.009344
1434181_at Fermt2: fermitin family homolog 2 (Drosophila) -1.79 0.003962
1434357_a_at Kpnb1: karyopherin (importin) beta 1 -2.23 0.007152
1434370_s_at Faf1: Fas-associated factor 1 -1.84 0.003088
1434419_s_at Tardbp: TAR DNA binding protein -1.77 0.000683
1434465_x_at Vldlr: very low density lipoprotein receptor -1.91 0.000398
1435872_at Transcribed locus -2.88 0.046918
1436746_at Wnk1: WNK lysine deficient protein kinase 1 2.38 0.03966
1436909_at Slc25a44: solute carrier family 25, member 44 1.6 0.00352
1437133_x_at Akr1b3: aldo-keto reductase family 1, member B3 (aldose reductase) 2.17 0.004414
1437289_at Impad1: inositol monophosphatase domain containing 1 1.68 0.005258
1437324_x_at Fmod: fibromodulin -2.48 0.0499
1437513_a_at Serinc1: serine incorporator 1 -1.64 0.00444
1438167_x_at Flcn: Folliculin -1.72 0.01018
1438397_a_at Rbm39: RNA binding motif protein 39 -2.02 0.030328
1438743_at Cyp7a1: cytochrome P450, family 7, subfamily a, polypeptide 1 2.61 0.028814
1439036_a_at Atp1b1: ATPase, Na+/K+ transporting, beta 1 polypeptide -1.79 0.026428
1439120_at BC010304: cDNA sequence BC010304 -1.93 0.001818
1439256_x_at Gpr137b-ps: G protein-coupled receptor 137B, pseudogene -1.74 0.008774
1440221_at AA408650: expressed sequence AA408650 1.59 0.004013
1448009_at LOC100044322: similar to UDP-glucose ceramide glucosyltransferase-like 1 1.89 0.000855
1448127_at Rrm1: ribonucleotide reductase M1 -1.81 0.000918
1448231_at Fkbp5: FK506 binding protein 5 -1.83 0.010303
1448239_at Hmox1: heme oxygenase (decycling) 1 -6.01 0.000075
1448348_at Caprin1: cell cycle associated protein 1 -1.85 0.006648
1448364_at Ccng2: cyclin G2 -1.99 0.004915
1448482_at Slc39a8: solute carrier family 39 (metal ion transporter), member 8 -2.07 0.027961
1448534_at Sirpa: signal-regulatory protein alpha -1.73 0.00374
1448607_at Pbef1: pre-B-cell colony-enhancing factor 1 -2.31 0.045081
1448688_at Podxl: podocalyxin-like 1.59 0.003046
1448847_at Serinc3: serine incorporator 3 -1.94 0.013767
1448852_at Rgn: regucalcin 1.51 0.0012151449051_at Ppara: peroxisome proliferator activated receptor alpha -2.03 0.004285
1449262_s_at Lin7c: lin-7 homolog C (C. elegans) -2.49 0.002731
1449335_at Timp3: tissue inhibitor of metalloproteinase 3 -1.77 0.028633
1449341_a_at Stom: stomatin -1.92 0.00229
1449347_a_at
LOC100044048 /// LOC100044049 /// LOC100046087 /// Xlr4a /// Xlr4b /// 
Xlr4c /// Xlr4e: X-linked lymphocyte-regulated 4B /// 4C /// 4A /// 4E ///  1.94 0.023384
1449348_at Mpp6: membrane protein, palmitoylated 6 (MAGUK p55 subfamily member 6) -1.83 0.046581
1449457_at Acot12: acyl-CoA thioesterase 12 -1.86 0.003299
1449670_x_at
Gpr137b /// LOC100044979: G protein-coupled receptor 137B /// similar to 
Gpr137b protein -1.79 0.038478
1449862_a_at Pi4k2b: phosphatidylinositol 4-kinase type 2 beta -1.62 0.00329
1449875_s_at
H2-T10 /// H2-T22 /// H2-T9 /// LOC100044190 /// LOC100044191: 
histocompatibility 2, T region locus 10 /// locus 22 /// locus 9 ///  1.65 0.004279
1449931_at Cpeb4: cytoplasmic polyadenylation element binding protein 4 -2.51 0.022915
1450006_at
EG627557 /// Ncoa4: nuclear receptor coactivator 4 /// predicted gene, 
EG627557 -1.86 0.003071
1450007_at
1500003O03Rik /// LOC100048622: RIKEN cDNA 1500003O03 gene /// similar 
to EF-hand Ca2+ binding protein p22 -2.15 0.005709
1450104_at Adam10: a disintegrin and metallopeptidase domain 10 -1.96 0.001934
1450109_s_at Abcc2: ATP-binding cassette, sub-family C (CFTR/MRP), member 2 1.9 0.025603
1450113_at Mpp5: membrane protein, palmitoylated 5 (MAGUK p55 subfamily member 5) -1.98 0.002464
1450136_at Cd38: CD38 antigen -1.85 0.003523
1450157_a_at Hmmr: hyaluronan mediated motility receptor (RHAMM) -1.62 0.001296
1450161_at Ikbkg: inhibitor of kappaB kinase gamma -1.7 0.003181
1450368_a_at
Ppp3r1: protein phosphatase 3, regulatory subunit B, alpha isoform (calcineurin 
B, type I) -2.24 0.023175
1450387_s_at
Ak3l1 /// LOC100047616: adenylate kinase 3 alpha-like 1 /// similar to adenylate 
kinase 4 -1.78 0.044632
1450392_at Abca1: ATP-binding cassette, sub-family A (ABC1), member 1 -2.93 0.001511
1450396_at Stag2: stromal antigen 2 -1.65 0.00987
1450407_a_at Anp32a: acidic (leucine-rich) nuclear phosphoprotein 32 family, member A -1.61 0.01398
1450522_a_at H1f0: H1 histone family, member 0 -1.64 0.009476
1450703_at
Slc7a2: solute carrier family 7 (cationic amino acid transporter, y+ system), 
member 2 -2.75 0.014162
1450846_at Bzw1: basic leucine zipper and W2 domains 1 -1.64 0.0047961450970_at Got1: glutamate oxaloacetate transaminase 1, soluble -1.79 0.019086
1451072_a_at Rnf4: ring finger protein 4 -1.73 0.004409
1451109_a_at Nedd4: neural precursor cell expressed, developmentally down-regulted gene 4 -1.67 0.00331
1451263_a_at Fabp4: fatty acid binding protein 4, adipocyte -1.74 0.008121
1451355_at Asah3l: N-acylsphingosine amidohydrolase 3-like -1.94 0.012644
1451456_at 6430706D22Rik: RIKEN cDNA 6430706D22 gene 2.09 0.004218
1451622_at Lmbrd1: LMBR1 domain containing 1 -1.69 0.010409
1451658_a_at Polr3c: polymerase (RNA) III (DNA directed) polypeptide C -2.47 0.003352
1451743_at D19Wsu162e: DNA segment, Chr 19, Wayne State University 162, expressed -1.84 0.014519
1451794_at Tmcc3: transmembrane and coiled coil domains 3 -1.69 0.003473
1451807_at Nr1i2: nuclear receptor subfamily 1, group I, member 2 -1.88 0.031888
1451914_a_at Add2: adducin 2 (beta) -2.15 0.012339
1451943_a_at Ppm1a: protein phosphatase 1A, magnesium dependent, alpha isoform -1.65 0.007818
1452026_a_at Pla2g12a: phospholipase A2, group XIIA -1.57 0.001774
1452080_a_at
Dcun1d1: DCUN1D1 DCN1, defective in cullin neddylation 1, domain containing 
1 (S. cerevisiae) -1.58 0.005927
1452162_at Wdr48: WD repeat domain 48 -1.66 0.019634
1452228_at Tbc1d23: TBC1 domain family, member 23 -1.8 0.010231
1452315_at Kif11: kinesin family member 11 -2.13 0.001605
1452427_s_at Ptplad1: protein tyrosine phosphatase-like A domain containing 1 -2.24 0.000256
1452457_a_at Prkab1: protein kinase, AMP-activated, beta 1 non-catalytic subunit -1.84 0.003264
1452504_s_at Ctbs: chitobiase, di-N-acetyl- -1.57 0.002394
1452527_a_at P2rx4: purinergic receptor P2X, ligand-gated ion channel 4 -2.15 0.008256
1452830_s_at
Cad: carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and 
dihydroorotase 1.65 0.012043
1452986_at Hgd: homogentisate 1, 2-dioxygenase 1.75 0.002075
1453604_a_at Hbs1l: Hbs1-like (S. cerevisiae) -2.15 0.001737
1453623_a_at Rad23a: RAD23a homolog (S. cerevisiae) -1.62 0.005637
1453724_a_at Serpinf1: serine (or cysteine) peptidase inhibitor, clade F, member 1 -1.54 0.001019
1453748_a_at Kif23: kinesin family member 23 -2.02 0.022062
1454107_a_at Kif2a: kinesin family member 2A -1.67 0.014793
1454120_a_at Pcgf6: polycomb group ring finger 6 -2.28 0.048782
1454168_a_at Clpb: ClpB caseinolytic peptidase B homolog (E. coli) -1.88 0.047516
1454174_a_at C330007P06Rik: RIKEN cDNA C330007P06 gene -2.14 0.0037451455061_a_at
Acaa2: acetyl-Coenzyme A acyltransferase 2 (mitochondrial 3-oxoacyl-
Coenzyme A thiolase) -1.66 0.004763
1455315_at Trp53i13: transformation related protein 53 inducible protein 13 2.08 0.014328
1455801_x_at Tbcd: tubulin-specific chaperone d 1.66 0.004664
1455904_at Gas5: growth arrest specific 5 1.67 0.006306
1456080_a_at Serinc3: serine incorporator 3 -1.81 0.007701
1456107_x_at Eftud2: elongation factor Tu GTP binding domain containing 2 1.75 0.002327
1456262_at Rbm5: RNA binding motif protein 5 1.86 0.038059
1456494_a_at AI451617 /// Trim30: tripartite motif protein 30 /// expressed sequence AI451617 2.97 0.011689
1456590_x_at Akr1b3: aldo-keto reductase family 1, member B3 (aldose reductase) 1.94 0.015481
1460279_a_at Gtf2i: general transcription factor II I -1.59 0.001799
1460295_s_at Il6st: interleukin 6 signal transducer -1.8 0.014423
1460521_a_at Obfc2a: oligonucleotide/oligosaccharide-binding fold containing 2A -2.5 0.008642
1428412_at Tm9sf3: transmembrane 9 superfamily member 3 1.56 0.000915
1429009_at Snrp70: U1 small nuclear ribonucleoprotein polypeptide A 2.09 0.037677
1429337_at Tmem87b: transmembrane protein 87B -1.83 0.016159
1429413_at Cpm: carboxypeptidase M -2.89 0.001247
1429501_s_at Ppm1a: protein phosphatase 1A, magnesium dependent, alpha isoform -1.79 0.010635
1429545_at
EG546265 /// F830028O17Rik /// LOC100044900 /// Ube2i: ubiquitin-conjugating 
enzyme E2I /// RIKEN cDNA F830028O17 gene ///  2.75 0.00401
1429778_at Optn: optineurin -1.97 0.012328
1429809_at Tmtc2: transmembrane and tetratricopeptide repeat containing 2 -1.92 0.002831
1430566_at 4733401A01Rik: RIKEN cDNA 4733401A01 gene 2.56 0.001863
1430697_at
Ammecr1: Alport syndrome, mental retardation, midface hypoplasia and 
elliptocytosis chromosomal region gene 1 homolog (human) 2.72 0.004264
1430981_s_at Gpbp1: GC-rich promoter binding protein 1 -2.19 0.012382
1430984_at Azin1: antizyme inhibitor 1 -3.02 0.006748
1431018_at 1810013L24Rik: RIKEN cDNA 1810013L24 gene -1.62 0.009814
1431061_s_at Peli1: pellino 1 -2.32 0.00346
1431183_at 1700066M21Rik: RIKEN cDNA 1700066M21 gene -1.82 0.011274
1431197_at Arl6ip2: ADP-ribosylation factor-like 6 interacting protein 2 -2.26 0.000657
1431206_at 5730601F06Rik: RIKEN cDNA 5730601F06 gene -2.05 0.027247
1431430_s_at
LOC630539 /// Trim59: tripartite motif-containing 59 /// similar to mouse RING 
finger 1 -2.42 0.0003731432304_a_at 9030624J02Rik: RIKEN cDNA 9030624J02 gene -2.46 0.005099
1433633_at Irf2bp2: interferon regulatory factor 2 binding protein 2 -2.3 0.01103
1434905_at Ndufa4l2: NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 -1.89 0.011617
1435396_at Stxbp6: syntaxin binding protein 6 (amisyn) 1.81 0.008299
1435867_at
Jhdm1d: jumonji C domain-containing histone demethylase 1 homolog D (S. 
cerevisiae) -1.62 0.001522
1436035_at 3830431G21Rik: RIKEN cDNA 3830431G21 gene 2.46 0.045584
1436070_at Glo1: glyoxalase 1 2.18 0.005461
1436169_at C730029A08Rik: RIKEN cDNA C730029A08 gene 1.61 0.001579
1436194_at Prelid2: PRELI domain containing 2 -1.81 0.008396
1436456_at 9130023D20Rik: RIKEN cDNA 9130023D20 gene -1.61 0.006166
1437638_at Srrm2: serine/arginine repetitive matrix 2 2.12 0.036937
1437862_at Rbm25: RNA binding motif protein 25 1.87 0.009844
1438265_at
NOD-derived CD11c +ve dendritic cells cDNA, RIKEN full-length enriched library, 
clone:F630001G16 product: 1.89 0.013669
1438268_at Rc3h2: ring finger and CCCH-type zinc finger domains 2 1.78 0.012543
1438410_at Prtg: protogenin homolog (Gallus gallus) -2.33 0.006175
1438433_at Whdc1: WAS protein homology region 2 domain containing 1 2.78 0.008947
1439158_at Tlk1: tousled-like kinase 1 -1.79 0.013609
1439173_at Hook1: hook homolog 1 (Drosophila) 1.73 0.004961
1441272_at Matr3: Matrin 3 2.06 0.028419
1441860_x_at Ide: Insulin degrading enzyme 1.77 0.00174
1442041_at LOC552876: hypothetical LOC552876 1.91 0.019388
1442100_at Inpp5f: inositol polyphosphate-5-phosphatase F 2.3 0.037039
1442109_at
Activated spleen cDNA, RIKEN full-length enriched library, clone:F830222N19 
product: 2.82 0.002018
1442418_at B930096F20Rik: RIKEN cDNA B930096F20 gene 1.86 0.022219
1442549_at Mbnl3: muscleblind-like 3 (Drosophila) 1.82 0.004367
1443522_s_at Phip: pleckstrin homology domain interacting protein -2.25 0.003737
1443792_at Tsga14: testis specific gene A14 2.1 0.039553
1444271_at Anapc1: anaphase promoting complex subunit 1 2.36 0.019917
1444330_at D2Ertd173e: DNA segment, Chr 2, ERATO Doi 173, expressed 3.45 0.001175
1444333_at Mm.216315.1 -1.9 0.041505
1444436_at 9630030I15Rik /// Hsf2: heat shock factor 2 /// RIKEN cDNA 9630030I15 gene 2.83 0.0012631444612_at 3222402P14Rik: RIKEN cDNA 3222402P14 gene -2.3 0.019401
1444677_at C77673: expressed sequence C77673 1.8 0.005173
1444827_at Mm.182613.1 2.24 0.038149
1446284_at Mtss1: metastasis suppressor 1 2.17 0.03126
1446844_at Chchd7: coiled-coil-helix-coiled-coil-helix domain containing 7 -1.8 0.017099
1447063_at Sept14: septin 14 3.15 0.011794
1447258_at Mm.210555.1 1.8 0.006526
1452906_at Meg3: maternally expressed 3 2.18 0.002968
1453009_at Cpm: carboxypeptidase M -2.54 0.002255
1453041_at Tmem16j: transmembrane protein 16J -2.39 0.001034
1453140_at 9030612M13Rik: RIKEN cDNA 9030612M13 gene 2.15 0.000222
1453189_at Ube2i: ubiquitin-conjugating enzyme E2I 2.31 0.008989
1453227_at Rhobtb3: Rho-related BTB domain containing 3 -1.88 0.002914
1453290_at Hmgb2l1: high mobility group box 2-like 1 3.11 0.006481
1453760_at Mier1: mesoderm induction early response 1 homolog (Xenopus laevis -2.66 0.016102
1453776_at Snx21: sorting nexin family member 21 -2.09 0.046079
1454003_at Afg3l2: AFG3(ATPase family gene 3)-like 2 (yeast) -3.77 0.000099
1454649_at Srd5a1: steroid 5 alpha-reductase 1 1.79 0.022663
1455876_at Slc4a7: solute carrier family 4, sodium bicarbonate cotransporter, member 7 2.58 0.006464
1455933_at Tra2a: transformer 2 alpha homolog (Drosophila) 2.34 0.013907
1455998_at LOC667118: similar to Zinc finger BED domain containing protein 4 2.29 0.006551
1456156_at Lepr: leptin receptor -1.71 0.008329
1456329_at Prtg: protogenin homolog (Gallus gallus) -1.87 0.007925
1456596_at 6430550H21Rik: RIKEN cDNA 6430550H21 gene -3.53 0.001931
1457122_at Mm.208214.1 1.71 0.009358
1457542_at Nup133: nucleoporin 133 1.99 0.036872
1457554_at Apob: apolipoprotein B 1.84 0.016115
1457782_at Tln1: talin 1 1.92 0.014177
1457987_at 6030458C11Rik: RIKEN cDNA 6030458C11 gene 5.02 0.000052
1458150_at D030051N19Rik: RIKEN cDNA D030051N19 gene 2.19 0.035363
1458297_s_at Marco: macrophage receptor with collagenous structure -2.13 0.023327
1458403_at Tnik: TRAF2 and NCK interacting kinase 2.19 0.049389
1458609_at
14 days embryo liver cDNA, RIKEN full-length enriched library, 
clone:I530025F13 product: -5.29 0.0000461458685_at Garnl1: GTPase activating RANGAP domain-like 1 3.52 0.00907
1458719_at
Transcribed locus, moderately similar to XP_001117064.1  BTB (POZ) domain 
containing 9 [Macaca mulatta] 1.87 0.009768
1459734_at Mm.212401.1 1.93 0.002868
1459984_at Mia3: melanoma inhibitory activity 3 2.19 0.016172
Table AI.15: Candidate probe sets with apparent differential expression for switch versus 9% casein (baseline) class 
comparison using low stringency criteria and excluding one sample outlier from each class.  Median FDR was 4.9%Affx Probe set Gene information
Fold 
change p-value
1416193_at Car1: carbonic anhydrase 1 -1.82 0.015721
1423556_at Akr1b7: aldo-keto reductase family 1, member B7 2.6 0.006555
1424350_s_at Lpgat1: lysophosphatidylglycerol acyltransferase 1 1.52 0.005077
1425065_at Oas2: 2'-5' oligoadenylate synthetase 2 2.01 0.033493
1436462_at OTTMUSG00000016327: predicted gene, OTTMUSG00000016327 -2 0.010695
1438644_x_at Commd9: COMM domain containing 9 2.69 0.011373
1452677_at LOC100044383 /// Pnpt1: polyribonucleotide nucleotidyltransferase 1 ///  3.03 0.032029
1432651_at 2510019K15Rik: RIKEN cDNA 2510019K15 gene 2.02 0.042047
1435770_at Txndc13: thioredoxin domain containing 13 2.42 0.044705
1440443_at E030016H06Rik: RIKEN cDNA E030016H06 gene 3.68 0.004556
1442069_at D5Wsu178e: DNA segment, Chr 5, Wayne State University 178, expressed 2.39 0.02548
1442100_at Inpp5f: inositol polyphosphate-5-phosphatase F 1.69 0.00733
1443512_at Mm.103030.1 1.65 0.005017
1445695_at
0 day neonate lung cDNA, RIKEN full-length enriched library, clone:E030049G11 
product: 1.84 0.04605
1445826_at Ankrd17: ankyrin repeat domain 17 1.94 0.048757
1446284_at Mtss1: metastasis suppressor 1 2.25 0.02209
1457458_at Zc3h4: zinc finger CCCH-type containing 4 3.03 0.031387
1457554_at Apob: apolipoprotein B 1.95 0.017958
Table AI.16: Candidate probe sets with apparent differential expression for switch versus 18% casein (baseline) class 
comparison using low stringency criteria and excluding one sample outlier from each class.  Median FDR was 83.3%
Affx probe 
set Gene information Fold change p-value
1415771_at Ncl: nucleolin 1.49 0.003631
1415773_at Ncl: nucleolin 1.96 0.002835
1415784_at Vps35: vacuolar protein sorting 35 1.94 0.002317
1415988_at Hdlbp: high density lipoprotein (HDL) binding protein 2.05 0.0210491416656_at Clic1: chloride intracellular channel 1 2.05 0.001959
1417576_a_at Otub2: OTU domain, ubiquitin aldehyde binding 2 1.75 0.020222
1418129_at Dhcr24: 24-dehydrocholesterol reductase -3.45 0.013174
1419030_at Ero1l: ERO1-like (S. cerevisiae) 1.8 0.00129
1419098_at Stom: stomatin 2.16 0.005589
1419099_x_at Stom: stomatin 2.21 0.003188
1419382_a_at Dhrs4: dehydrogenase/reductase (SDR family) member 4 1.63 0.003468
1420904_at Il17ra: interleukin 17 receptor A 2.16 0.005609
1421008_at Rsad2: radical S-adenosyl methionine domain containing 2 1.95 0.047598
1421011_at Hsd17b11: hydroxysteroid (17-beta) dehydrogenase 11 1.74 0.00284
1421076_at Sertad3: SERTA domain containing 3 1.8 0.004447
1421077_at Sertad3: SERTA domain containing 3 2.1 0.002635
1421600_a_at Trim26: tripartite motif protein 26 3.43 0.015389
1421866_at Nr3c1: nuclear receptor subfamily 3, group C, member 1 2.2 0.012703
1422512_a_at Ogfr: opioid growth factor receptor 1.78 0.007322
1422797_at Mapbpip: mitogen activated protein binding protein interacting protein 1.93 0.002532
1422966_a_at Tfrc: transferrin receptor 1.84 0.034195
1422967_a_at Tfrc: transferrin receptor 2.48 0.040924
1423601_s_at Tcof1: Treacher Collins Franceschetti syndrome 1, homolog -1.76 0.009364
1424684_at Rab5c: RAB5C, member RAS oncogene family -1.73 0.014339
1424937_at 2310076L09Rik: RIKEN cDNA 2310076L09 gene 1.72 0.026302
1425451_s_at Chi3l3 /// Chi3l4: chitinase 3-like 3 /// chitinase 3-like 4 1.99 0.009219
1425457_a_at Grb10: growth factor receptor bound protein 10 2.47 0.01139
1425617_at Dhx9: DEAH (Asp-Glu-Ala-His) box polypeptide 9 2.04 0.010173
1425732_a_at Mxi1: Max interacting protein 1 1.7 0.003673
1426519_at P4ha1: procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha 1 polypeptide 1.98 0.004679
1426805_at
Smarca4: SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, 
member 4 -2.13 0.012558
1426975_at Os9: amplified in osteosarcoma 1.87 0.031046
1427359_at Jhdm1d: jumonji C domain-containing histone demethylase 1 homolog D (S. cerevisiae) 1.76 0.008571
1431030_a_at Rnf14: ring finger protein 14 2.02 0.018955
1431213_a_at
LOC100041156 /// LOC100041932: hypothetical protein LOC100041156 /// hypothetical protein 
LOC100041932 -12.4 0.020197
1431743_a_at Slc4a1: solute carrier family 4 (anion exchanger), member 1 1.66 0.0184241432344_a_at Aplp2: amyloid beta (A4) precursor-like protein 2 1.87 0.016731
1433480_at 2900010J23Rik: RIKEN cDNA 2900010J23 gene 1.78 0.00123
1448231_at Fkbp5: FK506 binding protein 5 1.73 0.013801
1448239_at Hmox1: heme oxygenase (decycling) 1 4.7 0.00011
1448332_at Pex19: peroxisome biogenesis factor 19 1.58 0.00444
1448566_at Slc40a1: solute carrier family 40 (iron-regulated transporter), member 1 1.57 0.014528
1449051_at Ppara: peroxisome proliferator activated receptor alpha 1.71 0.008169
1449262_s_at Lin7c: lin-7 homolog C (C. elegans) 1.76 0.01137
1449341_a_at Stom: stomatin 1.74 0.00379
1450007_at
1500003O03Rik /// LOC100048622: RIKEN cDNA 1500003O03 gene /// similar to EF-hand Ca2+ 
binding protein p22 1.82 0.011059
1450392_at Abca1: ATP-binding cassette, sub-family A (ABC1), member 1 1.92 0.004622
1450703_at Slc7a2: solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 2.21 0.020347
1450970_at Got1: glutamate oxaloacetate transaminase 1, soluble 1.72 0.002514
1451658_a_at Polr3c: polymerase (RNA) III (DNA directed) polypeptide C 1.67 0.008802
1451920_a_at Rfc1: replication factor C (activator 1) 1 -1.96 0.022646
1452030_a_at Hnrnpr: heterogeneous nuclear ribonucleoprotein R 1.95 0.037933
1452830_s_at Cad: carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase -1.65 0.00045
1454174_a_at C330007P06Rik: RIKEN cDNA C330007P06 gene 1.68 0.009491
1430984_at Azin1: antizyme inhibitor 1 2.05 0.009384
1431061_s_at Peli1: pellino 1 1.81 0.009172
1431197_at Arl6ip2: ADP-ribosylation factor-like 6 interacting protein 2 1.72 0.013244
1431220_at
LOC100040353 /// LOC100046169: similar to splicing coactivator subunit SRm300 /// hypothetical 
protein LOC100046169 2.09 0.019093
1432304_a_at 9030624J02Rik: RIKEN cDNA 9030624J02 gene 2.02 0.008879
1438763_at Dnahc2: dynein, axonemal, heavy chain 2 2.8 0.013799
1439882_at Sec23ip: Sec23 interacting protein 1.58 0.01375
1441915_s_at 2310076L09Rik: RIKEN cDNA 2310076L09 gene 1.68 0.006802
1442760_x_at Mm.209585.1 -1.84 0.023385
1444330_at D2Ertd173e: DNA segment, Chr 2, ERATO Doi 173, expressed -2.36 0.030702
1444436_at 9630030I15Rik /// Hsf2: heat shock factor 2 /// RIKEN cDNA 9630030I15 gene -2.35 0.006199
1447258_at Mm.210555.1 -1.87 0.003539
1447757_x_at Inpp5f: inositol polyphosphate-5-phosphatase F -2.36 0.013168
1452906_at Meg3: maternally expressed 3 -2.25 0.0381671453189_at Ube2i: ubiquitin-conjugating enzyme E2I -1.93 0.024951
1453290_at Hmgb2l1: high mobility group box 2-like 1 -2.55 0.013424
1454003_at Afg3l2: AFG3(ATPase family gene 3)-like 2 (yeast) 2.37 0.015738
1455773_at
0 day neonate kidney cDNA, RIKEN full-length enriched library, clone:D630004N14 
product:unclassifiable, full insert sequence -2.9 0.00904
1455933_at Tra2a: transformer 2 alpha homolog (Drosophila) -2.16 0.017576
1458505_at LOC552901: hypothetical LOC552901 1.98 0.019674
1458609_at
14 days embryo liver cDNA, RIKEN full-length enriched library, clone:I530025F13 
product:unclassifiable, full insert sequence 3.49 0.006039
1459734_at Mm.212401.1 -1.69 0.008013
Table AI.17: Candidate probe sets with apparent differential expression for 9% casein versus 18% casein (baseline) class 
comparison using low stringency criteria and excluding one sample outlier from each class.  Median FDR was 23.7%Appendix II
Electro    -blotting transfer buffer, pH 8.3    
Tris base 6.06 g
Glycine 22.5 g
SDS 1 g
Methanol 500 ml
Deionised H2O 1500 mlAppendix III
Anaesthetic     – K.A.T. mix maximum dose per 50 g mouse     
Saline 355 µl
100 mg/ml Ketamine 100 µl
10 mg/ml Acepromazine 25 µl
300 µg/ml Buprenorphine (Temgesic) 20 µl
Total 500 µl
Culture Media
Stock T6 PVP H6 PVP
H2O 7.8 ml 7.8 ml
F 1.0 ml 1.00 ml
B 1.0 ml 0.16 ml
G 0.10 ml 0.10 ml
H 0.10 ml 0.10 ml
E N/A 0.84 ml
BSA N/A N/A
PVP 60 mg 60 mg
20%
NaCl
40 µl 60 µl
NaCl
15 mg/ml
N/A N/A
Phenol
red
25 µl N/A
Media Osmolarity 280-290mOsmStock solutions
Stock F:                                                             
Sodium Chloride                                                       4.720 g
Potassium Chloride                                                 0.110 g
Sodium Dihydrogen Orthophosphate                       0.060 g
Magnesium Chloride                                                 0.100 g 
D – Glucose                                                              1.000 g 
DL – Lactic Acid (60%)                                              3.4 ml
Make up to 100 ml with H2O      
mOsm 2555 +/- 200
Stock G:                                                             
Pyruvic Acid                                                              0.030 g
Penicillin                                                                    0.060 g
Streptomycin                                                             0.050 g
Add 10 ml of H2O
mOsm 60 +/- 10
Stock B:                                                                   
Sodium Hydrogen Carbonate                                   0.210 g
Add 10 ml of H2O
mOsm 444 +/- 20
Stock H:                                                                        
Calcium Chloride 2 – Hydrate                                  0.260 g
Add 10 ml of H2O
mOsm 415 +/- 20
Stock E:                                                                        
Hepes                                                                      2.9785 g
Add 50 ml of H2O
mOsm 354 +/- 20
pH to 7.4 with 5M NaOH before checking the mOsm.
Other solutions:
20% sodium Chloride
(2 g in 10 ml H2O)
5 ml Sodium Chloride 15 mg/ml (made up fresh).
Phenol Red is brought in as a solution.  Reference List
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